



83	7	2.3	67	21	Arabidopsis thaliana
84	7	2.3	70	21	Arabidopsis thaliana
85	7	2.3	71	22	Human polypeptide
86	7	2.3	73	22	Proionibacterium
87	7	2.3	78	22	Novel human diaphano
88	7	2.3	87	22	Human novel extrac
89	7	2.3	87	23	ABP48012
90	7	2.3	89	21	AA600327
91	7	2.3	89	24	ABP58692
92	7	2.3	92	21	AA659054
93	7	2.3	92	21	AA660335
94	7	2.3	97	23	ABP07319
95	7	2.3	102	20	AA73830
96	7	2.3	104	22	AA009976
97	7	2.3	106	22	AA682299
98	7	2.3	110	21	AA659053
99	7	2.3	110	21	AA660334
100	7	2.3	119	23	ABP40383

## ALIGNMENTS

RESULT 1  
AA96294  
ID AA96294 standard; protein; 310 AA.

XX	AA96294;	
DT	16-AUG-2000 (first entry)	
XX		
DE	Human IGFAM-6 immunoglobulin.	
KW	Human; immunoglobulin; IGFAM-6; IGFAM; immune disorder; cancer;	
KW	Infection; inflammation; haematopoiesis; AIDS; allergy.	
OS	Homo sapiens.	
XX		
PH	Key	Location/Qualifiers
FT	Peptide	1..30
FT	Protein	/label= signal_peptide
FT		31..310
FT		/label= IGFAM-6
FT	Domain	46..117
FT		/label= Ig_domain
FT	Domain	153..221
FT		/label= Ig_domain
FT	Domain	238..260
FT		/label= transmembrane_domain
XX		
PN	WO200029583-A2.	
XX		
PD	25-MAY-2000.	
XX		
PF	19-NOV-1999;	99WO-US27566.
XX		
PR	19-NOV-1998;	99US-0113635.
PR	22-DEC-1998;	98US-0113635.
PR	07-APR-1999;	99US-0128194.
XX		
PA	(INCY-) INCYTE PHARM INC.	
XX		
PI	Yue H, Tang YT, Corley NC, Guegler KJ, Gorgone GA, Baughn MR;	
PI	Lu DM, Lai P, Hillman JL, Yang J;	
XX		
DR	WPI; 2000-387796/33.	
DR	N-PSDB; AAA27386.	
XX		
PT	Immunoglobulin superfamily proteins, the agonist and antagonist of the	
PT	protein is useful for preventing and treating disorders associated with	
PT	altered levels of the protein such as cancer, immune system disorders	
XX		

PS	Claim 1; Page 82-83; 105pp; English.
XX	
XX	The present sequence is the human immunoglobulin superfamily protein
CC	IGFAM-6. Its gene was isolated from a cDNA library of leg
CC	tissue. It is expressed in reproductive, nervous and
CC	cardiovascular tissue, where cancer and inflammation are common. The
CC	gene, protein, its antibodies, agonists and antagonists are suitable for
CC	diagnosing and treating many diseases, including cancer, immune system
CC	disorders (such as inflammation, AIDS, allergies, anaemia,
CC	arteriosclerosis, asthma, atherosclerosis, cholecystitis, Crohn's
CC	disease, diabetes mellitus, emphysema, Graves' disease, hepatitis,
CC	multiple sclerosis, psoriasis, rheumatoid arthritis, scleroderma,
CC	systemic lupus erythematosus and ulcerative colitis), complications of
CC	cancer, haemodialysis and extracorporeal circulation, trauma and
CC	haematopoietic cancer (such as leukaemia) and infections caused by
CC	bacteria, viruses, fungi or parasites.
XX	
SQ	Sequence 310 AA;

Query Match 100.0%; Score 310; DB 21; Length 310;  
Best Local Similarity 100.0%; Pred. No. 6.2e-296;  
Matches 310; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1 MALRRPRLRLCARLDPDFLLLLFRGLIGAVNLKSNRPVQEFSEVLSCLITDSQT 60
DB	1 MALRRPRLRLCARLDPDFLLLLFRGLIGAVNLKSNRPVQEFSEVLSCLITDSQT 60
QY	61 SDPRIEWKKIQDEQTTTYVFEDNKKIQDLAGRAEIIIGKTSLSKTMWTRRSALYRCEVAR 120
DB	61 SDPRIEWKKIQDEQTTTYVFEDNKKIQDLAGRAEIIIGKTSLSKTMWTRRSALYRCEVAR 120
QY	121 NDRKEIDEIVIELTYOVKVPVCRKPAVPKGMATLHCQSEGHPRPHYMYNDVPL 180
DB	121 NDRKEIDEIVIELTYOVKVPVCRKPAVPKGMATLHCQSEGHPRPHYMYNDVPL 180
QY	181 PTDSRANPRFRNSSSHLNSETGLVFTAVHKDSCGYCICASNDASARCEQEMEYVDL 240
DB	181 PTDSRANPRFRNSSSHLNSETGLVFTAVHKDSCGYCICASNDASARCEQEMEYVDL 240
QY	241 NIGGIIGVLYLVAVLALITLIGICAYRRGVYINNKQDESKYKNGKPGVNYITDEEG 300
DB	241 NIGGIIGVLYLVAVLALITLIGICAYRRGVYINNKQDESKYKNGKPGVNYITDEEG 300
QY	301 DFRHKSFPYI 310
DB	301 DFRHKSFPYI 310

RESULT 2	
AA27276	
ID AAB27276 standard; Protein; 310 AA.	
XX	
AC	AAB27276;
XX	
DT	23-FEB-2001 (first entry)
XX	
DE	Human confluency regulated adhesion molecule 1 #2.
KW	Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;
KW	Inflammation; cancer; wound; angiogenesis; human;
KW	confluency regulated adhesion molecule 1; CRM-1; JAM-2.
XX	
OS	Homo sapiens.
XX	
PN	WO200053749-A2.
XX	
PD	14-SEP-2000.
XX	
PF	13-MAR-2000; 2000WO-EP02219.
XX	
PR	11-MAR-1999; 99EP-0200746.
XX	
PA	(RMFD-) RMF DICTAGENE SA.

XX XX Imhof BA, Aurand-Lions M;  
 XX XX WPI: 2000-587436/55.  
 DR N-PSDB; AAA95306.  
 XX XX  
 PT Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (GRAM-1 or  
 CC GRAM-2) polypeptide, useful for treatment of tumors, inflammation  
 PT reactions and modulating vascular permeability -  
 CC  
 XX  
 PS Claim 2; Fig 6; 59pp; English.  
 XX  
 CC The present sequence is the human confluency regulated adhesion molecule  
 CC 1 (GRAM-1, also known as JMB-2). GRAM-1 is one of the vascular adhesion  
 CC proteins of the immunoglobulin superfamily (Ig sf). The GRAM-1 protein  
 CC and coding sequence can be used in the treatment of cancer, inflammation,  
 CC to modulate cell-cell interactions and angiogenesis, and in the  
 CC modulation of wound healing.  
 CC  
 XX  
 SO Sequence 310 AA;  
 Query Match 67.4%; Score 209; DB 21; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDFELLFRGCLIGAVNLKSNRTPVQEFSEVLSCTITDSQT 60  
 Db 1 MALRRPRLRLCARLPDFELLFRGCLIGAVNLKSNRTPVQEFSEVLSCTITDSQT 60  
 QY 61 SDPRIEMWKIODEQTTVFPDNKIQGDLAGRAEILGKTSLKIMVTRDSALYRCEVVAR 120  
 Db 61 SDPRIEMWKIODEQTTVFPDNKIQGDLAGRAEILGKTSLKIMVTRDSALYRCEVVAR 120  
 QY 121 NDRKEIDIEIVELTYQVKVTPVCRVPAVPGKATLHCQSBSEHPRPHYSWRNDVPL 180  
 Db 121 NDRKEIDIEIVELTYQVKVTPVCRVPAVPGKATLHCQSBSEHPRPHYSWRNDVPL 180  
 QY 121 NDRKEIDIEIVELTYQVKVTPVCRVPAVPGKATLHCQSBSEHPRPHYSWRNDVPL 180  
 Db 121 NDRKEIDIEIVELTYQVKVTPVCRVPAVPGKATLHCQSBSEHPRPHYSWRNDVPL 180  
 QY 181 PTDSRANRPNSSSHLSSETGLVFTAVHKDDSGQYCIASNDGASRCEQEMEVYDL 240  
 Db 181 PTDSRANRPNSSSHLSSETGLVFTAVHKDDSGQYCIASNDGASRCEQEMEVYDL 240  
 QY 241 NIGGIIGVAVLVAVLALITLIGICCAVRRGYFINNKDQGESYKXPKGQGVNVRTDEG 300  
 Db 241 NIGGIIGVAVLVAVLALITLIGICCAVRRGYFINNKDQGESYKXPKGQGVNVRTDEG 300  
 QY 301 DFRHKSFEVI 310  
 Db 301 DFRHKSFEVI 310  
 RESULT 3  
 AAB33457  
 ID AAB33457 standard; Protein; 310 AA.  
 XX  
 AC AAB33457;  
 XX  
 DT 29-JAN-2001 (first entry)  
 XX  
 DE Human PRO1868 protein UNQ859 SEQ ID NO:193.  
 XX  
 KW Human; immune related disease; diagnosis; anti-inflammatory; cardiac;  
 KW dermatological; antidiabetic; antihypertensive; immunosuppressive;  
 KW haemostatic; antithyroid; antidiabetic; neurotropic; neuroprotective;  
 KW antineoplastic; hepatotropic; vitruide; antiproliferative; antiallergic;  
 KW antineoplastic; systemic lupus erythematosus; rheumatoid arthritis;  
 KW osteoarthritis; spondyloarthritis; systemic sclerosis; sarcoidosis;  
 KW idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;  
 KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;  
 KW autoimmune thrombocytopenia; immune-mediated renal disease;  
 KW demyelinating disease; hepatobiliary disease; Whipple's disease;  
 KW inflammatory bowel disease; gluten-sensitive enteropathy;  
 KW autoimmune disease; immune-mediated skin disease; allergic disease;  
 KW immunological disease; transplantation associated disease;

KW graft rejection; graft-versus-host-disease.  
 XX  
 OS Homo sapiens.  
 XX  
 EN WO200053758-A2.  
 XX  
 PD 14-SEP-2000.  
 XX  
 PF 02-MAR-2000; 2000WO-US05841.  
 XX  
 PR 08-MAR-1999; 99WO-US05028.  
 PR 10-MAR-1999; 99US-0123618.  
 PR 12-MAR-1999; 99US-0123957.  
 PR 23-MAR-1999; 99US-0125775.  
 PR 12-APR-1999; 99US-0128849.  
 PR 20-APR-1999; 99WO-US08615.  
 PR 28-APR-1999; 99US-0131445.  
 PR 04-MAY-1999; 99US-0132371.  
 PR 14-MAY-1999; 99US-0134287.  
 PR 02-JUN-1999; 99WO-US12252.  
 PR 23-JUN-1999; 99US-0141037.  
 PR 20-JUL-1999; 99US-0144758.  
 PR 26-JUL-1999; 99US-0145658.  
 PR 28-JUL-1999; 99US-0146222.  
 PR 01-SEP-1999; 99WO-US20111.  
 PR 08-SEP-1999; 99WO-US20594.  
 PR 13-SEP-1999; 99WO-US20944.  
 PR 15-SEP-1999; 99WO-US21090.  
 PR 15-SEP-1999; 99WO-US21547.  
 PR 05-SEP-1999; 99WO-US23089.  
 PR 05-OCT-1999; 99WO-US23089.  
 PR 29-OCT-1999; 99US-0162506.  
 PR 29-NOV-1999; 99WO-US28214.  
 PR 30-NOV-1999; 99WO-US28313.  
 PR 30-NOV-1999; 99WO-US28409.  
 PR 01-DEC-1999; 99WO-US28301.  
 PR 01-DEC-1999; 99WO-US28634.  
 PR 02-DEC-1999; 99WO-US28551.  
 PR 02-DEC-1999; 99WO-US28564.  
 PR 02-DEC-1999; 99WO-US28565.  
 PR 16-DEC-1999; 99WO-US30095.  
 PR 20-DEC-1999; 99WO-US30999.  
 PR 30-DEC-1999; 99WO-US31274.  
 PR 05-JAN-2000; 2000WO-US00219.  
 PR 06-JAN-2000; 2000WO-US00277.  
 PR 06-JAN-2000; 2000WO-US00376.  
 PR 11-FEB-2000; 2000WO-US03565.  
 PR 18-FEB-2000; 2000WO-US04341.  
 PR 18-FEB-2000; 2000WO-US04342.  
 PR 22-FEB-2000; 2000WO-US04414.  
 XX  
 RA (GETH ) GENENTECH INC.  
 XX  
 PI Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W;  
 PI Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V;  
 PI Stewart RA, Tumas D, Watanabe CK, Wood WI, Yan M;  
 DR WPI: 2000-572271/53.  
 DR N-PSDB; AAC58622.  
 XX  
 PT Sixty four PRO polypeptides, useful in the diagnosis and treatment of  
 PT immune related disorders, e.g. systemic lupus erythematosus, rheumatoid  
 PT arthritis, osteoarthritis, thyroiditis and diabetes mellitus -  
 XX  
 PS Claim 33; Fig 86; 309pp; English.  
 XX  
 CC The present invention describes sixty four human PRO proteins which can  
 CC be used in the treatment of immune related diseases. The human PRO  
 CC proteins, anti-PRO antibodies, agonists and antagonists are useful for  
 CC treating and diagnosing immune related disorders. The disorders are  
 CC selected from systemic lupus erythematosus, rheumatoid arthritis,  
 CC osteoarthritis, juvenile chronic arthritis, spondyloarthritis,  
 CC systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's  
 CC syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic

CC anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,  
CC immune-mediated renal disease, demyelinating diseases of the central  
CC and peripheral nervous systems, hepatobiliary diseases, inflammatory  
CC bowel disease, gluten-sensitive enteropathy and Whipple's disease,  
CC autoimmune or immune-mediated skin diseases, allergic diseases,  
CC immunological diseases of the lung, and transplantation associated  
CC diseases including graft rejection and graft-versus-host-disease.  
CC AAC58397 to AAC58578 represent PCR primers and hybridisation probes used  
CC in the isolation of human PRO sequences. AAC58579 to AAC58642 and  
CC AAB33414 to AAB33477 represent human PRO polynucleotide and protein  
CC sequences given in the exemplification of the present invention.

XX Sequence 310 AA;

Query Match 67.4%; Score 209; DB 21; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLRLCARLPDPFLLLFPGCLIGAVNLKSSNTPVVOEFESVELSCIITDSQT 60  
DB 1 MALRRPRLRLCARLPDPFLLLFPGCLIGAVNLKSSNTPVVOEFESVELSCIITDSQT 60  
QY 61 SPPRIEMKKIOEQTYVFFDNKIOGDLGRAEILGKTSIKTMWTRRSALYRCVVAR 120  
DB 61 SPPRIEMKKIOEQTYVFFDNKIOGDLGRAEILGKTSIKTMWTRRSALYRCVVAR 120  
QY 121 NDRKEIDEIVIELTVQVKVTPVCRKAVPVGKMATLHCQSEEGHPRPHYSWYRNDVPL 180  
DB 121 NDRKEIDEIVIELTVQVKVTPVCRKAVPVGKMATLHCQSEEGHPRPHYSWYRNDVPL 180  
QY 181 PTDSSRANPRFRNSSSHLNSETGTLVFTAVHKDSDGQYCIASNDAGSARCEQEMEVYDL 240  
DB 181 PTDSSRANPRFRNSSSHLNSETGTLVFTAVHKDSDGQYCIASNDAGSARCEQEMEVYDL 240  
QY 241 NIGGIIGLVNLAVALITLIGICCAVRRGYFINNKQDESYNPKPGVNIYRTDEBG 300  
DB 241 NIGGIIGLVNLAVALITLIGICCAVRRGYFINNKQDESYNPKPGVNIYRTDEBG 300  
QY 301 DFRHKSSFVI 310  
DB 301 DFRHKSSFVI 310

RESULT 4  
AAV96735  
ID AAV96735 standard; Protein; 310 AA.

XX AAV96735;  
AC 26-SEP-2000 (first entry)  
XX  
XX  
DE PRO1868, an A33 antigen homologue.  
XX  
XX PRO1868, A33 antigen, secreted protein, transmembrane protein;  
KW anti-inflammatory; cytosolic; recombinant production; gene therapy.  
XX  
OS Homo sapiens.  
XX

PH Key Location/Qualifiers  
FT Peptide 1..30  
FT /label= Signal\_peptide  
FT Modified-site 26..31  
FT /note= "N-myristoylation site"  
FT Modified-site 69..77  
FT /note= "Tyrosine kinase phosphorylation site"  
FT Modified-site 104..107  
FT /note= "N-glycosylation site"  
FT Modified-site 106..109  
FT /note= "Casein kinase II phosphorylation site"  
FT Modified-site 107..110  
FT /note= "cAMP- and cGMP-dependent protein kinase phosphorylation site"  
FT Modified-site 192..195

FT /note= "N-glycosylation site"  
FT Modified-site 215..220  
FT /note= "N-myristoylation site"  
FT Modified-site 226..231  
FT /note= "N-myristoylation site"  
FT Domain 243..263  
FT /label= Transmembrane domain  
FT Modified-site 243..248  
FT /note= "N-myristoylation site"  
FT Modified-site 244..249  
FT /note= "N-myristoylation site"  
FT Modified-site 262..267  
FT /note= "N-myristoylation site"  
FT Modified-site 296..299  
FT /note= "Casein kinase II phosphorylation site"  
PN WO200036102-A2.  
PD 22-JUN-2000.  
XX  
XX 01-DEC-1999; 99WO-US28634.  
XX  
PR 16-DEC-1998; 98US-0112851.  
PR 16-DEC-1998; 98US-0113145.  
PR 22-DEC-1998; 98US-0113511.  
PR 12-JAN-1999; 99US-0115558.  
PR 12-JAN-1999; 99US-0115565.  
PR 12-JAN-1999; 99US-0115733.  
PR 09-FEB-1999; 99US-0119341.  
PR 10-FEB-1999; 99US-0119537.  
PR 12-FEB-1999; 99US-0119965.  
PR 02-JUN-1999; 99WO-US12252.  
XX  
PA (GENTH ) GENENTECH INC.  
XX Botstein D, Desnovers L, Ferrara N, Feng S, Gao W, Goddard A;  
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;  
PI Wood WI;  
XX  
XX WPI: 2000-431586/37.  
DR N-PEDB; MAAS1265.  
XX  
XX Isolated nucleic acid molecule encodes a PRO polypeptide which is a  
PT transmembrane polypeptide  
PS Claim 1; Fig 14; 154pp; English.  
XX  
XX This is PRO1868, a putative homologue of A33 antigen, a known  
CC colorectal cancer-associated marker. The invention concerns novel  
CC secreted and transmembrane proteins, designated PRO polypeptides. The  
CC cDNA and gene sequences are useful in the recombinant production of PRO  
CC polypeptides, as a hybridization probe to screen libraries to isolate  
CC cDNAs with sequence identity to PRO polypeptides or to map the gene  
CC encoding the PRO polypeptides and analyzing genetic disorders. The  
CC cDNA/gene can also be used to produce transgenic animals useful for the  
CC development and screening of therapeutically useful reagents. They can  
CC also be used in gene therapy, e.g. to replace a defective gene.  
XX  
SQ Sequence 310 AA;  
Query Match 67.4%; Score 209; DB 21; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MALRRPRLRLCARLPDPFLLLFPGCLIGAVNLKSSNTPVVOEFESVELSCIITDSQT 60  
DB 1 MALRRPRLRLCARLPDPFLLLFPGCLIGAVNLKSSNTPVVOEFESVELSCIITDSQT 60  
QY 61 SPPRIEMKKIOEQTYVFFDNKIOGDLGRAEILGKTSIKTMWTRRSALYRCVVAR 120  
DB 61 SPPRIEMKKIOEQTYVFFDNKIOGDLGRAEILGKTSIKTMWTRRSALYRCVVAR 120  
QY 121 NDRKEIDEIVIELTVQVKVTPVCRKAVPVGKMATLHCQSEEGHPRPHYSWYRNDVPL 180

```

Db      121 NDRKEIDIEIVELTVQVPEVTPVCRVPKAVPVGKMATLHCQESGHPPEPHYSWYRNDVPL 180
Qy      181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDQSGQYTCIASNDAGSARCEOEWEVYDL 240
Db      181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDQSGQYTCIASNDAGSARCEOEWEVYDL 240
Qy      241 NIGGIIGVVLVAVLALITLIGICCAVRGFFINNKGDESKNPKGPDGVNYIRTDDEG 300
Db      241 NIGGIIGVVLVAVLALITLIGICCAVRGFFINNKGDESKNPKGPDGVNYIRTDDEG 300
Qy      301 DFRHKSFEVI 310
Db      301 DFRHKSFEVI 310

RESULT 5
AAM93323
ID      AAM93323 standard; Protein; 310 AA.
XX
AC      AAM93323;
XX
DT      06-NOV-2001 (first entry)
XX
DE      Human polypeptide, SEQ ID NO: 2845.
XX
KW      Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS      Homo sapiens.
XX
PN      EP1130094-A2.
XX
PD      05-SEP-2001.
XX
PF      07-JUL-2000; 2000EP-0114089.
XX
PR      08-JUL-1999; 99JP-0194486.
XX
PR      11-JAN-2000; 2000JP-0118774.
XX
PR      02-MAY-2000; 2000JP-0183765.
XX
PA      (HELI-) HELIX RES INST.
XX
PI      Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI      Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR      WPI; 2001-524255/58.
XX
DR      N-PSDB; AAK94243.
XX
PT      830 Primers useful for synthesizing full length cDNA clones and their
PT      use in genetic manipulation -
XX
PS      Claim 8; SEQ ID NO 2845; 1380bp + sequence listing; English.
XX
CC      The invention relates to primers for synthesizing full length cDNA
CC      clones. 830 cDNA molecules encoding a human protein have been
CC      isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC      molecules have been determined. Primers for synthesizing the full length
CC      cDNA are useful for clarifying the function of the protein encoded by
CC      the cDNA. The full length clones were obtained by construction of full
CC      length enriched cDNA libraries that were synthesised by the oligo-capping
CC      method. The primers enable the production of the full length cDNA easily
CC      without any special methods. The present sequence is a polypeptide
CC      encoded by a full length human cDNA of the invention.
CC      Note: The sequence data for this patent did not form part of the printed
CC      specification, but was obtained in CD-ROM format directly from EPO.
XX
SQ      Sequence 310 AA;

Query Match      67.4%; Score 209; DB 22; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1 MALRRPRLRLCARLPDFLLLPFGCLIGAVNLKSNRTPVVOEFESVELSCIITDSQT 60

```

```

Db      1 MALRRPRLRLCARLPDFLLLPFGCLIGAVNLKSNRTPVVOEFESVELSCIITDSQT 60
Qy      61 SDPRLEMKKIQODEQTTVPFPNKKIQGLAGRAEILGKTSLKIMVTRDSALYRCEVVAR 120
Db      61 SDPRLEMKKIQODEQTTVPFPNKKIQGLAGRAEILGKTSLKIMVTRDSALYRCEVVAR 120
Qy      121 NDRKEIDIEIVELTVQVPEVTPVCRVPKAVPVGKMATLHCQESGHPPEPHYSWYRNDVPL 180
Db      121 NDRKEIDIEIVELTVQVPEVTPVCRVPKAVPVGKMATLHCQESGHPPEPHYSWYRNDVPL 180
Qy      181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDQSGQYTCIASNDAGSARCEOEWEVYDL 240
Db      181 PTDSRANPRFRNSSSHLNSETGTLVFTAVHKDQSGQYTCIASNDAGSARCEOEWEVYDL 240
Qy      241 NIGGIIGVVLVAVLALITLIGICCAVRGFFINNKGDESKNPKGPDGVNYIRTDDEG 300
Db      241 NIGGIIGVVLVAVLALITLIGICCAVRGFFINNKGDESKNPKGPDGVNYIRTDDEG 300
Qy      301 DFRHKSFEVI 310
Db      301 DFRHKSFEVI 310

RESULT 6
AAM93905
ID      AAM93905 standard; Protein; 310 AA.
XX
AC      AAM93905;
XX
DT      06-NOV-2001 (first entry)
XX
DE      Human polypeptide, SEQ ID NO: 4051.
XX
KW      Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS      Homo sapiens.
XX
PN      EP1130094-A2.
XX
PD      05-SEP-2001.
XX
PF      07-JUL-2000; 2000EP-0114089.
XX
PR      08-JUL-1999; 99JP-0194486.
XX
PR      11-JAN-2000; 2000JP-0118774.
XX
PR      02-MAY-2000; 2000JP-0183765.
XX
PA      (HELI-) HELIX RES INST.
XX
PI      Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI      Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR      WPI; 2001-524255/58.
XX
DR      N-PSDB; AAK94867.
XX
PT      830 Primers useful for synthesizing full length cDNA clones and their
PT      use in genetic manipulation -
XX
PS      Claim 8; SEQ ID NO 4051; 1380bp + sequence listing; English.
XX
CC      The invention relates to primers for synthesizing full length cDNA
CC      clones. 830 cDNA molecules encoding a human protein have been
CC      isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC      molecules have been determined. Primers for synthesizing the full length
CC      cDNA are useful for clarifying the function of the protein encoded by
CC      the cDNA. The full length clones were obtained by construction of full
CC      length enriched cDNA libraries that were synthesised by the oligo-capping
CC      method. The primers enable the production of the full length cDNA easily
CC      without any special methods. The present sequence is a polypeptide
CC      encoded by a full length human cDNA of the invention.
CC      Note: The sequence data for this patent did not form part of the printed
CC      specification, but was obtained in CD-ROM format directly from EPO.

```

```

XX SQ Sequence 310 AA;
Query Match 67.4%; Score 209; DB 22; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLRLCARLPDFLLFRGCLIGAVNLKSSNRPVQEFSEVELSCITTSQT 60
DB 1 MALRRPRLRLCARLPDFLLFRGCLIGAVNLKSSNRPVQEFSEVELSCITTSQT 60
QY 61 SPPRIEMKKIOBOQTYYFEDNKIQDLAGRAEILGKTSKIMWTRDSALYRCVVAR 120
DB 61 SPPRIEMKKIOBOQTYYFEDNKIQDLAGRAEILGKTSKIMWTRDSALYRCVVAR 120
QY 121 NDRKEIDEIVIELTVQVAVTPVCRVPAVPYKMATLHCQSESGHPRPHYSWYRNDVPL 180
DB 121 NDRKEIDEIVIELTVQVAVTPVCRVPAVPYKMATLHCQSESGHPRPHYSWYRNDVPL 180
QY 181 PTDSRANPRFRNSSSHLNSSETGLVFTAVHKDSCQYCIASNDGASARCEQEMEYVDL 240
DB 181 PTDSRANPRFRNSSSHLNSSETGLVFTAVHKDSCQYCIASNDGASARCEQEMEYVDL 240
QY 241 NIGGIIGVVLVAVLALITLIGICAYRRGYFINNKQGESYKNGPKPGVNVYIRTDDEG 300
DB 241 NIGGIIGVVLVAVLALITLIGICAYRRGYFINNKQGESYKNGPKPGVNVYIRTDDEG 300
QY 301 DFRHKSSFYI 310
DB 301 DFRHKSSFYI 310

RESULT 7
AAU12440
ID AAU12440 standard; Protein; 310 AA.
XX AC AAU12440;
XX DT 24-OCT-2001 (first entry)
XX DE Human PRO1868 polypeptide sequence.
XX KW Human secretory and transmembrane; PRO; mammalian; cancer; lung;
KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
KW adipocyte; A-peptide; factor VIIA; gene therapy.
XX OS Homo sapiens.
XX PN WO200140466-A2.
XX PD 07-JUN-2001.
XX PF 01-DEC-2000; 2000WO-US32678.
XX PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28651.
PR 02-DEC-1999; 99WO-US28664.
PR 02-DEC-1999; 99WO-US28665.
PR 09-DEC-1999; 99US-0170262.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 30-DEC-1999; 99WO-US31243.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.

```

```

PR 01-MAR-2000; 2000WO-US05601.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 10-NOV-2000; 2000WO-US30873.
XX (GENTECH ) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerritsen ME, Goddard A, Godowski PJ, Gunney AU, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
DR MPI: 2001-408281/43.
DR N-PSDB; MAS21512.
XX Isolated, secretory and transmembrane PRO polypeptide used to detect
PT other PRO polypeptides, link bioactive molecules to cells expressing
PT PRO polypeptides, and detect the presence of mammalian tumours e.g.
PT lung, breast, prostate, cervical
PS Claim 12; Fig 538; 813pp; English.
XX AAU12172-AAU12446 represent novel human secretory and transmembrane
CC PRO polypeptides. The PRO polypeptides are useful to detect other
CC PRO polypeptides, to link bioactive molecules to cells expressing
CC PRO polypeptides, to modulate biological activities of cells expressing
CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample.
CC Some of the 275 sequences are also useful to stimulate the release of
CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
CC proliferation or differentiation of chondrocytes, the proliferation or
CC gene expression in pericyte cells, the release of proteoglycans from
CC cartilage, the proliferation of inner ear utricular supporting cells or
CC of T-lymphocytes, the release of a cytokine from peripheral blood
CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
CC skeletal muscle cells or by adipocytes, or inhibit binding of A-peptide
CC to factor VIIA. The PRO polypeptides can be used in assays to identify
CC molecules involved in binding interactions. The polynucleotides encoding
CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy.
XX SQ Sequence 310 AA;
Query Match 67.4%; Score 209; DB 22; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLRLCARLPDFLLFRGCLIGAVNLKSSNRPVQEFSEVELSCITTSQT 60
DB 1 MALRRPRLRLCARLPDFLLFRGCLIGAVNLKSSNRPVQEFSEVELSCITTSQT 60
QY 61 SPPRIEMKKIOBOQTYYFEDNKIQDLAGRAEILGKTSKIMWTRDSALYRCVVAR 120
DB 61 SPPRIEMKKIOBOQTYYFEDNKIQDLAGRAEILGKTSKIMWTRDSALYRCVVAR 120
QY 121 NDRKEIDEIVIELTVQVAVTPVCRVPAVPYKMATLHCQSESGHPRPHYSWYRNDVPL 180
DB 121 NDRKEIDEIVIELTVQVAVTPVCRVPAVPYKMATLHCQSESGHPRPHYSWYRNDVPL 180
QY 181 PTDSRANPRFRNSSSHLNSSETGLVFTAVHKDSCQYCIASNDGASARCEQEMEYVDL 240
DB 181 PTDSRANPRFRNSSSHLNSSETGLVFTAVHKDSCQYCIASNDGASARCEQEMEYVDL 240
QY 241 NIGGIIGVVLVAVLALITLIGICAYRRGYFINNKQGESYKNGPKPGVNVYIRTDDEG 300
DB 241 NIGGIIGVVLVAVLALITLIGICAYRRGYFINNKQGESYKNGPKPGVNVYIRTDDEG 300

```

QY 301 DFRHSSSVI 310  
 |||||  
 Db 301 DFRHSSSVI 310

RESULT 8  
 AAB80272  
 ID AAB80272 standard; Protein; 310 AA.

AC AAB80272;

DT 24-APR-2001 (first entry)

DE Human PRO1868 protein.

Human; PRO; dermatological; antipruritic; cytostatic; antiinflammatory;  
 antiiprkinsonian nootropic; neuroprotective; vulnary; cardiac;  
 antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;  
 antiarthritic; antifertility; antidiabetic; antiviral; diabetes;  
 ophthalmological; gene therapy; skin disease; gastrointestinal disorder;  
 ischaemia; inflammation.

OS Homo sapiens.

PN WO200104311-A1.

PD 18-JAN-2001

PF 22-FEB-2000; 2000WO-US04414.

XX 07-JUL-1999; 99US-0143048.

XX 26-JUL-1999; 99US-0145698.

XX 28-JUL-1999; 99US-0146222.

XX 08-SEP-1999; 99WO-US20594.

XX 13-SEP-1999; 99WO-US20944.

XX 15-SEP-1999; 99WO-US21090.

XX 05-OCT-1999; 99WO-US23089.

XX 29-NOV-1999; 99WO-US28214.

XX 30-NOV-1999; 99WO-US28313.

XX 16-DEC-1999; 99WO-US30095.

XX 20-DEC-1999; 99WO-US30911.

XX 05-JAN-2000; 99WO-US30999.

XX (GETH) GENENTECH INC.

XX Ashkenazi AJ, Botstein D, Desnovers L, Eaton DL, Ferrara N;

XX Filvaroff E, Fong S, Gao W, Gerber H, Gertsen ME, Goddard A;

XX Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kljavin IJ;

XX Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;

XX Williams FM, Wood WI;

XX WPI; 2001-081051/09.

XX N-PSDB; AAF72433.

XX Sixty one nucleic acids encoding PRO polypeptides which are useful in

XX the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung

XX squamous cell carcinoma) and neurodegenerative diseases (e.g.

XX Alzheimer's disease) -

CC The PRO nucleic acids have applications in molecular biology, including  
 CC use as hybridization probes, and in chromosome and gene mapping.  
 CC  
 XX  
 SO Sequence 310 AA;

Query Match 67.4%; Score 209; DB 22; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLRLCARLPDFILLFRGLIGAVNLKSSNRTPVQEFSSVLSCTITTSOT 60

Db 1 MALRRPRLRLCARLPDFILLFRGLIGAVNLKSSNRTPVQEFSSVLSCTITTSOT 60

QY 61 SDPRIEWKKIODEQTTVPFDNKLQGLAGRAELIGKTSIKINVTTRDSALYCEVVAR 120

Db 61 SDPRIEWKKIODEQTTVPFDNKLQGLAGRAELIGKTSIKINVTTRDSALYCEVVAR 120

QY 121 NDRKEIDEIYIELTVQKVPYTPVCRVKAAPVGMATLHCQESBGRPHYSWYRNDVPL 180

Db 121 NDRKEIDEIYIELTVQKVPYTPVCRVKAAPVGMATLHCQESBGRPHYSWYRNDVPL 180

QY 181 PTDSRANPRRNSSSHNSETGTLVFAVHKDSSGQYYCIAANDAGSARCEBQEMEYVDL 240

Db 181 PTDSRANPRRNSSSHNSETGTLVFAVHKDSSGQYYCIAANDAGSARCEBQEMEYVDL 240

QY 241 NIGGIIGVTLVLAVALITLIGICCAVRRGYFINNKODGESYKPKGPDGVNYIRTDDEG 300

Db 241 NIGGIIGVTLVLAVALITLIGICCAVRRGYFINNKODGESYKPKGPDGVNYIRTDDEG 300

QY 301 DFRHSSSVI 310

Db 301 DFRHSSSVI 310

RESULT 9  
 AAB80383  
 ID AAB80383 standard; protein; 310 AA.

XX AAB80383;

XX 24-APR-2001 (first entry)

XX Secreted protein encoded by gene #13.

XX Secreted protein; human; autoimmune; hyperproliferation;

XX cardiovascular; cerebrovascular; infection; food.

XX Homo sapiens.

XX WO200107459-A1.

XX 01-FEB-2001.

XX 20-JUL-2000; 2000WO-US19735.

XX 23-JUL-1999; 99US-0145220.

XX (HUMA-) HUMAN GENOME SCI INC.

XX Rosen CA, Ruben SM, Ebner R, Duan RD, Ni J, Soppet DR, Moore PA;

XX Shi Y, Lafleur DW, Olsen HS, Birse CE, Komatsoulis GA;

XX WPI; 2001-123261/13.

XX New isolated nucleic acid encoding 29 secreted proteins, for

XX diagnosing, preventing and treating e.g. autoimmune,

XX hyperproliferative, cardiovascular, and ocular diseases or disorders

XX and microorganism infections -

XX Claim 11; Page 538-539; 601pp; English.

XX The present invention relates to 29 human secreted proteins. The

XX invention is used to prevent autoimmune diseases e.g. rheumatoid

CC arthritis, hyperproliferative disorders e.g. neoplasms of the  
CC breast or liver, cardiovascular disorders e.g. cardiac arrest,  
CC cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,  
CC nervous system disorders e.g. Alzheimer's disease, infections  
CC caused by bacteria, viruses and fungi and ocular disorders e.g.  
CC corneal infection. Also used in food preparations.

XX Sequence 310 AA;

Query Match 67.4%; Score 209; DB 22; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLRLCARLPDFLLLFRCGLIGAVNLKSSNRPVQEFSEVLSCTITDSQT 60  
DB 1 MALRRPRLRLCARLPDFLLLFRCGLIGAVNLKSSNRPVQEFSEVLSCTITDSQT 60  
QY 61 SDPRIEMKKIODEQTTTYFFDNKIOGDLGRAEILGKTSLKIMVTRRDSALYRCEVVAR 120  
DB 61 SDPRIEMKKIODEQTTTYFFDNKIOGDLGRAEILGKTSLKIMVTRRDSALYRCEVVAR 120  
QY 121 NDRKEIDELVIELTVQVAVPTVPCRPVPAVPGKATLHCQSEEGHPRPHYSWYRNDVPL 180  
DB 121 NDRKEIDELVIELTVQVAVPTVPCRPVPAVPGKATLHCQSEEGHPRPHYSWYRNDVPL 180  
QY 181 PTDSSANPRFRNSSSHLNSETGTLVFTAVHKDSCGYCICIASNDGASARCEOEEMEVYDL 240  
DB 181 PTDSSANPRFRNSSSHLNSETGTLVFTAVHKDSCGYCICIASNDGASARCEOEEMEVYDL 240  
QY 241 NIGGIIGVLYVLAVALITLIGICCAVRRGYFINNKQDESYKNGKPGGVNYIRTDDEG 300  
DB 241 NIGGIIGVLYVLAVALITLIGICCAVRRGYFINNKQDESYKNGKPGGVNYIRTDDEG 300  
QY 301 DFRHKSSFVI 310  
DB 301 DFRHKSSFVI 310

#### RESULT 10

AAB80408  
ID AAB80408 standard; protein; 310 AA.

XX AAB80408;

DT 24-APR-2001 (first entry)

DE Secreted protein encoded by gene #38.

KW Secreted protein; human; autoimmune; hyperproliferation;

KM cardiovascular; cerebrovascular; infection; food.

OS Homo sapiens.

XX WO200107459-A1.

PD 01-FEB-2001.

PF 20-JUL-2000; 2000WO-US19735.

PR 23-JUL-1999; 99US-0145220.

PA (HUMA-) HUMAN GENOME SCI INC.

PI Rosen CA, Ruben SM, Ebner R, Duan RD, Ni J, Soppet DR, Moore PA;

PI Shi Y, Lafleur DW, Olsen HS, Birse CE, Komatsoulis GA;

DR WPI; 2001-123261/13.

PT New isolated nucleic acid encoding 29 secreted proteins, for  
PT diagnosing, preventing and treating e.g. autoimmune,  
PT hyperproliferative, cardiovascular, and ocular diseases or disorders  
PT and microorganism infections

PS Claim 11; Page 557-558; 601pp; English.

XX The present invention relates to 29 human secreted proteins. The  
XX invention is used to prevent autoimmune diseases e.g. rheumatoid  
CC arthritis, hyperproliferative disorders e.g. neoplasms of the  
CC breast or liver, cardiovascular disorders e.g. cardiac arrest,  
CC cerebrovascular disorders e.g. cerebral ischemia, angiogenesis,  
CC nervous system disorders e.g. Alzheimer's disease, infections  
CC caused by bacteria, viruses and fungi and ocular disorders e.g.  
CC corneal infection. Also used in food preparations.

XX Sequence 310 AA;

Query Match 67.4%; Score 209; DB 22; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLRLCARLPDFLLLFRCGLIGAVNLKSSNRPVQEFSEVLSCTITDSQT 60  
DB 1 MALRRPRLRLCARLPDFLLLFRCGLIGAVNLKSSNRPVQEFSEVLSCTITDSQT 60  
QY 61 SDPRIEMKKIODEQTTTYFFDNKIOGDLGRAEILGKTSLKIMVTRRDSALYRCEVVAR 120  
DB 61 SDPRIEMKKIODEQTTTYFFDNKIOGDLGRAEILGKTSLKIMVTRRDSALYRCEVVAR 120  
QY 121 NDRKEIDELVIELTVQVAVPTVPCRPVPAVPGKATLHCQSEEGHPRPHYSWYRNDVPL 180  
DB 121 NDRKEIDELVIELTVQVAVPTVPCRPVPAVPGKATLHCQSEEGHPRPHYSWYRNDVPL 180  
QY 181 PTDSSANPRFRNSSSHLNSETGTLVFTAVHKDSCGYCICIASNDGASARCEOEEMEVYDL 240  
DB 181 PTDSSANPRFRNSSSHLNSETGTLVFTAVHKDSCGYCICIASNDGASARCEOEEMEVYDL 240  
QY 241 NIGGIIGVLYVLAVALITLIGICCAVRRGYFINNKQDESYKNGKPGGVNYIRTDDEG 300  
DB 241 NIGGIIGVLYVLAVALITLIGICCAVRRGYFINNKQDESYKNGKPGGVNYIRTDDEG 300  
QY 301 DFRHKSSFVI 310  
DB 301 DFRHKSSFVI 310

#### RESULT 11

AAB80409  
ID AAB80409 standard; protein; 310 AA.

XX AAB80409;

DT 24-APR-2001 (first entry)

DE Secreted protein encoded by gene #39.

KW Secreted protein; human; autoimmune; hyperproliferation;

KM cardiovascular; cerebrovascular; infection; food.

OS Homo sapiens.

XX WO200107459-A1.

PD 01-FEB-2001.

PF 20-JUL-2000; 2000WO-US19735.

PR 23-JUL-1999; 99US-0145220.

PA (HUMA-) HUMAN GENOME SCI INC.

PI Rosen CA, Ruben SM, Ebner R, Duan RD, Ni J, Soppet DR, Moore PA;

PI Shi Y, Lafleur DW, Olsen HS, Birse CE, Komatsoulis GA;

DR WPI; 2001-123261/13.

PT New isolated nucleic acid encoding 29 secreted proteins, for

FT diagnosing, preventing and treating e.g. autoimmune,  
PT hyperproliferative, cardiovascular, and ocular diseases or disorders  
FT and microorganism infections -  
XX  
PS Claim 11; Page 559-560; 601pp; English.  
XX  
CC The present invention relates to 29 human secreted proteins. The  
CC invention is used to prevent autoimmune diseases e.g. rheumatoid  
CC arthritis, hyperproliferative disorders e.g. neoplasms of the  
CC breast or liver, cardiovascular disorders e.g. cardiac arrest,  
CC cerebrovascular disorders e.g. cerebral ischemia, angiodysplasia,  
CC nervous system disorders e.g. Alzheimer's disease, infections  
CC caused by bacteria, viruses and fungi and ocular disorders e.g.  
CC corneal infection. Also used in food preparations.  
XX  
SQ Sequence 310 AA;  
  
Query Match 67.4%; Score 209; DB 22; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1 MALRRPPLRLCARLPDFLLFRGCLIGAVNLKSSRTVQGFSEVLSCTITDSQT 60  
D 1 MALRRPPLRLCARLPDFLLFRGCLIGAVNLKSSRTVQGFSEVLSCTITDSQT 60  
QY 61 SDPRIEMWKIODEQTTVFYFNKIQGLAGRAEILGKTSLKIMVYTRDSALYRCEVAV 120  
D 61 SDPRIEMWKIODEQTTVFYFNKIQGLAGRAEILGKTSLKIMVYTRDSALYRCEVAV 120  
QY 121 NDRKEIDIVIELTVQVCPVTPVCRPAVPGKMATLHCOSESGHPRPHYSWRNDVPL 180  
D 121 NDRKEIDIVIELTVQVCPVTPVCRPAVPGKMATLHCOSESGHPRPHYSWRNDVPL 180  
QY 121 PTDSRANRFRNSSHNSRGTLVFTVHNDGQYQYCIASNDAGSRCEQMEVYDL 240  
D 121 PTDSRANRFRNSSHNSRGTLVFTVHNDGQYQYCIASNDAGSRCEQMEVYDL 240  
QY 181 PTDSRANRFRNSSHNSRGTLVFTVHNDGQYQYCIASNDAGSRCEQMEVYDL 240  
D 181 PTDSRANRFRNSSHNSRGTLVFTVHNDGQYQYCIASNDAGSRCEQMEVYDL 240  
QY 241 NIGGIGVAVLVAVLALITIGICCAVRYGYFINNKQGESYKNGKPDGVNYIRTDDEG 300  
D 241 NIGGIGVAVLVAVLALITIGICCAVRYGYFINNKQGESYKNGKPDGVNYIRTDDEG 300  
QY 301 DFRKKSFPVI 310  
D 301 DFRKKSFPVI 310  
  
RESULT 12  
ABG31401  
ID ABG31401 standard; Protein; 310 AA.  
XX  
AC ABG31401;  
XX  
DT 29-NOV-2002 (first entry)  
XX  
DE Human PRO1868 polypeptide.  
XX  
KW Human; secreted and transmembrane polypeptide; PRO polypeptide;  
KW T-lymphocyte proliferation; inflammatory disease; rheumatoid arthritis;  
KW inflammatory bowel disease; Sjogren's syndrome; thyroiditis;  
KW autoimmune haemolytic anaemia; diabetes mellitus; multiple sclerosis;  
KW hepatitis; contact dermatitis; allergic disease; psoriasis; vitreous;  
KW immune related disease; kidney disease; anti-inflammatory; antichryoid;  
KW antineumatic; antirheumatic; immunosuppressive; antianemic;  
KW antidiabetic; neuroprotective; hepatocytic; antiinflammatory;  
KW dermatological; antiallergic; antipsoriatic; PRO1868.  
XX  
OS Homo sapiens.  
XX  
FH Key 1.30 Location/Qualifiers  
FT Peptide /label= Signal\_peptide  
FT Modified-site 26..31  
FT /note= "N-myristoylation site"

FT Protein 31..310  
FT /label= Mature\_PRO1868  
FT Modified-site 69..77  
FT /note= "Tyrosine kinase phosphorylation site"  
FT Modified-site 104..107  
FT /note= "N-glycosylation site"  
FT Modified-site 106..109  
FT /note= "Casein kinase II phosphorylation site"  
FT Modified-site 107..110  
FT /note= "cAMP- and cGMP-dependent protein kinase phosphorylation site"  
FT Modified-site 192..195  
FT /note= "N-glycosylation site"  
FT Modified-site 215..220  
FT /note= "N-myristoylation site"  
FT Modified-site 226..231  
FT /note= "N-myristoylation site"  
FT Domain 243..263  
FT /label= Transmembrane\_domain  
FT Modified-site 243..248  
FT /note= "N-myristoylation site"  
FT Modified-site 244..249  
FT /note= "N-myristoylation site"  
FT Modified-site 262..267  
FT /note= "N-myristoylation site"  
FT Modified-site 296..299  
FT /note= "Casein kinase II phosphorylation site"  
  
US2002098507-A1.  
25-JUL-2002.  
27-DEC-2001; 2001US-0033326.  
XX  
PR 02-JUN-1999; 99WO-US12252.  
PR 01-DEC-1999; 99WO-US28634.  
PR 02-DEC-1999; 99WO-US28551.  
PR 11-FEB-2000; 2000WO-US03565.  
PR 22-FEB-2000; 2000WO-US04414.  
PR 02-MAR-2000; 2000WO-US05841.  
PR 30-MAR-2000; 2000WO-US08439.  
PR 30-MAY-2000; 2000WO-US14941.  
PR 02-JUN-2000; 2000WO-US15264.  
PR 01-DEC-2000; 2000WO-US32678.  
PR 16-DEC-1998; 98US-113145P.  
PR 22-DEC-1998; 98US-113511P.  
PR 12-JAN-1999; 99US-115558P.  
PR 12-JAN-1999; 99US-115565P.  
PR 12-JAN-1999; 99US-115733P.  
PR 09-FEB-1999; 99US-119341P.  
PR 10-FEB-1999; 99US-119537P.  
PR 12-FEB-1999; 99US-119565P.  
PR 29-OCT-1999; 99US-162506P.  
  
(GETH ) GENENTECH INC.  
XX  
PI Borstein D, Deenoyers L, Ferrara N, Fong S, Gao W, Goddard A;  
PI Gutney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;  
PI Wood WI;  
XX  
DR WPI; 2002-673823/72.  
DR N-PSDB; ABS53477.  
XX  
FT Novel PRO polypeptides and nucleic acids encoding the polypeptides,  
FT useful for preparing a medicament for the treatment of inflammatory and  
FT immune related disorders -  
XX  
PS Claim 12; Fig 14; 125pp; English.  
XX  
CC The present invention relates to the isolation of novel human  
CC secreted and transmembrane polypeptides, designated PRO polypeptides,  
CC and the polynucleotide sequences encoding them. The PRO polypeptides  
CC of the invention include PRO1800, PRO539, PRO982, PRO1434, PRO1863,

CC PRO1917, PRO1668, PRO3434 and PRO1927. The PRO polypeptides can  
CC inhibit the stimulation of T-lymphocyte proliferation. The PRO  
CC polypeptides are useful for the diagnosis and treatment of inflammatory  
CC diseases (e.g. inflammatory bowel disease, rheumatoid arthritis,  
CC Sjogren's syndrome, autoimmune haemolytic anaemia, thyroiditis, diabetes  
CC mellitus, multiple sclerosis, hepatitis, contact dermatitis, allergic  
CC diseases and psoriasis), immune related diseases, and kidney diseases  
CC in humans. The present sequence represents human PRO1668 polypeptide.

XX Sequence 310 AA;

Query Match 67.4%; Score 209; DB 23; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLCARLPDFLLFRGCLIGAVNLKSSNTPVVOEFESVELSCITTSOT 60  
DB 1 MALRRPRLCARLPDFLLFRGCLIGAVNLKSSNTPVVOEFESVELSCITTSOT 60  
QY 61 SDPRIEMKKIODEQTTVFEDNKIQGDLGRAEILGKTSLKIMVTRDSALYRCEVAR 120  
DB 61 SDPRIEMKKIODEQTTVFEDNKIQGDLGRAEILGKTSLKIMVTRDSALYRCEVAR 120  
QY 121 NDRKEIDEIVIELTVQVKVTPVCRVPAVPVGRKATLHCQSEEGHPRHYSWYRNDVPL 180  
DB 121 NDRKEIDEIVIELTVQVKVTPVCRVPAVPVGRKATLHCQSEEGHPRHYSWYRNDVPL 180  
QY 181 PTDNRANPRFRNSSSHLNSSETGLVFTAVHKDQSGQYCIASNDGASARCEQEMEVYDL 240  
DB 181 PTDNRANPRFRNSSSHLNSSETGLVFTAVHKDQSGQYCIASNDGASARCEQEMEVYDL 240  
QY 241 NIGGIIGVLLVAVLALITLIGICAYRRGYPINNKKODESYKNGPKPDGVNYIRTDDEG 300  
DB 241 NIGGIIGVLLVAVLALITLIGICAYRRGYPINNKKODESYKNGPKPDGVNYIRTDDEG 300  
QY 301 DFRHKSSFYI 310  
DB 301 DFRHKSSFYI 310

RESULT 13

ABG91361  
ID ABG91361 standard; Protein; 310 AA.  
XX  
AC ABG91361;  
XX  
DT 29-NOV-2002 (first entry)  
XX  
DE Novel human secreted protein #7.  
XX  
KW Human; secreted protein; transmembrane protein; gene mapping;  
KM transgenic; immunogenic.  
XX  
OS Homo sapiens.  
XX  
PN US2002098505-A1.  
XX  
PD 25-JUL-2002.  
XX  
PF 28-DEC-2001; 2001US-0033246.  
XX  
PR 02-JUN-1999; 99WO-US12252.  
PR 01-DEC-1999; 99WO-US28634.  
PR 02-DEC-1999; 99WO-US28651.  
PR 11-FEB-2000; 2000WO-US03565.  
PR 22-FEB-2000; 2000WO-US0414.  
PR 02-MAR-2000; 2000WO-US05841.  
PR 30-MAR-2000; 2000WO-US08439.  
PR 30-MAY-2000; 2000WO-US14941.  
PR 02-JUN-2000; 2000WO-US15264.  
PR 01-DEC-2000; 2000WO-US32678.  
PR 16-DEC-1998; 98US-113145P.  
PR 22-DEC-1998; 98US-113511P.

PR 12-JAN-1999; 99US-115558P.  
PR 12-JAN-1999; 99US-115565P.  
PR 12-JAN-1999; 99US-115733P.  
PR 09-FEB-1999; 99US-119341P.  
PR 10-FEB-1999; 99US-119537P.  
PR 12-FEB-1999; 99US-119965P.  
PR 29-OCT-1999; 99US-162506P.

XX (GETH ) GENENTECH INC.

XX Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;  
PI Gurey AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;  
PI Wood WT;

DR WPI; 2002-665999/71.  
DR N-PSDB; ABS67460.

PT New human secreted and transmembrane (PRO) polypeptides, useful for  
PT treating conditions requiring PRO polypeptides, for screening PRO  
PT antagonists and agonists useful as drug candidates -

XX Claim 12; Figure 14; 125pp; English.

XX The invention relates to new human secreted and transmembrane proteins  
CC (PRO) and nucleic acids of the invention. The polypeptides can be  
CC administered therapeutically, especially by expressing encoding  
CC polynucleotides, e.g. in therapeutic compositions. They can be used to  
CC screen for PRO polypeptide antagonists and agonists useful to identify  
CC drug candidates. They can also be used to produce antibodies, useful to  
CC detect PRO polypeptides (e.g. diagnostically), purify PRO polypeptides or  
CC therapeutically (e.g. as antagonists or to target and/or deliver  
CC cytotoxic agents). The polynucleotides are useful therapeutically e.g. to  
CC produce antisense sequences to inhibit polypeptide production. They can  
CC be used to produce probes and primers useful to detect or isolate  
CC sequences encoding PRO polypeptides or similar sequences e.g. variants or  
CC sequences from other species. They are also useful for gene mapping and  
CC to generate transgenic animals. ABG91355-ABG91363 represent human PRO  
CC amino acid sequences of the invention.

XX Sequence 310 AA;

Query Match 67.4%; Score 209; DB 23; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRLCARLPDFLLFRGCLIGAVNLKSSNTPVVOEFESVELSCITTSOT 60  
DB 1 MALRRPRLCARLPDFLLFRGCLIGAVNLKSSNTPVVOEFESVELSCITTSOT 60  
QY 61 SDPRIEMKKIODEQTTVFEDNKIQGDLGRAEILGKTSLKIMVTRDSALYRCEVAR 120  
DB 61 SDPRIEMKKIODEQTTVFEDNKIQGDLGRAEILGKTSLKIMVTRDSALYRCEVAR 120  
QY 121 NDRKEIDEIVIELTVQVKVTPVCRVPAVPVGRKATLHCQSEEGHPRHYSWYRNDVPL 180  
DB 121 NDRKEIDEIVIELTVQVKVTPVCRVPAVPVGRKATLHCQSEEGHPRHYSWYRNDVPL 180  
QY 181 PTDNRANPRFRNSSSHLNSSETGLVFTAVHKDQSGQYCIASNDGASARCEQEMEVYDL 240  
DB 181 PTDNRANPRFRNSSSHLNSSETGLVFTAVHKDQSGQYCIASNDGASARCEQEMEVYDL 240  
QY 241 NIGGIIGVLLVAVLALITLIGICAYRRGYPINNKKODESYKNGPKPDGVNYIRTDDEG 300  
DB 241 NIGGIIGVLLVAVLALITLIGICAYRRGYPINNKKODESYKNGPKPDGVNYIRTDDEG 300  
QY 301 DFRHKSSFYI 310  
DB 301 DFRHKSSFYI 310

RESULT 14

ABG92709  
ID ABG92709 standard; Protein; 310 AA.

XX ABG32709;  
 AC  
 XX  
 DT 18-NOV-2002 (first entry)  
 XX  
 DE Human secreted protein PRO1868.  
 XX  
 XX Human; secreted and transmembrane protein; PRO1800; PRO539;  
 KW PRO982; PRO1434; PRO1868; PRO1917; PRO1868; PRO3434; PRO1927;  
 KW inflammatory disorder; immune related disease; rheumatoid arthritis;  
 KW systemic lupus erythematosus; systemic sclerosis; thyroiditis;  
 KW autoimmune haemolytic anaemia; diabetes mellitus; infectious hepatitis;  
 KW psoriasis; allergic disease of the lung; graft-versus host disease;  
 KW tumour; gene therapy.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002098506-A1.  
 XX  
 PD 25-JUL-2002.  
 XX  
 PE 27-DEC-2001; 2001US-0033301.  
 XX  
 PR 04-AUG-1998; 98US-095325P.  
 PR 16-DEC-1998; 98US-112851P.  
 PR 16-DEC-1998; 98US-113145P.  
 PR 22-DEC-1998; 98US-113511P.  
 PR 12-JAN-1999; 99US-115558P.  
 PR 12-JAN-1999; 99US-115565P.  
 PR 12-JAN-1999; 99US-115733P.  
 PR 10-FEB-1999; 99US-119341P.  
 PR 10-FEB-1999; 99US-119537P.  
 PR 12-FEB-1999; 99US-119965P.  
 PR 29-OCT-1999; 99US-162506P.  
 PR 02-JUN-1999; 99WO-US12252.  
 PR 01-DEC-1999; 99WO-US28634.  
 PR 02-DEC-1999; 99WO-US28551.  
 PR 11-FEB-2000; 2000WO-US03565.  
 PR 22-FEB-2000; 2000WO-US04414.  
 PR 02-MAR-2000; 2000WO-US05841.  
 PR 30-MAR-2000; 2000WO-US08439.  
 PR 30-MAY-2000; 2000WO-US14941.  
 PR 02-JUN-2000; 2000WO-US15264.  
 PR 01-DEC-2000; 2000WO-US32678.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Botstein D, Desnovers L, Ferrara N, Fong S, Gao W, Goddard A;  
 PI Gurey AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;  
 PI Wood WJ;  
 XX  
 DR WPI; 2002-690475/74.  
 XX  
 DR N-PSDB; ABS68392.  
 XX  
 PT Novel secreted and transmembrane polypeptides and polynucleotides  
 PT useful for diagnosis and treatment of inflammatory disorders and  
 PT immune-related diseases, and identifying modulators  
 XX  
 XX Claim 12; Fig 14; 125pp; English.  
 XX  
 XX The invention relates to an isolated polypeptide having at least 80%  
 XX amino acid sequence identity to secreted and transmembrane polypeptides  
 XX PRO1800, PRO539, PRO982, PRO1434, PRO1863, PRO1917, PRO1868, PRO3434 or  
 XX PRO1927 and their encoding nucleic acids. Also included are vectors, host  
 XX cells and antibodies against PRO polypeptides. PRO proteins are useful  
 XX for identifying modulators of the polypeptide. PRO1868 useful for the  
 XX diagnosis and treatment of inflammatory and immune related diseases  
 XX including systemic lupus erythematosus, rheumatoid arthritis, systemic  
 XX sclerosis, autoimmune haemolytic anaemia, thyroiditis, diabetes mellitus,  
 XX infectious hepatitis, psoriasis, allergic diseases of the lung and  
 XX graft-versus host disease and tumours. Pro nucleic acids are useful for  
 XX constructing hybridisation probes for mapping the gene that encodes that  
 XX PRO and for the genetic analysis of individuals with genetic disorders,

CC and for generating transgenic animals which are useful in the development  
 CC and screening of therapeutically useful reagents. PRO nucleic acids are  
 CC also useful for gene therapy, chromosome identification, and tissue  
 CC typing. PRO proteins are useful as molecular weight markers for protein  
 CC electrophoresis purposes. The anti-PRO antibodies are useful in  
 CC diagnostic assays for PRO, e.g. detecting its expression in specific  
 CC cells, tissues or serum and for affinity purification of PRO.  
 CC The present sequence represents a PRO protein.  
 XX  
 SQ Sequence 310 AA;  
 XX  
 QY Query Match 67.4%; Score 209, DB 23; length 310;  
 Db Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDFELLFRGCLIGAVNKKSSNRTPVQEFSEVELSCITTSOT 60  
 Db 1 MALRRPRLRLCARLPDFELLFRGCLIGAVNKKSSNRTPVQEFSEVELSCITTSOT 60  
 QY 61 SDPRIEMWKIDQETTVFFDNKIQGDLAGRAEILGKTSLKIMVTRDSALYRCEVVAR 120  
 Db 61 SDPRIEMWKIDQETTVFFDNKIQGDLAGRAEILGKTSLKIMVTRDSALYRCEVVAR 120  
 QY 121 NDRKEIDIVIELTVQVKTPTVPCRVPAVGVKMATLHCQESGHPHYSWRNDVPL 180  
 Db 121 NDRKEIDIVIELTVQVKTPTVPCRVPAVGVKMATLHCQESGHPHYSWRNDVPL 180  
 QY 181 PTDSRANRPNSSSHNSETGLVFTVNHDDSQVYCIASNAGSARCEQENEVDL 240  
 Db 181 PTDSRANRPNSSSHNSETGLVFTVNHDDSQVYCIASNAGSARCEQENEVDL 240  
 QY 241 NIGGIIGVVLVLAVALITLIGICCAVRRGYFINNKQGESYKPKGPGVNYIRTBEG 300  
 Db 241 NIGGIIGVVLVLAVALITLIGICCAVRRGYFINNKQGESYKPKGPGVNYIRTBEG 300  
 QY 301 DFRHKSFFVI 310  
 Db 301 DFRHKSFFVI 310  
 XX  
 RESULT 15  
 ABG65296  
 ID ABG65296 standard; Protein, 310 AA.  
 XX  
 AC ABG65296;  
 XX  
 DT 27-AUG-2002 (first entry)  
 XX  
 DE Human albumin fusion protein #1971.  
 XX  
 XX Albumin fusion protein; therapeutic protein X; human albumin; HA;  
 KW human serum albumin; HSA; cancer; reproductive disorder;  
 KW digestive disorder; immune disorder; endocrine disorder;  
 KW haematopoietic disorder; neural disorder; connective disorder;  
 KW cytostatic; anti-infectivity; anti-inflammatory; anticancer;  
 KW immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;  
 KW neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;  
 KW osteopathic; antiarthritic.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 PN WO200177137-A1.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PD 12-APR-2001; 2001WO-US11988.  
 XX  
 PR 12-APR-2000; 2000US-229358P.  
 PR 25-APR-2000; 2000US-199384P.  
 PR 21-DEC-2000; 2000US-256931P.  
 XX  
 PA (HUMA-) HUMAN GENOME SCI INC.

XX Rosen CA, Haseltine WA;  
 PI WPI; 2002-010886/01.  
 DR New fusion protein for treating disease e.g. diabetes comprises an  
 XX albumin fused to a therapeutic protein -  
 XX Claim 1; Page 1893-1894; 2102pp; English.  
 XX The present invention relates to albumin fusion proteins comprising a  
 CC therapeutic protein X and human albumin (HA, also known as human serum  
 CC albumin, HSA). The proteins are useful for treating a disease or  
 CC disorder that may be modulated by therapeutic protein X. The albumin  
 CC extends the shelf-life of protein X, and may increase its biological  
 CC in vitro/in vivo activity. The protein is useful for treating and  
 CC diagnosing disorders such as cancer, reproductive disorders, digestive  
 CC disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders  
 CC (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders  
 CC (e.g. diabetes), haematopoietic disorders, neural disorders  
 CC (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,  
 CC encephalomyelitis, meningitis, schizophrenia), and connective disorders  
 CC (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin  
 CC fusion proteins of the invention.  
 CC  
 SQ Sequence 310 AA;  
 Query Match 67.4%; Score 209; DB 23; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDPFLLFRGCLIGAVNLKSSNTPVQEFESVELSCIITDSQT 60  
 DB 1 MALRRPRLRLCARLPDPFLLFRGCLIGAVNLKSSNTPVQEFESVELSCIITDSQT 60  
 QY 61 SDPRIEMKKIOBQOTTYVEFDNKKIQDLAGRAEILGKTSIKIWNVTRRDSALYRCVVAR 120  
 DB 61 SDPRIEMKKIOBQOTTYVEFDNKKIQDLAGRAEILGKTSIKIWNVTRRDSALYRCVVAR 120  
 QY 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 DB 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 QY 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 DB 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 QY 181 PTDSRANPFRNSSSHLNSSTGTLVFTAVHKDQSGQYCIASNDASARCEOEEMEVYDL 240  
 DB 181 PTDSRANPFRNSSSHLNSSTGTLVFTAVHKDQSGQYCIASNDASARCEOEEMEVYDL 240  
 QY 241 NIIGIIGVLLVLAVALITLIGICAYRRGYFINNKQDESYKPKPGVNYIRTDSEG 300  
 DB 241 NIIGIIGVLLVLAVALITLIGICAYRRGYFINNKQDESYKPKPGVNYIRTDSEG 300  
 QY 301 DFRHKSSFVI 310  
 DB 301 DFRHKSSFVI 310  
 DB 301 DFRHKSSFVI 310  
 RESULT 16  
 ID ABG65297 standard; Protein; 310 AA.  
 XX ABG65297;  
 XX 27-AUG-2002 (first entry)  
 DE Human albumin fusion protein #1972.  
 XX Human albumin fusion protein #1972.  
 KM Albumin fusion protein; therapeutic protein X; human albumin; HA;  
 KM human serum albumin; HSA; cancer; reproductive disorder;  
 KM digestive disorder; immune disorder; endocrine disorder;  
 KM haematopoietic disorder; neural disorder; connective disorder;  
 KM cytotoxic; antifertility; antiinflammatory; antitumor;  
 KM immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;  
 KM neuroprotective; antiparkinsonian; antimicrobial; neuroleptic;

KM osteopathic; antiarthritic.  
 XX Homo sapiens.  
 OS Synthetic.  
 OS WO200177137-A1.  
 PN 18-OCT-2001.  
 PD 12-APR-2001; 2001WO-US11988.  
 PF 12-APR-2001; 2000US-229358P.  
 PR 25-APR-2000; 2000US-19384P.  
 PR 21-DEC-2000; 2000US-256931P.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 PA Rosen CA, Haseltine WA;  
 PI WPI; 2002-010886/01.  
 DR New fusion protein for treating disease e.g. diabetes comprises an  
 XX albumin fused to a therapeutic protein -  
 XX Claim 1; Page 1895; 2102pp; English.  
 XX The present invention relates to albumin fusion proteins comprising a  
 CC therapeutic protein X and human albumin (HA, also known as human serum  
 CC albumin, HSA). The proteins are useful for treating a disease or  
 CC disorder that may be modulated by therapeutic protein X. The albumin  
 CC extends the shelf-life of protein X, and may increase its biological  
 CC in vitro/in vivo activity. The protein is useful for treating and  
 CC diagnosing disorders such as cancer, reproductive disorders, digestive  
 CC disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders  
 CC (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders  
 CC (e.g. diabetes), haematopoietic disorders, neural disorders  
 CC (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,  
 CC encephalomyelitis, meningitis, schizophrenia), and connective disorders  
 CC (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin  
 CC fusion proteins of the invention.  
 CC  
 SQ Sequence 310 AA;  
 Query Match 67.4%; Score 209; DB 23; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDPFLLFRGCLIGAVNLKSSNTPVQEFESVELSCIITDSQT 60  
 DB 1 MALRRPRLRLCARLPDPFLLFRGCLIGAVNLKSSNTPVQEFESVELSCIITDSQT 60  
 QY 61 SDPRIEMKKIOBQOTTYVEFDNKKIQDLAGRAEILGKTSIKIWNVTRRDSALYRCVVAR 120  
 DB 61 SDPRIEMKKIOBQOTTYVEFDNKKIQDLAGRAEILGKTSIKIWNVTRRDSALYRCVVAR 120  
 QY 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 DB 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 QY 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 DB 121 NDRKEIDEIVELTVQVKVPTVCRCVPKAVPVGKMATLHCQSESGHPRHYSWRNDVPL 180  
 QY 181 PTDSRANPFRNSSSHLNSSTGTLVFTAVHKDQSGQYCIASNDASARCEOEEMEVYDL 240  
 DB 181 PTDSRANPFRNSSSHLNSSTGTLVFTAVHKDQSGQYCIASNDASARCEOEEMEVYDL 240  
 QY 241 NIIGIIGVLLVLAVALITLIGICAYRRGYFINNKQDESYKPKPGVNYIRTDSEG 300  
 DB 241 NIIGIIGVLLVLAVALITLIGICAYRRGYFINNKQDESYKPKPGVNYIRTDSEG 300  
 QY 301 DFRHKSSFVI 310  
 DB 301 DFRHKSSFVI 310  
 DB 301 DFRHKSSFVI 310  
 RESULT 17

ABG65298  
ID ABG65298 standard; Protein; 310 AA.  
AC ABG65298;  
XX 27-AUG-2002 (first entry)  
XX  
XX Human albumin fusion protein #1973.  
XX  
XX Albumin fusion protein; therapeutic protein X; human albumin; HA;  
KW human serum albumin; HSA; cancer; reproductive disorder;  
KW digestive disorder; immune disorder; endocrine disorder;  
KW haematopoietic disorder; neural disorder; connective disorder;  
KW cyostatic; antileptility; antinflammatory; antilucer;  
KW immunomodulator; anti-HIV; antidiabetic; haemostatic; nootropic;  
KW osteoprotective; antiparkinsonian; antitricobial; neuroleptic;  
KW osteopathic; antiarthritic.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX WO200177137-A1.  
XX  
XX 18-OCT-2001.  
XX  
XX 12-APR-2001; 2001WO-US11988.  
XX  
XX 12-APR-2000; 2000US-229358P.  
PR 25-APR-2000; 2000US-199384P.  
PR 21-DEC-2000; 2000US-256931P.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Rosen CA, Haseltine WA;  
PI WPI; 2002-010886/01.  
XX  
XX New fusion protein for treating disease e.g. diabetes comprises an  
PT albumin fused to a therapeutic protein -  
XX  
XX Claim 1; Page 1896-1897; 2102pp; English.  
XX  
XX The present invention relates to albumin fusion proteins comprising a  
CC therapeutic protein X and human albumin (HA), also known as human serum  
CC albumin, HSA). The proteins are useful for treating a disease or  
CC disorder that may be modulated by therapeutic protein X. The albumin  
CC extends the shelf-life of protein X, and may increase its biological  
CC in vitro/in vivo activity. The protein is useful for treating and  
CC diagnosing disorders such as cancer, reproductive disorders, digestive  
CC disorders (e.g. Crohn's disease, ulcerative colitis), immune disorders  
CC (e.g. acquired immunodeficiency syndrome, AIDS), endocrine disorders  
CC (e.g. diabetes), haematopoietic disorders, neural disorders  
CC (e.g. Alzheimer's, Parkinson's, Creutzfeldt-Jacob disease,  
CC encephalomyelitis, meningitis, schizophrenia), and connective disorders  
CC (e.g. osteoporosis, arthritis). ABG63326-ABG65518 represent albumin  
CC fusion proteins of the invention.  
XX  
XX Sequence 310 AA;  
SQ  
Query Match 67.4%; Score 209; DB 23; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DB 121 NDRKEIDEIVIELTVQKPVTPVCRKAVPVGMATLHCQESGHPHYSWYRNDVPL 180  
QY 181 PTDSRANPRFRNSSSHLNSSETGLVFTAVAHKDSGOYYCIAANDAGSARCEOMEYDYL 240  
DB 181 PTDSRANPRFRNSSSHLNSSETGLVFTAVAHKDSGOYYCIAANDAGSARCEOMEYDYL 240  
QY 241 NIGGIIGVLVLAVALITLIGICCAVRGFFINNKODGSYKPKGPDGVNVIKRTDEEG 300  
DB 241 NIGGIIGVLVLAVALITLIGICCAVRGFFINNKODGSYKPKGPDGVNVIKRTDEEG 300  
QY 301 DFRKSSFVI 310  
DB 301 DFRKSSFVI 310  
RESULT 18  
ID ABB95553 standard; Protein; 310 AA.  
XX  
XX ABB95553;  
XX  
XX 19-JUL-2002 (first entry)  
XX  
XX Human angiogenesis related protein PRO1868 SEQ ID NO: 262.  
XX  
XX Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;  
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;  
KW cardiant; cyostatic; antiangiogenic; hypotensive; vulnerary;  
KW antileptosteric.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200208284-A2.  
XX  
XX 31-JAN-2002.  
XX  
XX 09-JUL-2001; 2001WO-US21735.  
XX  
XX 20-JUL-2000; 2000US-219556P.  
PR 25-JUL-2000; 2000US-220624P.  
PR 25-JUL-2000; 2000US-220624P.  
PR 28-JUL-2000; 2000WO-US20710.  
PR 02-AUG-2000; 2000US-226959P.  
PR 17-AUG-2000; 2000US-0643657.  
PR 23-AUG-2000; 2000WO-US23522.  
PR 24-AUG-2000; 2000WO-US23238.  
PR 07-SEP-2000; 2000US-230978P.  
PR 15-SEP-2000; 2000US-000000P.  
PR 18-SEP-2000; 2000US-0664610.  
PR 18-SEP-2000; 2000US-0665350.  
PR 24-OCT-2000; 2000US-242922P.  
PR 08-NOV-2000; 2000US-0709238.  
PR 08-NOV-2000; 2000WO-US09592.  
PR 10-NOV-2000; 2000WO-US10873.  
PR 01-DEC-2000; 2000WO-US32678.  
PR 20-DEC-2000; 2000US-0747259.  
PR 20-DEC-2000; 2000WO-US34956.  
PR 22-JAN-2001; 2001US-0767609.  
PR 28-FEB-2001; 2001US-0796498.  
PR 28-FEB-2001; 2001WO-US06520.  
PR 01-MAR-2001; 2001US-0506666.  
PR 09-MAR-2001; 2001US-0802706.  
PR 14-MAR-2001; 2001US-0806889.  
PR 22-MAR-2001; 2001US-0816744.  
PR 05-APR-2001; 2001US-0828368.  
PR 10-MAY-2001; 2001US-0854208.  
PR 10-MAY-2001; 2001US-0854280.  
PR 25-MAY-2001; 2001US-0860280.  
PR 25-MAY-2001; 2001US-0866034.  
PR 25-MAY-2001; 2001WO-US17092.  
PR 30-MAY-2001; 2001US-0870574.  
PR 30-MAY-2001; 2001WO-US17443.  
PR 01-JUN-2001; 2001WO-US17800.

PR 20-JUN-2001; 2001WO-US19692.  
 PR 28-JUN-2001; 2001WO-US00000.  
 XX  
 PA (GETH ) GENENTECH INC.  
 PA (BAKE) BAKER K P.  
 PA (FERR) FERRARA N.  
 PA (GERB) GERBER H.  
 PA (GERR) GERRISEN M E.  
 PA (GODO) GODDARD A.  
 PA (GODO) GODOWSKI P J.  
 PA (GURN) GURNEY A L.  
 PA (HILL) HILLAN K J.  
 PA (MARS) MARSTERS S A.  
 PA (PANJ) PAN J.  
 PA (PAON) PAONI N F.  
 PA (STEP) STEPHAN J F.  
 PA (WATA) WATANABE C K.  
 PA (WILL) WILLIAMS P W.  
 PA (WOOD) WOOD W I.  
 XX  
 XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A,  
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF,  
 PI Stephan JF, Watanabe CK, Williams PW, Wood WI, Ye W;  
 XX  
 DR WPI; 2002-171999/22.  
 XX N-PSDB; ABL95691.

PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,  
 PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial  
 PT infarction), endothelial or angiogenic disorders in a mammal -  
 XX  
 PS Claim 11; Fig 262; 567pp; English.

CC The present invention provides the protein and coding sequences of human  
 CC PRO proteins. These are useful for treating or diagnosing a  
 CC cardiovascular, endothelial or angiogenic disorder, including cardiac  
 CC hypertrophy, trauma, cancer, age-related macular degeneration,  
 CC atherosclerosis, hypertension, arterial stenosis, rheumatoid arthritis,  
 CC angina, myocardial infarction, thrombophlebitis, lymphangitis, tumour  
 CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound  
 CC healing. The present sequence is a PRO protein of the invention.  
 CC  
 XX

Sequence 310 AA;

Query Match 67.4%; Score 209; DB 23; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196; 1; Indels 0; Gaps 0;  
 Matches 309; Conservative 0; Mismatches 1;

QY 1 MLRRPRLRLCARLDPFLLLFRCGLIGAVNLKSNRTFVQEFSEVELSCIITDSQT 60  
 DB 1 MLRRPRLRLCARLDPFLLLFRCGLIGAVNLKSNRTFVQEFSEVELSCIITDSQT 60  
 QY 61 SPPRIWKIKIOBQTTTVPFNDKIQGLDGRAEILKTSIKTNVTRDSALYRCVVAR 120  
 DB 61 SPPRIWKIKIOBQTTTVPFNDKIQGLDGRAEILKTSIKTNVTRDSALYRCVVAR 120  
 QY 121 NDRKEIDEVIELTVQVKPTPCRVKAVPGVKMATLHQSESEGHPRPHYSYRNDVPL 180  
 DB 121 NDRKEIDEVIELTVQVKPTPCRVKAVPGVKMATLHQSESEGHPRPHYSYRNDVPL 180  
 QY 181 PTDSRANPRFRNSSHLSSETGLVFTAVHKDSDGOYCIASNDAGSARCEOEEMEVYDL 240  
 DB 181 PTDSRANPRFRNSSHLSSETGLVFTAVHKDSDGOYCIASNDAGSARCEOEEMEVYDL 240  
 QY 241 NIGGIIGVVLVLAVALITLIGICCAVRRGYFINNKQDGSYNNPGKPDGVNIRIDEG 300  
 DB 241 NIGGIIGVVLVLAVALITLIGICCAVRRGYFINNKQDGSYNNPGKPDGVNIRIDEG 300  
 QY 301 DFRHKSSFVI 310  
 DB 301 DFRHKSSFVI 310

RESULT 19  
 ABB84947  
 ID ABB84947 standard; Protein; 310 AA.  
 XX  
 AC ABB84947;  
 XX  
 DT 16-MAY-2002 (first entry)  
 XX  
 DE Human PRO1868 protein sequence SEQ ID NO:262.  
 XX  
 KW Human; angiogenesis; cardiac; cyrostatic; antiangiogenic; hypotensive;  
 KW vulnerable; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;  
 KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;  
 KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;  
 KW age-related macular degeneration; arterial stenosis; angina;  
 KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;  
 KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;  
 KW wound healing; chromosome mapping; gene mapping.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200200690-A2.  
 XX  
 PD 03-JAN-2002.  
 XX  
 PF 20-JUN-2001; 2001WO-US19692.  
 XX

PR 23-JUN-2000; 2000US-213637P.  
 PR 20-JUL-2000; 2000US-219556P.  
 PR 25-JUL-2000; 2000US-220624P.  
 PR 28-JUL-2000; 2000US-220664P.  
 PR 02-AUG-2000; 2000US-220695P.  
 PR 17-AUG-2000; 2000US-064365P.  
 PR 23-AUG-2000; 2000US-064365P.  
 PR 24-AUG-2000; 2000US-232328P.  
 PR 07-SEP-2000; 2000US-230978P.  
 PR 18-SEP-2000; 2000US-0664610.  
 PR 18-SEP-2000; 2000US-0665350.  
 PR 24-OCT-2000; 2000US-242922P.  
 PR 08-NOV-2000; 2000US-070923P.  
 PR 08-NOV-2000; 2000US-070923P.  
 PR 10-NOV-2000; 2000US-070923P.  
 PR 01-DEC-2000; 2000US-074725P.  
 PR 20-DEC-2000; 2000US-074725P.  
 PR 20-DEC-2000; 2000US-074725P.  
 PR 22-JAN-2001; 2001US-0767609.  
 PR 28-FEB-2001; 2001US-0767609.  
 PR 28-FEB-2001; 2001US-0767609.  
 PR 01-MAR-2001; 2001US-0767609.  
 PR 09-MAR-2001; 2001US-0802706.  
 PR 14-MAR-2001; 2001US-0806889.  
 PR 22-MAR-2001; 2001US-0816744.  
 PR 05-APR-2001; 2001US-0828366.  
 PR 10-MAY-2001; 2001US-0854208.  
 PR 10-MAY-2001; 2001US-0854280.  
 PR 25-MAY-2001; 2001US-0866028.  
 PR 25-MAY-2001; 2001US-0866034.  
 PR 25-MAY-2001; 2001US-0866034.  
 PR 30-MAY-2001; 2001US-0870574.  
 PR 30-MAY-2001; 2001US-0870574.  
 PR 01-JUN-2001; 2001US-0870574.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A,  
 PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF,  
 PI Stephan JF, Watanabe CK, Williams PW, Wood WI, Ye W;  
 XX  
 DR WPI; 2002-090516/12.  
 DR N-PSDB; ABL88202.  
 XX

One hundred and eighty seven nucleic acids encoding PRO polypeptides.

PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial  
infarction), endothelial or angiogenic disorders in a mammal -  
PS Claim 11; Fig 262; 565pp; English.  
XX  
CC ABB88072 to ABB88258 encode the PRO proteins given in ABB88417 to  
CC ABB885003. The PRO proteins and polynucleotides have cardiant, cytostatic,  
CC antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic  
CC activities, and can be used in gene therapy. The PRO polynucleotides,  
CC proteins, agonists and antagonists are useful for treating or diagnosing  
CC a cardiovascular, endothelial or angiogenic disorder in a mammal,  
CC e.g. cardiac hypertrophy, trauma, cancer, age-related macular  
CC degeneration, atherosclerosis, hypertension, arterial reestenosis,  
CC rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,  
CC lymphangitis, tumour angiogenesis (such as breast carcinoma and liver  
CC carcinoma) and wound healing. The PRO polynucleotides have applications  
CC in molecular biology, including use as hybridisation probes, and in  
CC chromosome and gene mapping. ABB88259 to ABB88267 represent primers and  
CC probes used in the exemplification of the present invention.  
XX  
SQ Sequence 310 AA;  
Query Match 67.4%; Score 209; DB 23; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MALRRPRLRLCALPDPFLLLRGCLIGAVNKKSNRTVPVOEPESVELSCITTSQT 60  
Db 1 MALRRPRLRLCALPDPFLLLRGCLIGAVNKKSNRTVPVOEPESVELSCITTSQT 60  
QY 61 SDPRIEWKKIODEQITVFFPNKIQGDLGRAELIGKTSLKIMVTRRSALYRCEVAR 120  
Db 61 SDPRIEWKKIODEQITVFFPNKIQGDLGRAELIGKTSLKIMVTRRSALYRCEVAR 120  
QY 121 NDRKEIDEIVELVQVKVPTVCKVPAVVGKMATLHCESGHPHYRWYNDVPL 180  
Db 121 NDRKEIDEIVELVQVKVPTVCKVPAVVGKMATLHCESGHPHYRWYNDVPL 180  
QY 181 PTDSRANRPNSSSHNSERTGLVFTAVHKDDSGQVCIASNDAGSARCEQEMEVYDL 240  
Db 181 PTDSRANRPNSSSHNSERTGLVFTAVHKDDSGQVCIASNDAGSARCEQEMEVYDL 240  
QY 241 NIGGIIGVLLVAVLALITLIGICAYRGYFINNKDGESYKPKGPDGVNVRTDEG 300  
Db 241 NIGGIIGVLLVAVLALITLIGICAYRGYFINNKDGESYKPKGPDGVNVRTDEG 300  
QY 301 DFRHKSSEFVI 310  
Db 301 DFRHKSSEFVI 310  
RESULT 20  
ABU69682  
ID ABU69682 standard; Protein; 310 AA.  
XX  
AC ABU69682;  
XX  
DT 05-JUN-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO1868+H30.  
XX  
KW Human; secreted and transmembrane protein; gene therapy; psoriasis;  
KW enterocolitis; gastrointestinal ulceration; skin disease; keratinocyte  
KW keratinocyte differentiation; epithelial cancer; Alzheimer's disease;  
KW squamous cell carcinoma; Parkinson's disease; inflammatory disease;  
KW amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;  
KW multiple sclerosis; organ failure; atherosclerosis; cardiac injury;  
KW infertility; birth defect; premature aging; AIDS; cancer;  
KW diabetic complication; wound repair; tissue re-growth.  
XX  
OS Homo sapiens.  
XX  
PN US2003017463-A1.

XX 23-JAN-2003.  
PD 11-JUL-2001; 2001US-0903640.  
XX  
XX 10-SEP-1998; 98MO-US18924.  
PR 14-SEP-1998; 98MO-US19177.  
PR 16-SEP-1998; 98MO-US19310.  
PR 17-SEP-1998; 98MO-US19437.  
PR 01-DEC-1998; 98MO-US25108.  
PR 08-SEP-1999; 99MO-US20594.  
PR 13-SEP-1999; 99MO-US20944.  
PR 15-SEP-1999; 99MO-US21050.  
PR 15-SEP-1999; 99MO-US21547.  
PR 05-OCT-1999; 99MO-US23089.  
PR 29-NOV-1999; 99MO-US28214.  
PR 30-NOV-1999; 99MO-US28313.  
PR 01-DEC-1999; 99MO-US28301.  
PR 02-DEC-1999; 99MO-US28564.  
PR 02-DEC-1999; 99MO-US28565.  
PR 16-DEC-1999; 99MO-US30095.  
PR 20-DEC-1999; 99MO-US30911.  
PR 20-DEC-1999; 99MO-US30999.  
PR 05-JAN-2000; 2000MO-US00219.  
PR 11-FEB-2000; 2000MO-US03565.  
PR 22-FEB-2000; 2000MO-US04414.  
PR 24-FEB-2000; 2000MO-US05004.  
PR 02-MAR-2000; 2000MO-US05841.  
PR 20-MAR-2000; 2000MO-US07377.  
PR 30-MAR-2000; 2000MO-US08439.  
PR 22-MAY-2000; 2000MO-US14042.  
PR 02-JUN-2000; 2000MO-US15264.  
PR 28-JUL-2000; 2000MO-US20710.  
PR 24-AUG-2000; 2000MO-US23328.  
PR 17-SEP-1997; 97US-058113P.  
PR 17-SEP-1997; 97US-059115P.  
PR 17-SEP-1997; 97US-059117P.  
PR 17-SEP-1997; 97US-059119P.  
PR 17-SEP-1997; 97US-059121P.  
PR 17-SEP-1997; 97US-059122P.  
PR 17-SEP-1997; 97US-059184P.  
PR 18-SEP-1997; 97US-059263P.  
PR 18-SEP-1997; 97US-059266P.  
PR 15-OCT-1997; 97US-062125P.  
PR 17-OCT-1997; 97US-062285P.  
PR 17-OCT-1997; 97US-062287P.  
PR 21-OCT-1997; 97US-063486P.  
PR 24-OCT-1997; 97US-062814P.  
PR 24-OCT-1997; 97US-062816P.  
PR 24-OCT-1997; 97US-063045P.  
PR 24-OCT-1997; 97US-063120P.  
PR 24-OCT-1997; 97US-063121P.  
PR 24-OCT-1997; 97US-063127P.  
PR 24-OCT-1997; 97US-063128P.  
PR 27-OCT-1997; 97US-063329P.  
PR 27-OCT-1997; 97US-063329P.  
PR 28-OCT-1997; 97US-063541P.  
PR 28-OCT-1997; 97US-063542P.  
PR 28-OCT-1997; 97US-063544P.  
PR 28-OCT-1997; 97US-063549P.  
PR 28-OCT-1997; 97US-063550P.  
PR 28-OCT-1997; 97US-063564P.  
PR 29-OCT-1997; 97US-063435P.  
PR 29-OCT-1997; 97US-063704P.  
PR 29-OCT-1997; 97US-063732P.  
PR 29-OCT-1997; 97US-063734P.  
PR 29-OCT-1997; 97US-063735P.  
PR 29-OCT-1997; 97US-063738P.  
PR 29-OCT-1997; 97US-064215P.  
PR 31-OCT-1997; 97US-063870P.  
PR 31-OCT-1997; 97US-064103P.  
PR 03-NOV-1997; 97US-064248P.  
PR 07-NOV-1997; 97US-064809P.

PR 12-NOV-1997; 97US-065186P.  
 PR 17-NOV-1997; 97US-065846P.  
 PR 18-NOV-1997; 97US-065693P.  
 PR 21-NOV-1997; 97US-066120P.  
 PR 21-NOV-1997; 97US-066364P.  
 PR 24-NOV-1997; 97US-066453P.  
 PR 24-NOV-1997; 97US-066466P.  
 PR 24-NOV-1997; 97US-066511P.  
 PR 24-NOV-1997; 97US-066770P.  
 PR 24-NOV-1997; 97US-066772P.  
 PR 25-NOV-1997; 97US-066840P.  
 PR 12-DEC-1997; 97US-069425P.  
 PR 04-JUN-1998; 98US-088026P.  
 PR 10-SEP-1998; 98US-099803P.  
 PR 14-SEP-1998; 98US-100262P.  
 PR 17-SEP-1998; 98US-100858P.  
 PR 13-OCT-1998; 98US-104080P.  
 PR 20-NOV-1998; 98US-109304P.  
 PR 22-DEC-1998; 98US-113296P.  
 PR 07-JUL-1999; 99US-143048P.  
 PR 26-JUL-1999; 99US-145698P.  
 PR 28-JUL-1999; 99US-146222P.  
 PR 18-SEP-2000; 2000US-0665350.

(GETH ) GENENTECH INC.

PA Ashkenazi A, Borstein D, Desnoyers L, Eaton DL, Ferrara N;  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
 PI Godowski P, Grimaldi JC, Gurney AL, Hillan KJ, Kijavrin IJ;  
 PI Mather JP, Pan U, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;

DR WPI: 2003-341586/32.  
 DR N-PSDB: ACAS5169.

PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing  
 PT or treating inflammatory diseases, organ failure, atherosclerosis,  
 PT cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or  
 PT Parkinson's disease -

XX Claim 12; Fig 124; 473pp; English.

PS The invention describes sixty one nucleic acids encoding PRO polypeptides  
 XX (secreted and transmembrane). The PRO polypeptides and nucleic acids are  
 CC useful in diagnosing or treating enterocolitis, gastrointestinal  
 CC ulceration, skin diseases associated with abnormal keratinocyte  
 CC differentiation, e.g. psoriasis or epithelial cancers such as squamous  
 CC cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic  
 CC lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,  
 CC asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac  
 CC injury, infertility, birth defects, premature aging, AIDS, cancer,  
 CC diabetic complications, or mutations in general. The polypeptides are  
 CC also useful for wound repair and associated therapies concerned with  
 CC re-growth of tissue. The PRO polypeptides and nucleic acid molecules  
 CC are also useful in gene therapy, and anti-molecular weight markers for  
 CC protein electrophoresis purposes. The anti-PRO antibodies may be used  
 CC in diagnostic assays for PRO, or for the affinity purification of PRO  
 CC from recombinant cell culture or natural sources. This is the amino  
 CC acid sequence of a novel human PRO polypeptide.

CC Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;  
 Best Local Similarity 99.7%; Pred. NO. 1e-196; 1; Indels 0; Gaps 0;  
 Matches 309; Conservative 0; Mismatches 1;

QY 1 MALRRPRRLCARLDPFLLLRGCLIGAVNLKSSNRPVQEFESVELSCIITDSQT 60  
 DB 1 MALRRPRRLCARLDPFLLLRGCLIGAVNLKSSNRPVQEFESVELSCIITDSQT 60  
 QY 61 SDPRIEMKKIQDEQTTVFFPNKIQGLDLAGRAELIKTSIKIWNVTRDSALYRCEVVAR 120  
 DB 61 SDPRIEMKKIQDEQTTVFFPNKIQGLDLAGRAELIKTSIKIWNVTRDSALYRCEVVAR 120

QY 121 NDRKEIDEIVIELTVQVKNPVPICRVPKAVPVGKQATLHCQESGHPRPHTSWTRNDVPL 180  
 DB 121 NDRKEIDEIVIELTVQVKNPVPICRVPKAVPVGKQATLHCQESGHPRPHTSWTRNDVPL 180  
 QY 181 PTDSRANRFRNSSSHLNSFGLTVFTAVHNDSDGQVYCIASNDAGSARCEQOEWEVYDL 240  
 DB 181 PTDSRANRFRNSSSHLNSFGLTVFTAVHNDSDGQVYCIASNDAGSARCEQOEWEVYDL 240  
 QY 241 NIGGIIGVLVLAVALITLIGICCAVRRGYFINNKQDGESYKNPKGPDGVNVIPTDEEG 300  
 DB 241 NIGGIIGVLVLAVALITLIGICCAVRRGYFINNKQDGESYKNPKGPDGVNVIPTDEEG 300  
 QY 301 DERHNSFVI 310  
 DB 301 DERHNSFVI 310

RESULT 21

ID ABU71505 standard; Protein; 310 AA.

AC ABU71505;

DT 10-JUN-2003 (first entry)

DE Human PRO polypeptide #61.

XX Human; secreted and transmembrane protein; PRO polypeptide; cancer;  
 KW Alzheimer's disease; ischaemia; cytostatic; nootropic; vasotropic;  
 KW neuroprotective.

OS Homo sapiens.

XX US2002192659-A1.

XX 19-DEC-2002.

PF 10-JUL-2001; 2001US-0902853.

PR 10-SEP-1998; 98WO-US18824.  
 PR 14-SEP-1998; 98WO-US19177.  
 PR 16-SEP-1998; 98WO-US19330.  
 PR 17-SEP-1998; 98WO-US19437.  
 PR 01-DEC-1998; 98WO-US25108.  
 PR 08-SEP-1999; 99WO-US20594.  
 PR 13-SEP-1999; 99WO-US20944.  
 PR 15-SEP-1999; 99WO-US21090.  
 PR 15-SEP-1999; 99WO-US21547.  
 PR 05-OCT-1999; 99WO-US23089.  
 PR 02-DEC-1999; 99WO-US28301.  
 PR 02-DEC-1999; 99WO-US28564.  
 PR 16-DEC-1999; 99WO-US30095.  
 PR 20-DEC-1999; 99WO-US30911.  
 PR 05-JAN-2000; 2000WO-US00219.  
 PR 11-FEB-2000; 2000WO-US03565.  
 PR 22-FEB-2000; 2000WO-US04414.  
 PR 28-JUL-2000; 2000WO-US20710.  
 PR 24-AUG-2000; 2000WO-US23328.  
 PR 17-SEP-1997; 97US-059113P.  
 PR 17-SEP-1997; 97US-059115P.  
 PR 17-SEP-1997; 97US-059266P.  
 PR 18-SEP-1997; 97US-062125P.  
 PR 15-OCT-1997; 97US-062125P.  
 PR 17-OCT-1997; 97US-062287P.  
 PR 21-OCT-1997; 97US-063486P.  
 PR 24-OCT-1997; 97US-062814P.  
 PR 24-OCT-1997; 97US-062816P.

PA (GETH ) GENENTECH INC.

XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IU;  
PI Macher JP, Pan J, Paoni NP, Roy MA, Stewart TA, Tumas D;  
PI Williams FM, Wood WI;  
XX WPI; 2003-361832/34.  
DR N-PSDB; ACAS8654.  
XX  
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or  
PT PRO1868, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy  
XX  
PS Claim 12; Fig 124; 474p; English.  
XX  
CC The present invention relates to the isolation of novel human secreted  
CC and transmembrane proteins (PRO polypeptides), and the polynucleotide  
CC sequences encoding them. The polynucleotide sequences are useful in  
CC molecular biology, as hybridisation probes, in chromosome and gene  
CC mapping, in generating antisense RNA and DNA, and in gene therapy. The  
CC polynucleotide sequences may also be used in preparing PRO polypeptides  
CC by recombinant techniques, and in generating either transgenic animals  
CC or knock-out animals which, in turn, are useful in the development and  
CC screening of therapeutically useful reagents. The PRO polypeptides or  
CC their antibodies are useful in preparing a medicament for treating a  
CC condition responsive to the polypeptide or antibody, such as cancer.  
CC Alzheimer's disease or ischaemia, and in various diagnostic assays.  
CC ABU71445-ABU71505 represent human PRO polypeptides of the invention.  
XX  
SQ Sequence 310 AA;  
XX  
Query Match 67.4%; Score 209; DB 24; Length 310;  
Best Local Similarity 99.7%; Pred No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

XX OS Homo sapiens.  
XX XX US2003003530-A1.  
XX PD 02-JAN-2003.  
XX PF 11-JUL-2001; 2001US-0904011.  
XX PR 10-SEP-1998; 98WO-US18824.  
XX PR 14-SEP-1998; 98WO-US19177.  
XX PR 16-SEP-1998; 98WO-US19330.  
XX PR 17-SEP-1998; 98WO-US19437.  
XX PR 01-DEC-1998; 98WO-US25108.  
XX PR 08-SEP-1999; 99WO-US20594.  
XX PR 13-SEP-1999; 99WO-US20944.  
XX PR 15-SEP-1999; 99WO-US21090.  
XX PR 15-SEP-1999; 99WO-US21547.  
XX PR 05-OCT-1999; 99WO-US23089.  
XX PR 29-NOV-1999; 99WO-US28214.  
XX PR 30-NOV-1999; 99WO-US28313.  
XX PR 01-DEC-1999; 99WO-US28301.  
XX PR 02-DEC-1999; 99WO-US28564.  
XX PR 16-DEC-1999; 99WO-US28565.  
XX PR 20-DEC-1999; 99WO-US30911.  
XX PR 20-DEC-1999; 99WO-US30999.  
XX PR 05-JAN-2000; 2000WO-US00219.  
XX PR 11-FEB-2000; 2000WO-US03565.  
XX PR 22-FEB-2000; 2000WO-US04414.  
XX PR 24-FEB-2000; 2000WO-US05004.  
XX PR 02-MAR-2000; 2000WO-US05841.  
XX PR 20-MAR-2000; 2000WO-US07377.  
XX PR 30-MAR-2000; 2000WO-US08439.  
XX PR 22-MAY-2000; 2000WO-US14042.  
XX PR 02-JUN-2000; 2000WO-US15264.  
XX PR 28-JUL-2000; 2000WO-US20710.  
XX PR 24-AUG-2000; 2000WO-US23328.  
XX PR 17-SEP-1997; 97US-059113P.  
XX PR 17-SEP-1997; 97US-059115P.  
XX PR 17-SEP-1997; 97US-059117P.  
XX PR 17-SEP-1997; 97US-059119P.  
XX PR 17-SEP-1997; 97US-059121P.  
XX PR 17-SEP-1997; 97US-059122P.  
XX PR 17-SEP-1997; 97US-059184P.  
XX PR 18-SEP-1997; 97US-059263P.  
XX PR 18-SEP-1997; 97US-059266P.  
XX PR 15-OCT-1997; 97US-062125P.  
XX PR 17-OCT-1997; 97US-062285P.  
XX PR 17-OCT-1997; 97US-062287P.  
XX PR 21-OCT-1997; 97US-063486P.  
XX PR 24-OCT-1997; 97US-062814P.  
XX PR 24-OCT-1997; 97US-062816P.  
XX PR 24-OCT-1997; 97US-063045P.  
XX PR 24-OCT-1997; 97US-063120P.  
XX PR 24-OCT-1997; 97US-063121P.  
XX PR 24-OCT-1997; 97US-063127P.  
XX PR 24-OCT-1997; 97US-063128P.  
XX PR 27-OCT-1997; 97US-063327P.  
XX PR 27-OCT-1997; 97US-063329P.  
XX PR 28-OCT-1997; 97US-063541P.  
XX PR 28-OCT-1997; 97US-063542P.  
XX PR 28-OCT-1997; 97US-063544P.  
XX PR 28-OCT-1997; 97US-063549P.  
XX PR 28-OCT-1997; 97US-063550P.  
XX PR 28-OCT-1997; 97US-063564P.  
XX PR 29-OCT-1997; 97US-063435P.  
XX PR 29-OCT-1997; 97US-063704P.  
XX PR 29-OCT-1997; 97US-063732P.  
XX PR 29-OCT-1997; 97US-063734P.  
XX PR 29-OCT-1997; 97US-063735P.  
XX PR 29-OCT-1997; 97US-063738P.  
XX PR 29-OCT-1997; 97US-064215P.

PR 31-OCT-1997; 97US-063870P.  
 PR 31-OCT-1997; 97US-064103P.  
 PR 03-NOV-1997; 97US-064248P.  
 PR 07-NOV-1997; 97US-064809P.  
 PR 12-NOV-1997; 97US-065186P.  
 PR 17-NOV-1997; 97US-065846P.  
 PR 18-NOV-1997; 97US-065693P.  
 PR 21-NOV-1997; 97US-066120P.  
 PR 21-NOV-1997; 97US-066364P.  
 PR 24-NOV-1997; 97US-066453P.  
 PR 24-NOV-1997; 97US-066466P.  
 PR 24-NOV-1997; 97US-066511P.  
 PR 24-NOV-1997; 97US-066770P.  
 PR 24-NOV-1997; 97US-066772P.  
 PR 18-SEP-2000; 2000US-0665350.

(GENTH) GENENTECH INC.

PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,  
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gertschen ME, Goddard A,  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ,  
 PI Mathner JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D,  
 PI Williams PM, Wood WI;

WI: 2003-329602/31.  
 N-PSDB; ACA60361.

PT New transmembrane polypeptides and nucleic acids encoding the  
 PT polypeptides, useful in gene therapy, in chromosome identification, as  
 PT chromosome markers, in generating probes and in tissue typing

Claim 12; Fig 124; 484p; English.

XX The invention relates to an isolated nucleic acid with at least 80%  
 CC nucleic acid sequence identity to a nucleotide sequence encoding one of  
 CC 61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a  
 CC PRO protein extracellular domain. Also included are a vector comprising  
 CC the PRO nucleic acid, a host cell comprising the vector, producing a PRO  
 CC polypeptide (by culturing the host cell for the expression of the PRO  
 CC polypeptide, and recovering the PRO polypeptide from the cell culture),  
 CC an isolated PRO polypeptide (having at least 80% sequence identity  
 CC to: (a) an amino acid sequence selected from the 61 PRO proteins;  
 CC (b) an amino acid sequence encoded by a nucleic acid molecule deposited  
 CC with an ATCC number (detailed in the specification); or (c) an  
 CC extracellular domain of a PRO polypeptide or to a PRO polypeptide lacking  
 CC its associated signal peptide), a chimeric molecule comprising a PRO  
 CC polypeptide fused to a heterologous amino acid sequence, an anti-PRO  
 CC antibody, detecting a PRO245 or PRO1868 in a sample suspected of  
 CC containing the polypeptide, linking a bioactive molecule to a cell  
 CC expressing a PRO245 or PRO1868 and modulating at least one biological  
 CC activity of a cell expressing a PRO245 or PRO1868. Nucleic acids which  
 CC encode PRO can be used to generate either transgenic animals or knock-out  
 CC animals which may be used in the development and screening of  
 CC therapeutically useful reagents. The nucleic acids may also be used in  
 CC gene therapy, in chromosome identification, as chromosome markers, or in  
 CC generating probes. The PRO polypeptides are useful as molecular markers  
 CC for protein electrophoresis, and the isolated nucleic acids may be used  
 CC for recombinantly expressing those markers. The PRO polypeptides and  
 CC nucleic acids may also be used in tissue typing. Anti-PRO antibodies  
 CC are useful in diagnostic assays for PRO, and in affinity purification  
 CC of PRO from recombinant cell culture or natural sources. The  
 CC present sequence represents a PRO protein.

XX Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MALRRPRRLCARLDFLLILFRGCLIGAVNKKSNRTPVQEFSEVSLCTIDSDT 60  
 DB 1 MALRRPRRLCARLDFLLILFRGCLIGAVNKKSNRTPVQEFSEVSLCTIDSDT 60

QY 61 SDRPRLEMKIODEQTYTFPDKKIQGDLAGAEILGKTSKIMVNTDRDSALYRCVVAR 120  
 DB 61 SDRPRLEMKIODEQTYTFPDKKIQGDLAGAEILGKTSKIMVNTDRDSALYRCVVAR 120  
 QY 121 NDRKREIDIVIELTAYQVAPVTPVCKVPRKAVGVGKATLHCESECHPPHYSWYNDVPL 180  
 DB 121 NDRKREIDIVIELTAYQVAPVTPVCKVPRKAVGVGKATLHCESECHPPHYSWYNDVPL 180  
 QY 181 PTDSRANFRFNSSSHLNSGTGLVFTAVHKDDSGQYCIASNDAGSARCEQEMEVYDL 240  
 DB 181 PTDSRANFRFNSSSHLNSGTGLVFTAVHKDDSGQYCIASNDAGSARCEQEMEVYDL 240  
 QY 241 NIGGIIGVLLVAVLALITLIGICCAVRRGYFINNKKDGESEYKNGKPDGVNYITDEEG 300  
 DB 241 NIGGIIGVLLVAVLALITLIGICCAVRRGYFINNKKDGESEYKNGKPDGVNYITDEEG 300

QY 301 DFRHKSFEVI 310

DB 301 DFRHKSFEVI 310

RESULT 23

ID ABU66838 standard; Protein; 310 AA.

ABU66838;

DT 23-MAY-2003 (first entry)

DE Human PRO polypeptide #269.

KW Human; PRO polypeptide; secreted and transmembrane protein;  
 KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;  
 KW differentiation; chondrocyte; tumour; genetic disorder;

KW cytostatic.

OS Homo sapiens.

PN US2003036180-A1.

PD 20-FEB-2003.

XX 09-MAY-2002; 2002US-0143114.

PR 31-MAR-1997; 97WO-US05230.

PR 12-JUN-1998; 98WO-US12456.

PR 14-JUL-1998; 98WO-US14552.

PR 28-AUG-1998; 98WO-US17888.

PR 10-SEP-1998; 98WO-US18824.

PR 14-SEP-1998; 98WO-US19093.

PR 14-SEP-1998; 98WO-US19177.

PR 16-SEP-1998; 98WO-US19330.

PR 17-SEP-1998; 98WO-US19437.

PR 07-OCT-1998; 98WO-US21141.

PR 29-OCT-1998; 98WO-US22991.

PR 20-NOV-1998; 98WO-US24855.

PR 01-DEC-1998; 98WO-US25108.

PR 05-JAN-1999; 99WO-US00106.

PR 08-MAR-1999; 99WO-US00208.

PR 10-MAR-1999; 99WO-US05190.

PR 20-APR-1999; 99WO-US08615.

PR 14-MAY-1999; 99WO-US10733.

PR 02-JUN-1999; 99WO-US12252.

PR 01-SEP-1999; 99WO-US20111.

PR 08-SEP-1999; 99WO-US20944.

PR 13-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.

PR 05-OCT-1999; 99WO-US23089.

PR 29-NOV-1999; 99WO-US28214.

PR 30-NOV-1999; 99WO-US28313.

```

PR 30-NOV-1999; 99WO-US28409.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 02-DEC-1999; 99WO-US28551.
PR 02-DEC-1999; 99WO-US28564.
PR 02-DEC-1999; 99WO-US28565.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 20-DEC-1999; 99WO-US30999.
PR 22-DEC-1999; 99WO-US30720.
PR 30-DEC-1999; 99WO-US31243.
PR 30-DEC-1999; 99WO-US31274.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00277.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 18-FEB-2000; 2000WO-US04342.
PR 22-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 01-MAR-2000; 2000WO-US05601.
PR 02-MAR-2000; 2000WO-US05746.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 21-MAR-2000; 2000WO-US07532.
PR 30-MAR-2000; 2000WO-US08439.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUN-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 25-MAY-2001; 2001WO-US17092.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 22-JUN-2001; 2001WO-US20116.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 20-FEB-2000; 2000US-0747259.
PR 28-FEB-2001; 2001US-0796498.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 05-APR-2001; 2001US-0816744.
PR 22-MAR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 18-MAY-2001; 2001US-0860216.
PR 25-MAY-2001; 2001US-0866028.
PR 01-JUN-2001; 2001US-0872035.
PR 05-JUN-2001; 2001US-0874503.
PR 14-JUN-2001; 2001US-0882636.
PR 19-JUN-2001; 2001US-0886342.
PR 21-JUN-2001; 2001US-0887879.
PR 18-JUL-2001; 2001US-0908827.
PR 06-AUG-2001; 2001US-0924419.
PR 09-AUG-2001; 2001US-0927796.
PR 16-AUG-2001; 2001US-0931636.
PR 19-DEC-2001; 2001US-0028072.
PR
XX
XX
PA (GETH ) GENENTECH INC.
XX

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerltsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z,
DR WPI; 2003-332040/31.
DR N-PSDB; ACA03871.
XX
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in
PT tissue typing, and in chromosome identification -
XX
XX
PS Claim 12; Fig 538; 660pp; English.
XX
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The
CC PRO polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for
CC linking bioactive molecules to cells expressing PRO polypeptides,
CC for modulating biological activities of cells expressing PRO
CC polypeptides, and for identifying agonists or antagonists.
CC The PRO polypeptides are useful for stimulating the release of
CC tumour necrosis factor (TNF)-alpha from human blood, for stimulating the
CC proliferation or differentiation of chondrocytes, and detecting the
CC presence of tumours. The polynucleotide sequences encoding PRO
CC polypeptides are useful as hybridisation probes, in chromosome and
CC gene mapping, in the generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptides, for generating transgenic animals or
CC knockout animals, for the genetic analysis of individuals with genetic
CC disorders, and in gene therapy. AB06570-AB06844 represent the human
CC Note: The sequence data for this patent was obtained in electronic
CC format directly from the USPTO web site at
CC seqdata.uspto.gov/pepidentry.html.
XX
SQ Sequence 310 AA;
Query Match 67.4%; Score 209; DB 24; Length 310;
Best Local Similarity 99.7%; Pred. No. 1e-196;
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MALRRPRLRLCARLPDFLLLRGCLIGAVNKKSSNRTPVVOEFPSVELSCIITDSQT 60
DB 1 MALRRPRLRLCARLPDFLLLRGCLIGAVNKKSSNRTPVVOEFPSVELSCIITDSQT 60
QY 61 SDPRIEMWKIODEQTIVFPFNKIQGLAGRAELIGTSLKINWVTRDSALYCEVVAR 120
DB 61 SDPRIEMWKIODEQTIVFPFNKIQGLAGRAELIGTSLKINWVTRDSALYCEVVAR 120
QY 121 NDRKEIDEIVELTVQKPTVPVCRVPAVGVGMATLHCQESGHRPHYSWTRNDVPL 180
DB 121 NDRKEIDEIVELTVQKPTVPVCRVPAVGVGMATLHCQESGHRPHYSWTRNDVPL 180
QY 181 PTDSRANPRFRNSSSHINSETGLVFTAVHKDSDGOYCIASNDAGSARCEQMEYVDL 240
DB 181 PTDSRANPRFRNSSSHINSETGLVFTAVHKDSDGOYCIASNDAGSARCEQMEYVDL 240
QY 241 NIGGIIGVLLVLAVALITLIGICAYRRGYFINNKGDSYKNGKPGDGVNVRTDEG 300
DB 241 NIGGIIGVLLVLAVALITLIGICAYRRGYFINNKGDSYKNGKPGDGVNVRTDEG 300
QY 301 DFRKSSFVI 310
DB 301 DFRKSSFVI 310
RESULT 24
ABU67114
ID ABU67114 standard; Protein: 310 AA.
XX
XX AC ABU67114;
XX
XX DT 27-MAY-2003 (first entry)
XX

```

DE Human secreted/transmembrane, PRO, protein SEQ ID 538.  
XX  
XX Human; secreted protein; transmembrane protein; PRO;  
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;  
KW infertility; birth defects; premature aging; AIDS; biosensor;  
KW acquired immunodeficiency syndrome; cancer; diabetic complication;  
KW bioreactor; tumour.  
XX  
OS Homo sapiens.  
XX  
XX US2003032155-A1.  
XX  
XX 13-FEB-2003.  
XX  
XX 03-MAY-2002; 2002US-0137865.  
XX  
PR 31-MAR-1997; 97WO-US05330.  
PR 12-JUN-1998; 98WO-US12456.  
PR 14-JUL-1998; 98WO-US14552.  
PR 28-AUG-1998; 98WO-US17888.  
PR 10-SEP-1998; 98WO-US18824.  
PR 14-SEP-1998; 98WO-US19093.  
PR 14-SEP-1998; 98WO-US19094.  
PR 14-SEP-1998; 98WO-US19177.  
PR 16-SEP-1998; 98WO-US19330.  
PR 17-SEP-1998; 98WO-US19437.  
PR 07-OCT-1998; 98WO-US21141.  
PR 29-OCT-1998; 98WO-US22891.  
PR 29-OCT-1998; 98WO-US22892.  
PR 20-NOV-1998; 98WO-US24855.  
PR 01-DEC-1998; 98WO-US25108.  
PR 05-JAN-1999; 99WO-US00106.  
PR 08-MAR-1999; 99WO-US05028.  
PR 10-MAR-1999; 99WO-US05190.  
PR 20-APR-1999; 99WO-US08615.  
PR 14-MAY-1999; 99WO-US10733.  
PR 02-JUN-1999; 99WO-US12252.  
PR 01-SEP-1999; 99WO-US20111.  
PR 08-SEP-1999; 99WO-US20594.  
PR 13-SEP-1999; 99WO-US20934.  
PR 15-SEP-1999; 99WO-US21090.  
PR 15-SEP-1999; 99WO-US21547.  
PR 05-OCT-1999; 99WO-US23089.  
PR 29-NOV-1999; 99WO-US28214.  
PR 30-NOV-1999; 99WO-US28313.  
PR 01-DEC-1999; 99WO-US28409.  
PR 01-DEC-1999; 99WO-US28301.  
PR 02-DEC-1999; 99WO-US28634.  
PR 02-DEC-1999; 99WO-US28654.  
PR 02-DEC-1999; 99WO-US28655.  
PR 16-DEC-1999; 99WO-US30095.  
PR 20-DEC-1999; 99WO-US30911.  
PR 20-DEC-1999; 99WO-US30999.  
PR 22-DEC-1999; 99WO-US30720.  
PR 30-DEC-1999; 99WO-US31243.  
PR 30-DEC-1999; 99WO-US31274.  
PR 05-JAN-2000; 2000WO-US00219.  
PR 06-JAN-2000; 2000WO-US00277.  
PR 06-JAN-2000; 2000WO-US00376.  
PR 11-FEB-2000; 2000WO-US03565.  
PR 18-FEB-2000; 2000WO-US04341.  
PR 18-FEB-2000; 2000WO-US04442.  
PR 22-FEB-2000; 2000WO-US04414.  
PR 24-FEB-2000; 2000WO-US04914.  
PR 24-FEB-2000; 2000WO-US05004.  
PR 01-MAR-2000; 2000WO-US05601.  
PR 02-MAR-2000; 2000WO-US05746.  
PR 02-MAR-2000; 2000WO-US05841.  
PR 10-MAR-2000; 2000WO-US06319.  
PR 15-MAR-2000; 2000WO-US06884.  
PR 20-MAR-2000; 2000WO-US07377.  
PR 21-MAR-2000; 2000WO-US07532.  
  
PR 30-MAR-2000; 2000WO-US08439.  
PR 17-MAY-2000; 2000WO-US13705.  
PR 22-MAY-2000; 2000WO-US14042.  
PR 30-MAY-2000; 2000WO-US14941.  
PR 02-JUN-2000; 2000WO-US15264.  
PR 28-JUL-2000; 2000WO-US20710.  
PR 11-AUG-2000; 2000WO-US22031.  
PR 23-AUG-2000; 2000WO-US23522.  
PR 24-AUG-2000; 2000WO-US23328.  
PR 08-NOV-2000; 2000WO-US30952.  
PR 10-NOV-2000; 2000WO-US30873.  
PR 01-DEC-2000; 2000WO-US32678.  
PR 20-DEC-2000; 2000WO-US34956.  
PR 28-FEB-2001; 2001WO-US06520.  
PR 01-MAR-2001; 2001WO-US06666.  
PR 25-MAY-2001; 2001WO-US17092.  
PR 01-JUN-2001; 2001WO-US17800.  
PR 20-JUN-2001; 2001WO-US19692.  
PR 22-JUN-2001; 2001WO-US20116.  
PR 29-JUN-2001; 2001WO-US21066.  
PR 09-JUL-2001; 2001WO-US21735.  
PR 20-DEC-2000; 2000US-0747259.  
PR 28-FEB-2001; 2001US-0796498.  
PR 09-MAR-2001; 2001US-0802706.  
PR 14-MAR-2001; 2001US-0806899.  
PR 22-MAR-2001; 2001US-0816744.  
PR 05-APR-2001; 2001US-0828366.  
PR 10-MAY-2001; 2001US-0854208.  
PR 10-MAY-2001; 2001US-0854280.  
PR 18-MAY-2001; 2001US-0860216.  
PR 25-MAY-2001; 2001US-0866028.  
PR 25-MAY-2001; 2001US-0866034.  
PR 01-JUN-2001; 2001US-0872035.  
PR 05-JUN-2001; 2001US-0874503.  
PR 14-JUN-2001; 2001US-0882636.  
PR 19-JUN-2001; 2001US-0886342.  
PR 21-JUN-2001; 2001US-0887879.  
PR 18-JUL-2001; 2001US-0908827.  
PR 06-AUG-2001; 2001US-0924419.  
PR 09-AUG-2001; 2001US-0927796.  
PR 16-AUG-2001; 2001US-0931836.  
PR 19-DEC-2001; 2001US-0028072.  
  
XX  
XX (GENTH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Gunney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;  
XX  
XX WPI; 2003-331925/31.  
XX  
XX N-PSDB; ACA04292.  
XX  
XX  
XX New secreted and transmembrane nucleic acids and polypeptides,  
PT designated as PRO, useful for treating inflammation, organ failure,  
PT atherosclerosis, cardiac injury, infertility, birth defects, premature  
PT aging, AIDS, or cancer  
XX  
XX  
XX Claim 12; Fig 538; 659pp; English.  
PS  
XX  
XX The invention relates to an isolated nucleic acid comprising, or which is  
CC at least 80% identical to, or the full-length coding sequence of, any of  
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide  
CC (one of 275 secreted or transmembrane proteins). The nucleic acid  
CC further comprises the full-length coding sequence of the DNA deposited  
CC under American Type Culture Collection (ATCC) accession number in a list  
CC given in the specification. Also included are vectors and host  
CC cells for producing PRO proteins, PRO fusion proteins, anti-PRO  
CC antibodies, PRO extracellular domains and mature sequences, methods  
CC of detecting PRO proteins, methods for stimulating the release of  
CC TNF-alpha (tumour necrosis factor alpha) from human blood,  
CC (and the proliferation of differentiation of chondrocyte cells, the  
CC proliferation of, or gene expression in pericyte cells, the release or  
CC proteoglycans from cartilage, proliferation of inner ear utricular

CC supporting cells, the proliferation of T-lymphocyte cells, the release  
 CC of a cytokine from peripheral blood mononuclear cells (PBMC), or the  
 CC proliferation of endothelial cells, a method for modulating the uptake  
 CC of glucose or free fatty acid (FFA) by skeletal muscle cells,  
 CC a method for inhibiting the binding of A-peptide to factor VIIa,  
 CC or the differentiation of adipocyte cells, a method for detecting the  
 CC presence of a tumour in a mammal and an oligonucleotide probe derived  
 CC from any of the nucleotide sequences cited above. The nucleic acids and  
 CC polypeptides are useful for treating inflammatory diseases, organ  
 CC failure, atherosclerosis, cardiac injury, infertility, birth defects,  
 CC premature aging, AIDS (acquired immunodeficiency syndrome), cancer, or  
 CC diabetic complications. The nucleic acids are useful as hybridisation  
 CC probes, in chromosome and gene mapping, and in generating antisense RNA  
 CC or DNA. The polypeptides are useful as pharmaceuticals, diagnostics,  
 CC biosensors or bioreactors. Both are useful in tissue typing.  
 CC The present sequence represents a Pro protein of the invention.  
 CC  
 XX Sequence 310 AA;  
 SQ  
 Query Match 67.4%; Score 209; DB 24; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDFLLFRGLIGAVNLKSNRRTPVQEFSEVELSCIITDSQT 60  
 DB 1 MALRRPRLRLCARLPDFLLFRGLIGAVNLKSNRRTPVQEFSEVELSCIITDSQT 60  
 QY 61 SDPRLEWKKIDQEQTYVFPNKGIDLAGRAELIGKSLKIMVTRDSALYREVVAR 120  
 DB 61 SDPRLEWKKIDQEQTYVFPNKGIDLAGRAELIGKSLKIMVTRDSALYREVVAR 120  
 QY 121 NDRKEIDIVIELTQVQKVPVPCRVKPAVPGKMATJHCOSESGHPRPHYSWYNDVPL 180  
 DB 121 NDRKEIDIVIELTQVQKVPVPCRVKPAVPGKMATJHCOSESGHPRPHYSWYNDVPL 180  
 QY 121 NDRKEIDIVIELTQVQKVPVPCRVKPAVPGKMATJHCOSESGHPRPHYSWYNDVPL 180  
 DB 181 PTDSRANRFRNNSSHLNSEGTIVFAVHKDSCQYVCIASNDGASRCEQEMEVYDL 240  
 QY 181 PTDSRANRFRNNSSHLNSEGTIVFAVHKDSCQYVCIASNDGASRCEQEMEVYDL 240  
 DB 181 PTDSRANRFRNNSSHLNSEGTIVFAVHKDSCQYVCIASNDGASRCEQEMEVYDL 240  
 QY 241 NIGGIIGVVLVLAITLITGICCAVRRGYPINNKQGESYKXNGKPDGVNVIITDEEG 300  
 DB 241 NIGGIIGVVLVLAITLITGICCAVRRGYPINNKQGESYKXNGKPDGVNVIITDEEG 300  
 QY 301 DFRHKSFEVI 310  
 DB 301 DFRHKSFEVI 310

PR 14-SEP-1998; 98WO-US19177.  
 PR 16-SEP-1998; 98WO-US19330.  
 PR 17-SEP-1998; 98WO-US19437.  
 PR 01-DEC-1998; 98WO-US25108.  
 PR 08-SEP-1999; 99WO-US20594.  
 PR 13-SEP-1999; 99WO-US20944.  
 PR 15-SEP-1999; 99WO-US21090.  
 PR 15-SEP-1999; 99WO-US21547.  
 PR 05-OCT-1999; 99WO-US23089.  
 PR 29-NOV-1999; 99WO-US28214.  
 PR 30-NOV-1999; 99WO-US28313.  
 PR 01-DEC-1999; 99WO-US28301.  
 PR 02-DEC-1999; 99WO-US28565.  
 PR 16-DEC-1999; 99WO-US30095.  
 PR 20-DEC-1999; 99WO-US30911.  
 PR 20-DEC-1999; 99WO-US30999.  
 PR 05-JAN-2000; 2000WO-US00219.  
 PR 11-FEB-2000; 2000WO-US03565.  
 PR 22-FEB-2000; 2000WO-US04414.  
 PR 24-FEB-2000; 2000WO-US05004.  
 PR 02-MAR-2000; 2000WO-US05841.  
 PR 20-MAR-2000; 2000WO-US07377.  
 PR 30-MAR-2000; 2000WO-US08439.  
 PR 22-MAY-2000; 2000WO-US14042.  
 PR 02-JUN-2000; 2000WO-US15264.  
 PR 28-JUN-2000; 2000WO-US20710.  
 PR 24-AUG-2000; 2000WO-US23328.  
 PR 17-SEP-1997; 97US-059113P.  
 PR 17-SEP-1997; 97US-059115P.  
 PR 17-SEP-1997; 97US-059117P.  
 PR 17-SEP-1997; 97US-059119P.  
 PR 17-SEP-1997; 97US-059121P.  
 PR 17-SEP-1997; 97US-059122P.  
 PR 17-SEP-1997; 97US-059184P.  
 PR 18-SEP-1997; 97US-059263P.  
 PR 15-OCT-1997; 97US-062125P.  
 PR 17-OCT-1997; 97US-062285P.  
 PR 17-OCT-1997; 97US-062287P.  
 PR 21-OCT-1997; 97US-063486P.  
 PR 24-OCT-1997; 97US-062814P.  
 PR 24-OCT-1997; 97US-062816P.  
 PR 24-OCT-1997; 97US-063045P.  
 PR 24-OCT-1997; 97US-063120P.  
 PR 24-OCT-1997; 97US-063121P.  
 PR 24-OCT-1997; 97US-063127P.  
 PR 24-OCT-1997; 97US-063128P.  
 PR 27-OCT-1997; 97US-063327P.  
 PR 27-OCT-1997; 97US-063329P.  
 PR 28-OCT-1997; 97US-063541P.  
 PR 28-OCT-1997; 97US-063542P.  
 PR 28-OCT-1997; 97US-063544P.  
 PR 28-OCT-1997; 97US-063549P.  
 PR 28-OCT-1997; 97US-063550P.  
 PR 28-OCT-1997; 97US-063564P.  
 PR 29-OCT-1997; 97US-063435P.  
 PR 29-OCT-1997; 97US-063704P.  
 PR 29-OCT-1997; 97US-063732P.  
 PR 29-OCT-1997; 97US-063734P.  
 PR 29-OCT-1997; 97US-063735P.  
 PR 29-OCT-1997; 97US-063738P.  
 PR 29-OCT-1997; 97US-064215P.  
 PR 31-OCT-1997; 97US-063870P.  
 PR 31-OCT-1997; 97US-064103P.  
 PR 03-NOV-1997; 97US-064248P.  
 PR 07-NOV-1997; 97US-064809P.  
 PR 12-NOV-1997; 97US-065186P.  
 PR 17-NOV-1997; 97US-065846P.  
 PR 18-NOV-1997; 97US-065933P.  
 PR 21-NOV-1997; 97US-066120P.  
 PR 21-NOV-1997; 97US-066364P.  
 PR 24-NOV-1997; 97US-066453P.

PR 24-NOV-1997; 97US-066466P.  
PR 24-NOV-1997; 97US-066511P.  
PR 24-NOV-1997; 97US-066770P.  
PR 24-NOV-1997; 97US-066772P.  
PR 25-NOV-1997; 97US-066840P.  
PR 12-DEC-1997; 97US-069425P.  
PR 04-JUN-1998; 98US-088026P.  
PR 10-SEP-1998; 98US-098030P.  
PR 14-SEP-1998; 98US-100262P.  
PR 17-SEP-1998; 98US-100858P.  
PR 13-OCT-1998; 98US-104080P.  
PR 20-NOV-1998; 98US-109304P.  
PR 22-DEC-1998; 98US-113296P.  
PR 07-JUL-1999; 99US-143048P.  
PR 26-JUL-1999; 99US-145698P.  
PR 28-JUL-1999; 99US-146232P.  
PR 18-SEP-2000; 2000US-0665350.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;  
PI Filharoff E, Fong S, Gao W, Gerber H, Gertschen ME, Goddard A;  
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IU;  
PI Mather JP, Pan U, Paoni NF, Roy MA, Stewart TA, Tumas D;  
PI Williams PM, Wood WI;  
XX  
XX WPI; 2003-331485/31.  
DR N-PSDB; ACN05699.  
XX  
XX Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g.  
PT PRO245 or PRO1868, useful in chromosome and gene mapping, in generating  
PT antisense RNA and DNA, and in treating cancer and Alzheimer's disease -  
PS Disclosure; Fig 124; 481pp; English.  
XX  
XX The invention relates to sixty one nucleic acids encoding PRO  
CC polypeptides (secreted and transmembrane). The polynucleotide is useful  
CC in molecular biology, including uses as hybridisation probes, in  
CC chromosome and gene mapping, in generating antisense RNA and DNA, and in  
CC gene therapy. The polynucleotide may also be used in preparing PRO  
CC polypeptides by recombinant techniques, and in generating either  
CC transgenic animals or knock-out animals which, in turn, are useful in the  
CC development and screening of therapeutically useful reagents. The PRO  
CC polypeptide or the antibody is used in preparing a medicament for  
CC treating a condition responsive to the polypeptide or antibody, such as  
CC mucosal lesions e.g. ulcers and enterocolitis, skin disease e.g.  
CC psoriasis, cancer e.g. lung cancer and colon cancer, nerve cell disease  
CC e.g. Alzheimer's disease and Parkinson's disease, Usher syndrome,  
CC atrophla areata, angiogenesis, inflammatory disease e.g. asthma and  
CC rheumatoid arthritis, ischaemia, and in various diagnostic assays. The  
CC present sequence represents the amino acid sequence of a PRO polypeptide.  
XX  
SQ Sequence 310 AA;  
Query Match 67.4%; Score 209; DB 24; Length 310;  
Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MALRRPRLRLCARLDFLLILFRGLIGAVNLKSSNRPPVQEFSEVELSCITDSQT 60  
DB 1 MALRRPRLRLCARLDFLLILFRGLIGAVNLKSSNRPPVQEFSEVELSCITDSQT 60  
QY 61 SDRIRWKIKIQDQTYVFFDNKIQDLAGRAEILGTSKINWTRRBDALYRCCEVMAR 120  
DB 61 SDRIRWKIKIQDQTYVFFDNKIQDLAGRAEILGTSKINWTRRBDALYRCCEVMAR 120  
QY 121 NDRKEIDEIVELTVQKPTVPCRVKAVPVGKMATLHCQSESGHPRPHSYRRNDVPL 180  
DB 121 NDRKEIDEIVELTVQKPTVPCRVKAVPVGKMATLHCQSESGHPRPHSYRRNDVPL 180  
QY 181 PTDSSRANPRFRNSSSHLNSGTGLVFTAVAKDSDGGYYCIASNDAGSARCEBDEMEVYDL 240  
DB 181 PTDSSRANPRFRNSSSHLNSGTGLVFTAVAKDSDGGYYCIASNDAGSARCEBDEMEVYDL 240

QY 241 NIGGIIGVLVLAVALITITGICAYRGRGFIINNKQGESYKNGKPDGVNYIRTBEG 300  
DB 241 NIGGIIGVLVLAVALITITGICAYRGRGFIINNKQGESYKNGKPDGVNYIRTBEG 300  
QY 301 DFRHKSFFVI 310  
DB 301 DFRHKSFFVI 310  
RESULT 26  
ID ABUS9919 standard; Protein; 310 AA.  
XX ABUS9919;  
AC  
XX  
DT 13-MAY-2003 (first entry)  
XX  
XX Novel secreted and transmembrane protein PRO1868.  
DE  
XX Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;  
KW cardiac insufficiency disorder; cancer; tumour; immune response;  
KW adrenal cortical capillary endothelial growth; c-fos induction;  
KW vascular endothelial growth factor inhibition; VEGF inhibition;  
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;  
KW retinal neurons cell survival; rod photoreceptor cell survival;  
KW retinal disorder; retinitis pigmentosa; kidney disease;  
KW mammalian kidney mesangial cell proliferation; Berger disease;  
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;  
KW chondrocyte redifferentiation; sports injury; arthritis.  
XX  
XX Homo sapiens.  
OS  
XX  
XX US2003017563-A1.  
XX  
XX 23-JAN-2003.  
XX  
XX 07-MAY-2002; 2002US-0140808.  
XX  
PR 31-MAR-1997; 97WO-US05230.  
PR 12-JUN-1998; 98WO-US12456.  
PR 14-JUL-1998; 98WO-US14552.  
PR 28-AUG-1998; 98WO-US17888.  
PR 10-SEP-1998; 98WO-US18824.  
PR 14-SEP-1998; 98WO-US19093.  
PR 14-SEP-1998; 98WO-US19094.  
PR 14-SEP-1998; 98WO-US19177.  
PR 16-SEP-1998; 98WO-US19330.  
PR 17-SEP-1998; 98WO-US19437.  
PR 07-OCT-1998; 98WO-US21141.  
PR 29-OCT-1998; 98WO-US22991.  
PR 29-OCT-1998; 98WO-US22992.  
PR 20-NOV-1998; 98WO-US24855.  
PR 01-DEC-1998; 98WO-US25108.  
PR 05-JAN-1999; 99WO-US00106.  
PR 08-MAR-1999; 99WO-US05028.  
PR 10-MAR-1999; 99WO-US05190.  
PR 20-APR-1999; 99WO-US08615.  
PR 14-MAY-1999; 99WO-US10733.  
PR 02-JUN-1999; 99WO-US12252.  
PR 01-SEP-1999; 99WO-US20111.  
PR 08-SEP-1999; 99WO-US20594.  
PR 13-SEP-1999; 99WO-US20944.  
PR 15-SEP-1999; 99WO-US21090.  
PR 15-SEP-1999; 99WO-US21547.  
PR 05-OCT-1999; 99WO-US23089.  
PR 29-NOV-1999; 99WO-US28214.  
PR 30-NOV-1999; 99WO-US28313.  
PR 30-NOV-1999; 99WO-US28409.  
PR 01-DEC-1999; 99WO-US28301.  
PR 01-DEC-1999; 99WO-US28634.  
PR 02-DEC-1999; 99WO-US28551.  
PR 02-DEC-1999; 99WO-US28564.

PR 02-DEC-1999; 99WO-US28565.  
 PR 16-DEC-1999; 99WO-US30095.  
 PR 20-DEC-1999; 99WO-US30911.  
 PR 20-DEC-1999; 99WO-US30999.  
 PR 22-DEC-1999; 99WO-US30720.  
 PR 30-DEC-1999; 99WO-US31243.  
 PR 30-DEC-1999; 99WO-US31274.  
 PR 05-JAN-2000; 2000WO-US00219.  
 PR 06-JAN-2000; 2000WO-US00277.  
 PR 06-JAN-2000; 2000WO-US00376.  
 PR 11-FEB-2000; 2000WO-US03565.  
 PR 18-FEB-2000; 2000WO-US04341.  
 PR 18-FEB-2000; 2000WO-US04342.  
 PR 22-FEB-2000; 2000WO-US04914.  
 PR 24-FEB-2000; 2000WO-US04914.  
 PR 01-MAR-2000; 2000WO-US05004.  
 PR 02-MAR-2000; 2000WO-US05601.  
 PR 02-MAR-2000; 2000WO-US05746.  
 PR 10-MAR-2000; 2000WO-US05841.  
 PR 15-MAR-2000; 2000WO-US06319.  
 PR 20-MAR-2000; 2000WO-US07377.  
 PR 21-MAR-2000; 2000WO-US07532.  
 PR 30-MAR-2000; 2000WO-US08439.  
 PR 17-MAY-2000; 2000WO-US13705.  
 PR 22-MAY-2000; 2000WO-US14042.  
 PR 30-MAY-2000; 2000WO-US14941.  
 PR 02-JUN-2000; 2000WO-US15264.  
 PR 28-JUL-2000; 2000WO-US20710.  
 PR 11-AUG-2000; 2000WO-US22031.  
 PR 23-AUG-2000; 2000WO-US23522.  
 PR 24-AUG-2000; 2000WO-US23328.  
 PR 08-NOV-2000; 2000WO-US30952.  
 PR 10-NOV-2000; 2000WO-US30873.  
 PR 01-DEC-2000; 2000WO-US32678.  
 PR 20-DEC-2000; 2000WO-US34956.  
 PR 28-FEB-2001; 2001WO-US06520.  
 PR 01-MAR-2001; 2001WO-US06666.  
 PR 25-MAY-2001; 2001WO-US17092.  
 PR 01-JUN-2001; 2001WO-US17800.  
 PR 20-JUN-2001; 2001WO-US19692.  
 PR 22-JUN-2001; 2001WO-US20116.  
 PR 29-JUN-2001; 2001WO-US21066.  
 PR 09-JUL-2001; 2001WO-US21735.  
 PR 20-DEC-2000; 2000US-0747259.  
 PR 28-FEB-2001; 2001US-0796498.  
 PR 09-MAR-2001; 2001US-0802706.  
 PR 14-MAR-2001; 2001US-0806889.  
 PR 22-MAR-2001; 2001US-0816744.  
 PR 05-APR-2001; 2001US-0828366.  
 PR 10-MAY-2001; 2001US-0854208.  
 PR 10-MAY-2001; 2001US-0854280.  
 PR 18-MAY-2001; 2001US-0860216.  
 PR 25-MAY-2001; 2001US-0866028.  
 PR 01-JUN-2001; 2001US-0866034.  
 PR 05-JUN-2001; 2001US-0872035.  
 PR 14-JUN-2001; 2001US-0874503.  
 PR 14-JUN-2001; 2001US-0882636.  
 PR 19-JUN-2001; 2001US-0886342.  
 PR 21-JUN-2001; 2001US-0887879.  
 PR 18-JUL-2001; 2001US-0908827.  
 PR 06-AUG-2001; 2001US-0924419.  
 PR 09-AUG-2001; 2001US-0927796.  
 PR 16-AUG-2001; 2001US-0931836.  
 PR 19-DEC-2001; 2001US-0028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 PA Baker KP, Betesini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski FU, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-148238/14.

DR N-PSDB; ABX89409.  
 XX  
 PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346  
 PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes  
 PT are therapeutically useful for enhancing immune response and in cancer  
 PT treatments  
 XX  
 XX Claim 12; Fig 538; 659pp; English.  
 XX  
 CC The invention describes an isolated human PRO polypeptide. The PRO  
 CC polypeptides are useful in detecting PRO polypeptides in a sample, in  
 CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and  
 CC in modulating at least one biological activity of a cell expressing a PRO  
 CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus  
 CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186  
 CC stimulate adrenal cortical capillary endothelial growth, and PRO536,  
 CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,  
 CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus  
 CC useful for treating conditions or disorders where angiogenesis would be  
 CC beneficial, e.g. wound healing and antagonist of this polypeptide are  
 CC useful for treating cancerous tumours. PRO812 inhibits vascular  
 CC endothelial growth factor (VEGF) stimulated proliferation of endothelial  
 CC cells and is thus useful for inhibiting endothelial cell growth in  
 CC mammals which would be beneficial in inhibiting tumour growth. PRO826,  
 CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of  
 CC stimulated T-lymphocytes and are therapeutically useful for enhancing  
 CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of  
 CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of  
 CC rod photoreceptor cells) and therefore are useful for treating retinal  
 CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813  
 CC and PRO1106 induce proliferation of mammalian kidney mesangial cells,  
 CC and therefore are useful for treating kidney disorders associated with  
 CC decreased mesangial cell function such as Berger disease or other  
 CC nephropathies associated with dermatitis, herpeticiformis or Crohn's  
 CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the  
 CC proliferation and/or redifferentiation of chondrocytes in culture and  
 CC are thus useful for treating sports injuries, and arthritis. This  
 CC is the amino acid sequence of a novel human PRO protein.  
 XX  
 SQ Sequence 310 AA;  
 Query Match 67.4%; Score 209; DB 24; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDFLLLRPGCLIGAVNLKSNRTFVQEFSEVELSCITTSQT 60  
 DB 1 MALRRPRLRLCARLPDFLLLRPGCLIGAVNLKSNRTFVQEFSEVELSCITTSQT 60  
 QY 61 SDPRLEMKKIDDEQTYTFPNKIOGDLAGRAELIGKSLKIMWTRRDSALYREVAR 120  
 DB 61 SDPRLEMKKIDDEQTYTFPNKIOGDLAGRAELIGKSLKIMWTRRDSALYREVAR 120  
 QY 121 NDRKEIDRIVIELTVQVAPVTPVCVPAVAVGKATLHCOSSEGHPRPHYSWYENDVPL 180  
 DB 121 NDRKEIDRIVIELTVQVAPVTPVCVPAVAVGKATLHCOSSEGHPRPHYSWYENDVPL 180  
 QY 181 PTDSRANRFRNNSGHLNSETGTLVFAVHKDSSQYCIASNDGARSCEQEMEVYDL 240  
 DB 181 PTDSRANRFRNNSGHLNSETGTLVFAVHKDSSQYCIASNDGARSCEQEMEVYDL 240  
 QY 241 NIGGIIGVAVVLAVALITITGICAYARGFYFINNKQGESEKNGKRGDGVNYIRTDSEG 300  
 DB 241 NIGGIIGVAVVLAVALITITGICAYARGFYFINNKQGESEKNGKRGDGVNYIRTDSEG 300  
 QY 301 DFRHKSFFVI 310  
 DB 301 DFRHKSFFVI 310  
 RESULT 27  
 ABU60813  
 ID ABU60813 standard; Protein; 310 AA.

XX AC ABU60813;  
 XX XX  
 DT 06-MAY-2003 (first entry)  
 DE Human secreted/transmembrane protein, #7.  
 XX Human; PRO; secreted; transmembrane; pharmaceutical;  
 XX diagnostic; biosensor; bioreactor; therapeutic; gene therapy; tumour;  
 KM inflammatory disease; immune-related disease; inflammatory bowel disease;  
 KM IBD; systemic lupus erythematosus; rheumatoid arthritis; thyroiditis;  
 KM diabetes mellitus; glomerulonephritis; multiple sclerosis; cirrhosis;  
 KM psoriasis; graft rejection; antiinflammatory; immunosuppressive;  
 KM neuroprotective; hepatotropic.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002160392-A1.  
 XX  
 PD 31-OCT-2002.  
 XX  
 PF 27-DEC-2001; 2001US-0033245.  
 XX  
 PR 02-JUN-1999; 99WO-US12252.  
 PR 01-DEC-1999; 99WO-US28634.  
 PR 02-DEC-1999; 99WO-US28551.  
 PR 11-FEB-2000; 2000WO-US03565.  
 PR 22-FEB-2000; 2000WO-US04414.  
 PR 02-MAR-2000; 2000WO-US05841.  
 PR 30-MAR-2000; 2000WO-US08439.  
 PR 30-MAY-2000; 2000WO-US14941.  
 PR 02-JUN-2000; 2000WO-US15264.  
 PR 01-DEC-2000; 2000WO-US32678.  
 PR 04-AUG-1998; 98US-095325P.  
 PR 16-DEC-1998; 98US-112851P.  
 PR 16-DEC-1998; 98US-113145P.  
 PR 22-DEC-1998; 98US-113511P.  
 PR 12-JAN-1999; 99US-115558P.  
 PR 12-JAN-1999; 99US-115565P.  
 PR 12-JAN-1999; 99US-115733P.  
 PR 09-FEB-1999; 99US-119341P.  
 PR 10-FEB-1999; 99US-119537P.  
 PR 12-FEB-1999; 99US-119965P.  
 PR 29-OCT-1999; 99US-162506P.  
 PR 09-DEC-1999; 99US-170262P.  
 PR 03-MAR-2000; 2000US-187202P.  
 PR 25-MAY-2001; 2001US-0866034.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Botstein D, Desnovers L, Ferrara N, Fong S, Gao W, Goddard A;  
 PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;  
 PI Wood WI;  
 XX  
 DR WPI; 2003-275292/27.  
 DR N-PSDB; ABX90609.  
 XX  
 PT New isolated PRO polypeptide, e.g. PRO1800 or PRO539, useful for  
 PT diagnosing, preventing and treating tumors and inflammatory or  
 PT immune-related diseases, e.g. systemic lupus erythematosus,  
 PT thyroiditis, diabetes or psoriasis  
 XX  
 PS Claim 12; Fig 14; 119pp; English.  
 XX  
 CC The invention discloses isolated PRO secreted/transmembrane polypeptides  
 CC comprising a sequence without signal peptide and the nucleic acid  
 CC encoding them. The polypeptides can be used to raise antibodies that  
 CC specifically bind to the PRO polypeptide, for linking a bioactive  
 CC molecule to a cell expressing a PRO protein and for modulating at least  
 CC one biological activity of a cell. The PRO polypeptides and the antibody  
 CC are useful for diagnosing, preventing and treating tumors and  
 CC inflammatory or immune-related diseases, such as inflammatory bowel  
 CC disease (IBD), systemic lupus erythematosus, rheumatoid arthritis,

CC thyroiditis, diabetes mellitus, glomerulonephritis, multiple sclerosis,  
 CC cirrhosis, psoriasis or graft rejection. The proteins and the antibody  
 CC may also be used in preparing medicines and medicaments for treating the  
 CC above-mentioned diseases. The polynucleotide is useful in molecular  
 CC biology, including uses as hybridisation probes, in chromosome and gene  
 CC mapping, in generating antisense RNA and DNA, and in gene therapy. The  
 CC polynucleotide may also be used in preparing PRO polypeptides by  
 CC recombinant techniques, and in generating either transgenic animals or  
 CC knock-out animals which, in turn, are useful in the development and  
 CC screening of therapeutically useful reagents. The sequences presented in  
 CC ABU60807-ABU60815 are the human PRO polynucleotides of the invention.  
 XX  
 SQ Sequence 310 AA;  
 XX  
 Query Match 67.4%; Score 209; DB 24; Length 310;  
 Best local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDFLLLPFGCLIGAVNLKSNRPVQEPESVELSCIITDSQT 60  
 DB 1 MALRRPRLRLCARLPDFLLLPFGCLIGAVNLKSNRPVQEPESVELSCIITDSQT 60.  
 QY 61 SDPRIFEMKKIODEQTTVPFNDKIOGDLGRAEILGKTSLKTMVTRRPSALYRCGVAR 120  
 DB 61 SDPRIFEMKKIODEQTTVPFNDKIOGDLGRAEILGKTSLKTMVTRRPSALYRCGVAR 120  
 QY 121 NDRKEIDEIVIELTVQVKPTVCVRPKAVPVGKMATLHCQSESGHPRPHYSWRNDVPL 180  
 DB 121 NDRKEIDEIVIELTVQVKPTVCVRPKAVPVGKMATLHCQSESGHPRPHYSWRNDVPL 180  
 QY 121 NDRKEIDEIVIELTVQVKPTVCVRPKAVPVGKMATLHCQSESGHPRPHYSWRNDVPL 180  
 DB 121 NDRKEIDEIVIELTVQVKPTVCVRPKAVPVGKMATLHCQSESGHPRPHYSWRNDVPL 180  
 QY 181 PTDSRRANPRFRNSSSHLNSETGTLVFTAVHKDSSQGYICIASNDAGSARCEQNEVYDL 240  
 DB 181 PTDSRRANPRFRNSSSHLNSETGTLVFTAVHKDSSQGYICIASNDAGSARCEQNEVYDL 240  
 QY 241 NIGGIIIGVAVLVAVLALITLIGICAVRRGVRFINNKQDESKYKNGKPRGVYIRDEEG 300  
 DB 241 NIGGIIIGVAVLVAVLALITLIGICAVRRGVRFINNKQDESKYKNGKPRGVYIRDEEG 300  
 QY 301 DFRHKSSFVI 310  
 DB 301 DFRHKSSFVI 310  
 DB 301 DFRHKSSFVI 310  
 RESULT 28  
 ABU64559  
 ID ABU64559 standard; protein; 310 AA.  
 XX  
 AC ABU64559;  
 XX  
 DT 13-MAY-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein, #63.  
 XX  
 XX Human; PRO; secreted; transmembrane; pharmaceutical;  
 XX diagnostic; biosensor; bioreactor; therapeutic; hyperplasia;  
 XX endometriosis; cancer; tumour; ischaemia; coronary arterial disease;  
 XX polycystic kidney disease; renal failure; inflammatory response; asthma;  
 XX rheumatoid arthritis; psoriasis; multiple sclerosis; gene therapy;  
 XX cytostatic; gynecological; cardiac; nephrotropic; hepatotropic;  
 XX antiinflammatory.  
 OS Homo sapiens.  
 XX  
 PN US2002160374-A1.  
 XX  
 PD 31-OCT-2002.  
 XX  
 PF 12-JUL-2001; 2001US-0905291.  
 XX  
 PR 10-SEP-1998; 98WO-US19824.  
 PR 14-SEP-1998; 98WO-US19177.  
 PR 16-SEP-1998; 98WO-US19330.  
 PR 17-SEP-1998; 98WO-US19437.

PR	01-DEC-1996	98MO-US25108
PR	08-SEP-1996	99MO-US20594
PR	13-SEP-1999	99MO-US20944
PR	15-SEP-1999	99MO-US21090
PR	15-SEP-1999	99MO-US21547
PR	05-OCT-1999	99MO-US23089
PR	20-NOV-1999	99MO-US28323
PR	30-NOV-1999	99MO-US28314
PR	01-DEC-1999	99MO-US28301
PR	02-DEC-1999	99MO-US28564
PR	02-DEC-1999	99MO-US28565
PR	16-DEC-1999	99MO-US30915
PR	20-DEC-1999	99MO-US30911
PR	05-JAN-2000	99MO-US30999
PR	11-FEB-2000	2000MO-US20219
PR	11-FEB-2000	2000MO-US20356
PR	22-FEB-2000	2000MO-US20444
PR	24-FEB-2000	2000MO-US20504
PR	02-MAR-2000	2000MO-US205841
PR	20-MAR-2000	2000MO-US207317
PR	17-SEP-1997	99MO-US21122P
PR	17-SEP-1997	99MO-US21184P
PR	18-SEP-1997	99MO-US2263P
PR	18-SEP-1997	99MO-US2266P
PR	17-OCT-1997	99MO-US26125P
PR	17-OCT-1997	99MO-US26287P
PR	17-OCT-1997	99MO-US26287P
PR	21-OCT-1997	99MO-US26346P
PR	24-OCT-1997	99MO-US263814P
PR	24-OCT-1997	99MO-US263816P
PR	24-OCT-1997	99MO-US263045P
PR	24-OCT-1997	99MO-US263120P
PR	24-OCT-1997	99MO-US263121P
PR	24-OCT-1997	99MO-US263127P
PR	24-OCT-1997	99MO-US263128P
PR	27-OCT-1997	99MO-US26322P
PR	27-OCT-1997	99MO-US263325P
PR	28-OCT-1997	99MO-US263541P
PR	28-OCT-1997	99MO-US263542P
PR	28-OCT-1997	99MO-US263544P
PR	28-OCT-1997	99MO-US263549P
PR	28-OCT-1997	99MO-US263550P
PR	28-OCT-1997	99MO-US263564P
PR	28-OCT-1997	99MO-US263435P
PR	29-OCT-1997	99MO-US263704P
PR	29-OCT-1997	99MO-US263732P
PR	29-OCT-1997	99MO-US263734P
PR	29-OCT-1997	99MO-US263755P
PR	29-OCT-1997	99MO-US263738P
PR	29-OCT-1997	99MO-US264215P
PR	31-OCT-1997	99MO-US263870P
PR	31-OCT-1997	99MO-US264103P
PR	03-NOV-1997	99MO-US264238P
PR	07-NOV-1997	99MO-US264809P
PR	12-NOV-1997	99MO-US265186P
PR	17-NOV-1997	99MO-US265846P
PR	18-NOV-1997	99MO-US265931P
PR	21-NOV-1997	99MO-US266120P
PR	21-NOV-1997	99MO-US266366P
PR	24-NOV-1997	99MO-US266453P
PR	24-NOV-1997	99MO-US266466P
PR	24-NOV-1997	99MO-US266577P
PR	24-NOV-1997	99MO-US266770P

PR	24-NOV-1997;	97US-066772P.
PR	18-SEP-2000;	2000US-0665350.
PA	(GETH )	GENENTECH INC.
PI	Ashkenazi A,	Botstein D, Deenoyers L, Eaton DL, Ferrara N,
PI	Fildesoft E,	Fong S, Gao W, Garber H, Gertlesen ME, Goddard A,
PI	Gilwadi PJ,	Gilmair JC, Gurney AJ, Hillan KJ, Kijavini J,
PI	Mather JP,	Pan J, Paoni NF, Roy MA, Stewart TH, Tumas D,
PI	Williams PM,	Wood WI;
DR	WPI: 2003-286105/28.	
DR	N-PSDB: ABX96378.	
XX		
XX		
PT	New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245)	
PT	and genes encoding them, useful for detecting or treating e.g.	
PT	hyperplasia, endometriosis, cancers, ischemia, coronary arterial	
PT	disease or inflammations -	
PS	Claim 12; Fig 124; 477pp; English.	
XX		
XX		
CC	The invention discloses isolated PRO secreted/transmembrane polypeptides	
CC	and the nucleic acid encoding them. The polypeptides can be used to	
CC	raise antibodies that specifically bind to the PRO polypeptide, for	
CC	linking a bioactive molecule to a cell expressing a PRO protein and for	
CC	modulating at least one biological activity of a cell. The PRO	
CC	polypeptides or polynucleotides are also useful as pharmaceuticals,	
CC	diagnostics, biosensors or bioreactors, for detecting or treating e.g.	
CC	hyperplasia, endometriosis, cancers (e.g. those involving solid tumors),	
CC	ischemia, coronary arterial disease, polycystic kidney disease, chronic	
CC	or acute renal failure, or inflammatory responses (e.g. asthma,	
CC	rheumatoid arthritis, psoriasis or multiple sclerosis) in mammals. The	
CC	PRO genes may also be used in gene therapy, particularly for replacing a	
CC	defective gene. The sequences presented in ABU64499-ABU64559 are the	
CC	PRO polynucleotides of the invention.	
XX		
XX	Sequence 310 AA;	
QQ		
Query Match	67.4%; Score 209; DB 24; Length 310;	
Best Local Similarity	99.7%; Pred. No. 1e-196;	
Matches 309; Conservative	0; Mismatches 1; Indels 0; Gaps 0;	
QY	1 MALRRPPLRLCARLPDFLLLRGCLIGAVLNKSNRPVVOEFSEVLSCTITDSQT 60	
DB	1 MALRRPPLRLCARLPDFLLLRGCLIGAVLNKSNRPVVOEFSEVLSCTITDSQT 60	
QY	61 SDPRIEMWKIODEOTTYVFPDNKIQGLIAGHAEILGKTSKIMVTRRDSALYCEVAR 120	
DB	61 SDPRIEMWKIODEOTTYVFPDNKIQGLIAGHAEILGKTSKIMVTRRDSALYCEVAR 120	
QY	121 NDREIDEIVELVQKPVTVPCVRKAVGVGKATLHCQESGRPHPSWRNDVPL 180	
DB	121 NDREIDEIVELVQKPVTVPCVRKAVGVGKATLHCQESGRPHPSWRNDVPL 180	
QY	181 PTDRANRPFNSSSHINSETGLVFAVHKDSDGQYCIASNDAGSARCEQEMEYVDL 240	
DB	181 PTDRANRPFNSSSHINSETGLVFAVHKDSDGQYCIASNDAGSARCEQEMEYVDL 240	
QY	241 NIGGIIGVAVLAVLALITGLICCAVRRGYFINNKDGBSYPKPGKPDGVNVIIRTBEG 300	
DB	241 NIGGIIGVAVLAVLALITGLICCAVRRGYFINNKDGBSYPKPGKPDGVNVIIRTBEG 300	
QY	301 DFRHKSFTVI 310	
DB	301 DFRHKSFTVI 310	
RESULT 29		
ABG73314		
ID	ABG73314 standard; Protein, 310 AA.	
AC	ABG73314;	
XX		

DT 30-APR-2003 (first entry)  
 XX Human PRO1868 polypeptide.  
 XX Human; secreted and transmembrane polypeptide; PRO polypeptide;  
 KW inflammatory disease; immune-related disease; diabetes mellitus;  
 KW rheumatoid arthritis; glomerulonephritis; multiple sclerosis;  
 KW immune-mediated skin disease; contact dermatitis; graft rejection;  
 KW transplantation associated disease; graft-versus-host disease;  
 KW tumour diagnosis; tumour cell; antiinflammatory; immunosuppressive;  
 KW cytostatic; antineoplastic; antirheumatic; antirheumatic; antithyroid;  
 KW antidiabetic; nephrotropic; antiproliferative; dermatological; haemostatic;  
 KW hepatotropic; virucide; neuroprotective; PRO1868.  
 XX Homo sapiens:  
 XX Key Location/Qualifiers  
 FT Peptide 1..30  
 FT /label= Signal\_peptide  
 FT Protein 31..310  
 FT /label= Mature\_PRO1868\_polypeptide  
 XX US2002164646-A1.  
 XX 07-NOV-2002.  
 XX 27-DEC-2001, 2001US-0033223.  
 XX 02-JUN-1999; 99WO-US12252.  
 XX 01-DEC-1999; 99WO-US28634.  
 XX 02-DEC-1999; 99WO-US28551.  
 XX 11-FEB-2000; 2000WO-US03565.  
 XX 22-FEB-2000; 2000WO-US04414.  
 XX 02-MAR-2000; 2000WO-US05841.  
 XX 30-MAR-2000; 2000WO-US08439.  
 XX 30-MAY-2000; 2000WO-US14941.  
 XX 02-JUN-2000; 2000WO-US15264.  
 XX 01-DEC-2000; 2000WO-US32678.  
 XX 16-DEC-1998; 98US-113145P.  
 XX 22-DEC-1998; 98US-113511P.  
 XX 12-JAN-1999; 99US-115558P.  
 XX 12-JAN-1999; 99US-115558P.  
 XX 09-FEB-1999; 99US-115733P.  
 XX 10-FEB-1999; 99US-119341P.  
 XX 12-FEB-1999; 99US-119537P.  
 XX 29-OCT-1999; 99US-119655P.  
 XX (GETH ) GENENTECH INC.  
 XX Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;  
 PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;  
 PI Wood WI;  
 DR N-PSDB; ABX11173.  
 DR MPI: 2003-238305/23.  
 XX New PRO polypeptides and nucleic acid molecules, useful in diagnosing  
 PT or treating inflammatory diseases or immune-related diseases, e.g.,  
 PT inflammatory bowel disease, systemic lupus erythematosus or rheumatoid  
 PT arthritis -  
 XX Claim 12; Fig 14; 11pp; English.  
 XX The present invention relates to the isolation of novel human  
 CC secreted and transmembrane polypeptides designated PRO polypeptides  
 CC (PRO1800, PRO539, PRO982, PRO1434, PRO1863, PRO1868, PRO3434  
 CC and PRO1927), and the polynucleotide sequences encoding them. The PRO  
 CC polypeptides and polynucleotide sequences of the invention are useful  
 CC in diagnosing or treating inflammatory diseases or immune-related  
 CC diseases (e.g. inflammatory bowel disease, systemic lupus  
 CC erythematosus, rheumatoid arthritis, Sjogren's syndrome, autoimmune  
 CC haemolytic anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes

CC mellitus, glomerulonephritis, multiple sclerosis, infectious hepatitis,  
 CC immune-mediated skin diseases including psoriasis or contact dermatitis,  
 CC and transplantation associated diseases including graft rejection or  
 CC graft-versus-host disease). The PRO polypeptides are also useful for  
 CC diagnosing tumours, and for inhibiting the growth of tumour cells. The  
 CC PRO polynucleotide sequences may be used as hybridisation probes in  
 CC chromosome and gene mapping, and in generating antisense RNA and DNA.  
 CC They are also useful in preparing PRO polypeptides, in assays to  
 CC identify other proteins or molecules involved in a binding reaction,  
 CC to generate transgenic animals or knockout animals, which in turn are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents, for chromosome identification, and tissue typing. The PRO  
 CC polynucleotide sequences are also useful in gene therapy. Anti-PRO  
 CC antibodies may be used in diagnostic assays for PRO polypeptides.  
 CC The present sequence represents human PRO1868 polypeptide.  
 XX Sequence 310 AA:  
 XX  
 XX Query Match 67.4%; Score 209; DB 24; Length 310;  
 XX Best Local Similarity 99.7%; Pred. No. 1e-196;  
 XX Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLDPDFLLLPFGCLIGAVNLKSNRTPVQEFSEVLSCTITDSOT 60  
 DB 1 MALRRPRLRLCARLDPDFLLLPFGCLIGAVNLKSNRTPVQEFSEVLSCTITDSOT 60  
 QY 61 SDPRLEWKKIODEQTYVFDNKLIOGDLAAGRAELIGKTSLKIMVTRRDSALYRCEVVAR 120  
 DB 61 SDPRLEWKKIODEQTYVFDNKLIOGDLAAGRAELIGKTSLKIMVTRRDSALYRCEVVAR 120  
 QY 121 NDRKEIDELIVELTVQKVPVPCVQVPAVPGKAAATLHCQSESEHPRPHYSWYNVDPL 180  
 DB 121 NDRKEIDELIVELTVQKVPVPCVQVPAVPGKAAATLHCQSESEHPRPHYSWYNVDPL 180  
 QY 181 PTDSRANPRFRNSSHLSSETGLVFTVHKDQSGCYCIASNDGASRCEQEMEVYDL 240  
 DB 181 PTDSRANPRFRNSSHLSSETGLVFTVHKDQSGCYCIASNDGASRCEQEMEVYDL 240  
 QY 241 NIGGIIGVAVLAVLALITLIGICAYRGGYFINNKQGESYKNGKPGVNYIRTDDEG 300  
 DB 241 NIGGIIGVAVLAVLALITLIGICAYRGGYFINNKQGESYKNGKPGVNYIRTDDEG 300  
 QY 301 DFRHKSSFTV 310  
 DB 301 DFRHKSSFTV 310  
 XX RESULT 30  
 XX ABP71277  
 XX ID ABP71277 standard; Protein; 310 AA.  
 XX AC ABP71277;  
 XX DT 28-APR-2003 (first entry)  
 XX Human junctional adhesion molecule 3 (JAM3).  
 DE Human junctional adhesion molecule 3 (JAM3).  
 DE  
 XX Junctional adhesion molecule; JAM3; JAM2; antiaethmatic; antirheumatic;  
 KW antirheumatic; antithyroid; immunosuppressive; thymomimetic; virucide;  
 KW hepatotropic; antiinflammatory; antidiabetic; haemostatic; antiproliferative;  
 KW antiallergic; human; chromosome 11q25.  
 XX Homo sapiens.  
 XX OS  
 XX PN MO2003006673-A2.  
 XX 23-JAN-2003.  
 XX 10-JUL-2002; 2002WO-US21697.  
 XX 11-JUL-2001; 2001US-304603P.  
 XX (TEXA-) TEXAS BIOTECHNOLOGY CORP.

XX Cunningham S;  
 PI WPI: 2003-210431/20.  
 DR N-PSDB; AB258894.  
 XX  
 PT Identifying compounds that bind to junctional adhesion molecules (JAM3  
 PT or JAM2) or modulators of binding between JAM and other molecules for  
 PT treating or alleviating e.g. arthritis, hepatitis, Crohn's disease or  
 PT graft rejection -  
 XX  
 XX Examples; Page 85-86; 90pp; English.  
 CC The invention relates to identifying compounds that bind to junctional  
 CC adhesion molecule 3 (JAM3), JAM2, or modulators of binding between JAM3,  
 CC JAM2 and other junctional adhesion molecules by detecting binding between  
 CC JAM3 and a test compound, or detecting binding between JAM3 and other  
 CC molecules. The identified compounds or modulators may be employed for  
 CC treating or alleviating e.g. arthritis, asthma, rheumatoid arthritis,  
 CC systemic lupus erythematosus, thrombocytopenia, Grave's disease,  
 CC Hashimoto's thyroiditis, hepatitis, diabetes mellitus, Crohn's disease,  
 CC psoriasis, allergic rhinitis, idiopathic pulmonary fibrosis, graft  
 CC rejection or graft-versus-host disease. The present sequence represents  
 CC the human JAM3 polypeptide.  
 CC  
 XX Sequence 310 AA:  
 SQ  
 Query Match 67.4%; Score 209; DB 24; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDFLLFRGCLIGAVNLKSNRTPVQBFSEVSLCITTDQT 60  
 Db 1 MALRRPRLRLCARLPDFLLFRGCLIGAVNLKSNRTPVQBFSEVSLCITTDQT 60  
 QY 61 SDPRLEWKKIODEQTTVFFDNKIGDLAGRAELIGKTSLSKIMVTRDSALYRCEVAR 120  
 Db 61 SDPRLEWKKIODEQTTVFFDNKIGDLAGRAELIGKTSLSKIMVTRDSALYRCEVAR 120  
 QY 121 NDRKREIDIVLELTQVQKPVPCVPRKAVPKKATLHCQSESEHPRPHYSWRNDVPL 180  
 Db 121 NDRKREIDIVLELTQVQKPVPCVPRKAVPKKATLHCQSESEHPRPHYSWRNDVPL 180  
 QY 181 PTDSRANRFRNSSHLNSETGLVFTAVHKDSCQYCIASNDGASRCEQEMEVYDL 240  
 Db 181 PTDSRANRFRNSSHLNSETGLVFTAVHKDSCQYCIASNDGASRCEQEMEVYDL 240  
 QY 241 NIGGIIGVLLVAVLALITLIGICCAVRGYPINNKQDGESEYKNGKPDGVNVIKRTDEG 300  
 Db 241 NIGGIIGVLLVAVLALITLIGICCAVRGYPINNKQDGESEYKNGKPDGVNVIKRTDEG 300  
 QY 301 DFRHKSFEVI 310  
 Db 301 DFRHKSFEVI 310  
 RESULT 31  
 ABUS4407  
 ID ABUS4407 standard; Protein; 310 AA.  
 AC ABUS4407;  
 XX  
 XX 10-MAR-2003 (first entry)  
 XX  
 DE Human secreted/transmembrane protein PRO1866.  
 XX  
 KW Human; PRO; secreted protein; transmembrane protein; enterocolitis;  
 KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;  
 KW squamous cell carcinoma; Alzheimer's disease; Parkinson's disease;  
 KW amyotrophic lateral sclerosis; inflammatory disease;  
 KW rheumatoid arthritis; asthma; multiple sclerosis; organ failure;  
 KW atherosclerosis; cardiac injury; infertility; birth defect;

KW premature aging; AIDS; acquired immunodeficiency syndrome; cancer;  
 KW diabetic complication; wound repair.  
 XX  
 OS Homo sapiens.  
 XX  
 EN US2002132240-A1.  
 XX  
 PD 19-SEP-2002.  
 XX  
 PF 18-JUL-2001; 2001US-0909320.  
 XX  
 PR 10-SEP-1998; 98WO-US18824.  
 PR 14-SEP-1998; 98WO-US19177.  
 PR 16-SEP-1998; 98WO-US19330.  
 PR 17-SEP-1998; 98WO-US19437.  
 PR 01-DEC-1998; 98WO-US25108.  
 PR 08-SEP-1999; 99WO-US20594.  
 PR 13-SEP-1999; 99WO-US20944.  
 PR 15-SEP-1999; 99WO-US21090.  
 PR 15-SEP-1999; 99WO-US21547.  
 PR 05-OCT-1999; 99WO-US23089.  
 PR 01-DEC-1999; 99WO-US28301.  
 PR 02-DEC-1999; 99WO-US28564.  
 PR 02-DEC-1999; 99WO-US28565.  
 PR 16-DEC-1999; 99WO-US30095.  
 PR 20-DEC-1999; 99WO-US30911.  
 PR 20-DEC-1999; 99WO-US30999.  
 PR 06-JAN-2000; 2000WO-US00219.  
 PR 11-FEB-2000; 2000WO-US03565.  
 PR 22-FEB-2000; 2000WO-US04414.  
 PR 28-JUL-2000; 2000WO-US20710.  
 PR 24-AUG-2000; 2000WO-US23328.  
 PR 17-SEP-1997; 97US-059113P.  
 PR 17-SEP-1997; 97US-059115P.  
 PR 17-SEP-1997; 97US-059117P.  
 PR 15-OCT-1997; 97US-062125P.  
 PR 17-OCT-1997; 97US-062285P.  
 PR 17-OCT-1997; 97US-062287P.  
 PR 21-OCT-1997; 97US-063486P.  
 PR 24-OCT-1997; 97US-062814P.  
 PR 24-OCT-1997; 97US-062816P.  
 XX  
 PA (GERTH) GENENTECH INC.  
 XX  
 PI Ashkenazi A, Botstein D, Deenoyers L, Eaton DL, Ferrara N,  
 PI Filvaroff E, Fong S, Gao W, Gerder H, Gerritsen WE, Goddard A,  
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IV,  
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI: 2003-147434/14.  
 DR N-PSDB; ABX71810.  
 XX  
 PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing  
 PT or treating inflammatory diseases, organ failure, atherosclerosis,  
 PT cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or  
 PT Parkinson's disease -  
 XX  
 XX Claim 12; Fig 124; 473pp; English.  
 XX  
 CC The invention relates to an isolated PRO polypeptide having at least 80%  
 CC amino acid sequence identity to: (a) any one of 61 fully defined amino  
 CC acid sequences given in the specification (appearing as ABUS437-  
 CC ABUS4407); (b) an amino acid sequence encoded by the nucleotide sequence  
 CC deposited under American Type Culture Collection (accession numbers  
 CC listed in the specification); (c) any one of the PRO sequences which  
 CC lacks its associated signal peptide; (d) an extracellular domain of the  
 CC PRO polypeptide with its associated signal peptide; or (e) an  
 CC extracellular domain of the PRO polypeptide which lacks its associated  
 CC signal peptide. Also include are the nucleic acids encoding the PRO  
 CC polypeptides, vectors, host cells and anti-PRO antibodies.  
 CC The PRO polypeptides and nucleic acids are useful in diagnosing  
 CC or treating enterocolitis, gastrointestinal ulceration, skin diseases

associated with abnormal keratinocyte differentiation, e.g. psoriasis  
 or epithelial cancers such as squamous cell carcinoma, Alzheimer's  
 disease, Parkinson's disease, amyotrophic lateral sclerosis,  
 inflammatory diseases, e.g. rheumatoid arthritis, asthma or multiple  
 sclerosis, organ failure, atherosclerosis, cardiac injury, infertility,  
 birth defects, premature aging, AIDS, cancer, diabetic complications,  
 or mutations in general. The polypeptides are also useful for wound  
 repair and associated therapies concerned with re-growth of tissue. The  
 nucleotide sequences may be used as hybridisation probes in chromosome  
 and gene mapping, or in generating antisense RNA and DNA. PRO nucleic  
 acids are also useful in preparing PRO polypeptides, in assays to  
 identify other proteins or molecules involved in binding reaction, to  
 generate transgenic animals or knockout animals, which in turn are  
 useful in the development and screening of therapeutically useful  
 reagents, for chromosome identification, and tissue typing. The PRO  
 polypeptides and nucleic acid molecules are also useful in gene  
 therapy, and as molecular weight markers for protein electrophoresis  
 purposes. The anti-PRO antibodies may be used in diagnostic assays for  
 PRO, or for the affinity purification of PRO from recombinant cell  
 culture or natural sources. The present sequence represents a PRO  
 polypeptide.

Sequence 310 AA;

Query Match 67.4%; Score 209; DB 24; Length 310;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 MALRRPRLRLCARLDPDFLLFRGCLIGAVNLKSSNRTPVQEFESVELSCIITDSQT 60  
 1 MLRRPRLRLCARLDPDFLLFRGCLIGAVNLKSSNRTPVQEFESVELSCIITDSQT 60  
 61 SDPRIEMKKIODEQTTVFFDNKIOGDLGRAEIIKTSIKIWNVTRRSALYRCEVVAR 120  
 61 SDPRIEMKKIODEQTTVFFDNKIOGDLGRAEIIKTSIKIWNVTRRSALYRCEVVAR 120  
 121 NDRKEIDEIVIELTVQVKPTVPCRVKAVPVGKMATLHCQSEEGHPRHYSWYRNDVPL 180  
 121 NDRKEIDEIVIELTVQVKPTVPCRVKAVPVGKMATLHCQSEEGHPRHYSWYRNDVPL 180  
 121 NDRKEIDEIVIELTVQVKPTVPCRVKAVPVGKMATLHCQSEEGHPRHYSWYRNDVPL 180

181 PTDSSANPRFRNSSHINSETGLVFTVAHKDSSGOYCIASNDASACEQEMEVYDL 240  
 181 PTDSSANPRFRNSSHINSETGLVFTVAHKDSSGOYCIASNDASACEQEMEVYDL 240  
 241 NTGGIIGVLLVAVLALITLIGICAYRRGYFINNKODGESYKNGPKPGVNYIRTDDEG 300  
 241 NTGGIIGVLLVAVLALITLIGICAYRRGYFINNKODGESYKNGPKPGVNYIRTDDEG 300

301 DFRHKSSFYI 310  
 301 DFRHKSSFYI 310

RESULT 32  
 AAB38333  
 ID AAB38333 standard; Protein; 311 AA.

31-JAN-2001 (first entry)  
 Human secreted protein encoded by gene 13 clone HAPSA79.

Immunosuppressive; antiarthritic; antirheumatic; antiproliferative;  
 cytostatic; cardiac; vasotropic; cerebroprotective; neuroprotective;  
 nootropic; antibacterial; virucide; fungicide; ophthalmological; human;  
 vulnerable; gene therapy; infection; secreted protein.

OS Homo sapiens.  
 XX  
 XX WO200061623-A1.  
 XX  
 PD 19-OCT-2000.

06-APR-2000; 2000WO-US08979.  
 09-APR-1999; 99US-0128693.  
 26-APR-1999; 99US-0130991.  
 (HUMA-) HUMAN GENOME SCI INC.

Ruben SM, Ni J, Komatsoulis GA, Rosen CA, Soppet DR, Shi Y,  
 Lafleur DW, Olsen HS, Ebner R, Florence KA, Moore PA, Birse CE,  
 Young PE;  
 WPI; 2000-647418/62.

New nucleic acid molecules encoding 62 human secreted proteins for  
 diagnosing, preventing, treating or ameliorating medical conditions and  
 used as food additives or preservatives -  
 Claim 11; Page 603-604, 716pp; English.

Sequences AAB38321-B38396 represent the amino acid sequences of 62  
 human secreted proteins encoded by the genes AAC69512-C69587. The genes  
 and proteins are useful for preventing, ameliorating or treating medical  
 conditions, e.g. by protein or gene therapy. The genes are isolated from  
 a range of human tissues disclosed in the specification. The nucleic  
 acids, proteins, antibodies and (ant)agonists are useful in the  
 diagnosis, treatment and prevention of: (a) autoimmune diseases e.g.  
 rheumatoid arthritis; (b) hyperproliferative disorders e.g. neoplasms  
 of the breast or liver; (c) cardiovascular disorders e.g. cardiac  
 arrest; (d) cerebrovascular disorders e.g. cerebral ischemia; (e)  
 angiogenesis; (f) nervous system disorders e.g. Alzheimer's disease; (g)  
 infections caused by bacteria, viruses and fungi; and (h) ocular  
 disorders e.g. corneal infection. The polypeptides can also be used to  
 aid wound healing and epithelial cell proliferation, to prevent skin  
 aging due to sunburn, to maintain organs before transplantation, for  
 supporting cell culture of primary tissues, to regenerate tissues and in  
 chemotaxis.

Sequence 311 AA;

Query Match 67.4%; Score 209; DB 21; Length 311;  
 Best Local Similarity 99.7%; Pred. No. 1e-196;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1 MALRRPRLRLCARLDPDFLLFRGCLIGAVNLKSSNRTPVQEFESVELSCIITDSQT 60  
 1 MLRRPRLRLCARLDPDFLLFRGCLIGAVNLKSSNRTPVQEFESVELSCIITDSQT 60  
 61 SDPRIEMKKIODEQTTVFFDNKIOGDLGRAEIIKTSIKIWNVTRRSALYRCEVVAR 120  
 61 SDPRIEMKKIODEQTTVFFDNKIOGDLGRAEIIKTSIKIWNVTRRSALYRCEVVAR 120  
 121 NDRKEIDEIVIELTVQVKPTVPCRVKAVPVGKMATLHCQSEEGHPRHYSWYRNDVPL 180  
 121 NDRKEIDEIVIELTVQVKPTVPCRVKAVPVGKMATLHCQSEEGHPRHYSWYRNDVPL 180  
 121 NDRKEIDEIVIELTVQVKPTVPCRVKAVPVGKMATLHCQSEEGHPRHYSWYRNDVPL 180

181 PTDSSANPRFRNSSHINSETGLVFTVAHKDSSGOYCIASNDASACEQEMEVYDL 240  
 181 PTDSSANPRFRNSSHINSETGLVFTVAHKDSSGOYCIASNDASACEQEMEVYDL 240  
 241 NTGGIIGVLLVAVLALITLIGICAYRRGYFINNKODGESYKNGPKPGVNYIRTDDEG 300  
 241 NTGGIIGVLLVAVLALITLIGICAYRRGYFINNKODGESYKNGPKPGVNYIRTDDEG 300

301 DFRHKSSFYI 310  
 301 DFRHKSSFYI 310

RESULT 33  
 AAB38383  
 ID AAB38383 standard; Protein; 311 AA.

XX

AC AAB38383;  
 XX 31-JAN-2001 (first entry)  
 DE Human secreted protein encoded by gene 13 clone HAPSA79.  
 XX  
 XX Immunosuppressive; antiarthritic; antirheumatic; antiproliferative;  
 KM cytostatic; cardiant; vasotropic; cerebroprotective; neuroprotective;  
 KM nocrotropic; antibacterial; virucide; fungicide; ophthalmological; human;  
 KM vulnery; gene therapy; infection; secreted protein.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200061623-A1.  
 XX  
 XX 19-OCT-2000.  
 XX  
 XX 06-APR-2000; 2000WO-US08979.  
 XX  
 XX 09-APR-1999; 99US-0128693.  
 XX 26-APR-1999; 99US-0130991.  
 XX  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Ruben SM, Ni J, Komatsoulis GA, Rosen CA, Soppet DR, Shi Y,  
 PI Lafleur DW, Olsen HS, Ebner R, Florence KA, Moore PA, Birse CE,  
 PI Young PE;  
 XX  
 XX WPI, 2000-647418/62.  
 DR  
 XX  
 XX New nucleic acid molecules encoding 62 human secreted proteins for  
 PT diagnosing, preventing, treating or ameliorating medical conditions and  
 PT used as food additives or preservatives -  
 XX  
 PS Claim 11; Page 642-643; 716pp; English.  
 XX  
 XX Sequences AAB38321-B38396 represent the amino acid sequences of 62  
 CC human secreted proteins encoded by the genes AAC69512-C69587. The genes  
 CC and proteins are useful for preventing, ameliorating or treating medical  
 CC conditions, e.g. by protein or gene therapy. The genes are isolated from  
 CC a range of human tissues disclosed in the specification. The nucleic  
 CC acids, proteins, antibodies and (ant)agonists are useful in the  
 CC diagnosis, treatment and prevention of: (a) autoimmune diseases e.g.  
 CC rheumatoid arthritis; (b) hyperproliferative disorders e.g. neoplasms  
 CC of the breast or liver; (c) cardiovascular disorders e.g. cardiac  
 CC arrest; (d) cerebrovascular disorders e.g. cerebral ischemia; (e)  
 CC anglogenesis; (f) nervous system disorders e.g. Alzheimer's disease; (g)  
 CC infections caused by bacteria, viruses and fungi; and (h) ocular  
 CC disorders e.g. corneal infection. The polypeptides can also be used to  
 CC aid wound healing and epithelial cell proliferation, to prevent skin  
 CC aging due to sunburn, to maintain organs before transplantation, for  
 CC supporting cell culture of primary tissues, to regenerate tissues and in  
 CC chemotaxis.  
 CC  
 XX  
 XX Sequence 311 AA;  
 SQ  
 Query Match 67.4%; Score 209; DB 21; Length 311;  
 Best Local Similarity 99.7%; Pred. No. 1e-186; Indels 0; Gaps 0;  
 Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 MALRRPRLRLCARLPDFLLLLFRGCLIGANLKSSNTPVVOEFSEVELSCITTDQT 60  
 DB 1 MALRRPRLRLCARLPDFLLLLFRGCLIGANLKSSNTPVVOEFSEVELSCITTDQT 60  
 QY 61 SDPRIEWKKIQDEQTTTYVFEDNKKIQGLAGRAELIGKTSLSKTMVTRDSALYRECVAR 120  
 DB 61 SDPRIEWKKIQDEQTTTYVFEDNKKIQGLAGRAELIGKTSLSKTMVTRDSALYRECVAR 120  
 QY 121 NDRKEIDELVIELTQVQKVPVCRPKAVPVGKATLLHQSESGPRPHYSWYNDVPL 180  
 DB 121 NDRKEIDELVIELTQVQKVPVCRPKAVPVGKATLLHQSESGPRPHYSWYNDVPL 180  
 QY 181 PTDSRANPRFRNSSHLSNSETGLVFTAVHKDSDGOYYCIAASNDGARSARCEQEMEYVDL 240

DB 181 PTDSRANPRFRNSSHLSNSETGLVFTAVHKDSDGOYYCIAASNDGARSARCEQEMEYVDL 240  
 QY 241 NIGGIGGVVLLVLLTLTGICAVRGGVFINNKKDGSYSKPKGPDGNYRTREEG 300  
 DB 241 NIGGIGGVVLLVLLTLTGICAVRGGVFINNKKDGSYSKPKGPDGNYRTREEG 300  
 QY 301 DFRKKSSEFVI 310  
 DB 301 DFRKKSSEFVI 310  
 RESULT 34  
 AAB38384  
 ID AAB38384 standard; Protein; 311 AA.  
 XX  
 XX AAB38384;  
 XX  
 XX 31-JAN-2001 (first entry)  
 XX  
 XX Human secreted protein encoded by gene 13 clone HAPSA79.  
 DE  
 XX Immunosuppressive; antiarthritic; antirheumatic; antiproliferative;  
 KM cytostatic; cardiant; vasotropic; cerebroprotective; neuroprotective;  
 KM nocrotropic; antibacterial; virucide; fungicide; ophthalmological; human;  
 KM vulnery; gene therapy; infection; secreted protein.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200061623-A1.  
 XX  
 XX 19-OCT-2000.  
 XX  
 XX 06-APR-2000; 2000WO-US08979.  
 XX  
 XX 09-APR-1999; 99US-0128693.  
 XX 26-APR-1999; 99US-0130991.  
 XX  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Ruben SM, Ni J, Komatsoulis GA, Rosen CA, Soppet DR, Shi Y,  
 PI Lafleur DW, Olsen HS, Ebner R, Florence KA, Moore PA, Birse CE,  
 PI Young PE;  
 XX  
 XX WPI, 2000-647418/62.  
 DR  
 XX  
 XX New nucleic acid molecules encoding 62 human secreted proteins for  
 PT diagnosing, preventing, treating or ameliorating medical conditions and  
 PT used as food additives or preservatives -  
 XX  
 PS Claim 11; Page 643-644; 716pp; English.  
 XX  
 XX Sequences AAB38321-B38396 represent the amino acid sequences of 62  
 CC human secreted proteins encoded by the genes AAC69512-C69587. The genes  
 CC and proteins are useful for preventing, ameliorating or treating medical  
 CC conditions, e.g. by protein or gene therapy. The genes are isolated from  
 CC a range of human tissues disclosed in the specification. The nucleic  
 CC acids, proteins, antibodies and (ant)agonists are useful in the  
 CC diagnosis, treatment and prevention of: (a) autoimmune diseases e.g.  
 CC rheumatoid arthritis; (b) hyperproliferative disorders e.g. neoplasms  
 CC of the breast or liver; (c) cardiovascular disorders e.g. cardiac  
 CC arrest; (d) cerebrovascular disorders e.g. cerebral ischemia; (e)  
 CC anglogenesis; (f) nervous system disorders e.g. Alzheimer's disease; (g)  
 CC infections caused by bacteria, viruses and fungi; and (h) ocular  
 CC disorders e.g. corneal infection. The polypeptides can also be used to  
 CC aid wound healing and epithelial cell proliferation, to prevent skin  
 CC aging due to sunburn, to maintain organs before transplantation, for  
 CC supporting cell culture of primary tissues, to regenerate tissues and in  
 CC chemotaxis.  
 CC  
 XX  
 XX Sequence 311 AA;  
 SQ  
 Query Match 67.4%; Score 209; DB 21; Length 311;

Best Local Similarity 99.7%; Pred. No. 1e-196;  
Matches 309; Conservative 0; Mismatches 1; Indels 0; Gaps 0

Qy	1	MAJRRPRJLCARLDPFELLLFRCLGAVNLKSNRTPVQEFEEVELSCLITDSQT	60
Dp	1	MAJRRPRJLCARLDPFELLLFRCLGAVNLKSNRTPVQEFEEVELSCLITDSQT	60
Qy	61	SDPRIEWKKI QODQTYTVFPPDNKIQDLAGRAELIGKTSLKIMVTRDLSLYRCEVYAR	120
Dp	61	SDPRIEWKKI QODQTYTVFPPDNKIQDLAGRAELIGKTSLKIMVTRDLSLYRCEVYAR	120
Qy	121	NDRKEIDEIVIELTVQKVPVTCYCRPKVAPVGGKATLHCQESGHPHYXSWYRNDVPL	180
Dp	121	NDRKEIDEIVIELTVQKVPVTCYCRPKVAPVGGKATLHCQESGHPHYXSWYRNDVPL	180
Qy	181	PTSSRANPRRRNSSHLINSEGTGLVPTANHKDSSQYCIASNDAGSARCEQEMERYDL	240
Dp	181	PTSSRANPRRRNSSHLINSEGTGLVPTANHKDSSQYCIASNDAGSARCEQEMERYDL	240
Qy	241	NIGGIIIGVULVAVLALITLIGICAYRRGVYINNKGQESYKMPGKDGUVNYIRTDDEG	300
Dp	241	NIGGIIIGVULVAVLALITLIGICAYRRGVYINNKGQESYKMPGKRDGVNYIRTDDEG	300
Qy	301	DFRRKSSFVI 310	
Dp	301	DFRRKSSFVI 310	

RESULT 35  
AAB80431  
ID AAB80431 standard; peptide; 339 AA

XX	Sequence	339	AA;
SQ			

Query Match	67.4%	Score 209	DB 22	Length 339
Best Local Similarity	99.7%	Pred. No. 1.1e-196		
Matches	309	Conservative	0	Mismatches 1; Indels 0; Gaps 0
QY	1	MALRRPRLTCAALPDPFFLLLPFGCCLIGAVNNKSSNRTPVVOEFSESVETLSCTITDSDT	60	
DB	30	MALRRPRLTCAARLPDPFFLLLPFGCCLIGAVNNKSSNRTPVVOEFSESVETLSCTITDSDT	89	
QY	61	SDPRLEWKKIODEQTTVYFDPNKKIOGDLAGRAELIGKTSLKIMNTRRDSALRYCEVVAR	120	
DB	90	SDPRLEWKKIODEQTTVYFDPNKKIOGDLAGRAELIGKTSLKIMNTRRDSALRYCEVVAR	149	
QY	121	NDRREIDBIVELTVQVKPVPYCRVPRAVVGKATLHCQSEBGRPHYSWYENDVPL	180	
DB	150	NDRREIDBIVELTVQVKPVPYCRVPRAVVGKATLHCQSEBGRPHYSWYENDVPL	209	
QY	181	PTDSRANRFRNSSSHLNSSETGLVFTAVHKDDSQYYCIASNDAGSARCEOEEMEYVDL	240	
DB	210	PTDSRANRFRNSSSHLNSSETGLVFTAVHKDDSQYYCIASNDAGSARCEOEEMEYVDL	269	
QY	241	NIGGIGGVVLVLAALITLIGICAVYRGYFINNKKOGESYKNGKRGDGVYIRTTDEEG	300	
DB	270	NIGGIGGVVLVLAALITLIGICAVYRGYFINNKKOGESYKNGKRGDGVYIRTTDEEG	329	

RESULT 36  
ABP41902  
ID ABP41902 standard; Protein; 329 AA

PT neurological diseases -  
XX  
XX Claim 11; SEQ ID No 3034; 2922pp; English.  
CC The invention relates to 2175 novel human ovarian antigens (ABP41054-  
XX ABP43228) and to cDNAs encoding them (AB054131-AB056305), and also  
CC encompasses polypeptides 90% identical and polynucleotides 95% identical  
CC to the sequences of the invention. The invention additionally relates to  
CC recombinant vectors and host cells comprising human ovarian antigen  
CC polynucleotides, antibodies against human ovarian antigens, and the use  
CC of ovarian antigen polynucleotides and polypeptides in diagnosing,  
CC treating, prognosing or preventing various ovarian and/or breast-related  
CC disorders. Such conditions include ovarian cancer and breast cancer, and  
CC metastatic tumours of ovarian or breast origin, reproductive system  
CC disorders (e.g., infertility, disorders of pregnancy, anovulation,  
CC polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine  
CC disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic  
CC shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and  
CC vaginitis), immune disorders (e.g., congenital and acquired  
CC immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),  
CC blood-related disorders (e.g., anaemia), cardiovascular disorders,  
CC respiratory disorders, neurological disorders, gastrointestinal disorders  
CC and urinary system disorders. Ovarian antigen polypeptides and  
CC polynucleotides may also be used in screening for compounds which  
CC modulate ovarian antigen expression or activity. The polynucleotides may  
CC further be used for gene therapy, chromosome mapping, in the  
CC identification of individuals and in forensic analysis, and the  
CC polypeptides may be used as food additives or to prepare antibodies  
CC useful in disease diagnosis, drug targeting and phenotyping. The present  
CC sequence represents a human ovarian antigen of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences.  
XX  
XX  
SQ Sequence 329 AA;

Query Match 66.8%; Score 207; DB 23; Length 329;  
Best Local Similarity 99.7%; Pred. No. 1e-194;  
Matches 307; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 LRRPRLRLCARLPDFLLFRGCLIGAVNKKSNRTPVVOEFSEVLSCTITDSQTS 62  
DB 22 LRRPRLRLCARLPDFLLFRGCLIGAVNKKSNRTPVVOEFSEVLSCTITDSQTS 81  
QY 63 PRIEMKKIODEQTYVFPDNKIQSDLAGRAELIGKTSLKIMWVTRDSALRCEVARN 122  
DB 82 PRIEMKKIODEQTYVFPDNKIQSDLAGRAELIGKTSLKIMWVTRDSALRCEVARN 141  
QY 123 RKEIDEIYELTVQKVPVTPVCRVPAVPGKATLHCOESGHPHRYSWYRNDVPT 182  
DB 142 RKEIDEIYELTVQKVPVTPVCRVPAVPGKATLHCOESGHPHRYSWYRNDVPT 201  
QY 183 DSRANPRFRNSSSHLNSGTGLVFTAVHKDSDGQYYCIASNDAGSARCEDEMEVYDINI 242  
DB 202 DSRANPRFRNSSSHLNSGTGLVFTAVHKDSDGQYYCIASNDAGSARCEDEMEVYDINI 261  
QY 243 GGIIGGVVAVLAVALLITGLICCAVRGRTINNKDGSYKPKGPDGVNTRTDEGDF 302  
DB 262 GGIIGGVVAVLAVALLITGLICCAVRGRTINNKDGSYKPKGPDGVNTRTDEGDF 321  
QY 303 RHKSSFVI 310  
DB 322 RHKSSFVI 329

RESULT 37  
AB06037  
ID AB06037 standard; Protein; 321 AA.

XX AC AB06037;  
XX DT 10-MAY-2002 (first entry)  
XX

DE Human NS protein sequence SEQ ID NO:129.  
XX  
XX Human; cytostatic; osteopathic; gynaecological; neuroprotective;  
KW antihemnetic; antiarthritic; antipsoriatic; ophthalmological; anti-HIV;  
KW vasotropic; antiarteriosclerotic; antiinflammatory; dermatological;  
KW anorectic; muscular; antinfertility; cardiovascular; anticoagulant;  
KW antifibrinolytic; hypotension; antiaesthetic; immunomodulator; cardiant;  
KW anticonvulsant; antidiabetic; tranquilliser; antidepressant; neuroleptic;  
KW gastrointestinal; virocidic; antitumor; cerebroprotective; nootropic;  
KW contraceptive; vaccine; gene therapy; cancer; osteoporosis; dystonia;  
KW endometriosis; degenerative disease; multiple sclerosis; psoriasis;  
KW rheumatoid arthritis; catarract; restenosis; atherosclerosis; glaucoma;  
KW inflammation; skin disorder; obesity; muscular dystrophy; AIDS;  
KW infertility; cardiovascular disease; coagulation disease; hypertension;  
KW ischaemia; asthma; immune disease; epilepsy; angina; neurodegeneration;  
KW diabetes; anxiety; depression; schizophrenia; viral disease; stroke;  
KW gastric ulcer; Alzheimer's disease.

OS Homo sapiens.  
XX  
XX WO000206315-A2.  
XX  
XX 24-JAN-2002.  
XX  
XX 17-JUL-2001; 2001WO-1100653.  
XX  
XX 18-JUL-2000; 2000IL-0137345.  
XX 15-DEC-2000; 2000IL-0140354.  
XX  
XX (COMP-) COMPUGEN LTD.  
XX  
XX Mintz L, Freilich S, Bernstein J;  
XX WPI; 2002-155037/20.  
XX N-PSDB; ABL39691.  
XX  
XX One hundred and twenty eight novel nucleic acid sequences, useful for  
XX treating and diagnosing e.g. cancer, asthma and Alzheimer's -  
XX  
XX  
XX Claim 6; Page 148-149; 290pp; English.

ABU39691 to ABL39818 represent novel human nucleic acid sequences  
CC encoding the proteins given in AB06037 to AB06164. The novel sequences  
CC (NS) can have cytostatic, osteopathic, gynaecological, neuroprotective,  
CC antihemnetic, antiarthritic, antipsoriatic, ophthalmological, virocidic,  
CC vasotropic, antiarteriosclerotic, antiinflammatory, dermatological,  
CC anorectic, muscular, anti-HIV, antinfertility, cardiovascular,  
CC immunomodulator, anticonvulsant, antidiabetic, tranquilliser, antitumor,  
CC immunopressant, gastrointestinal, neuroleptic, cerebroprotective,  
CC nootropic and contraceptive activities. The NS can be used in vaccines,  
CC gene therapy and antineuse therapy. Nucleic acids, expression vectors and  
CC antibodies from the present invention can be used for treating and  
CC diagnosing e.g. cancer, osteoporosis, endometriosis, degenerative  
CC diseases, dystonia, multiple sclerosis, rheumatoid arthritis, psoriasis,  
CC catarracts, restenosis, atherosclerosis, inflammation, skin disorders,  
CC glaucoma, obesity, muscular dystrophy, AIDS, infertility, cardiovascular  
CC disease, coagulation disease, ischaemia, hypertension, asthma, immune  
CC disease, epilepsy, angina, neurodegeneration, diabetes, anxiety,  
CC depression, schizophrenia, viral disease, gastric ulcers, stroke,  
CC Alzheimer's disease and as a contraceptive.

XX  
SQ Sequence 321 AA;  
Query Match 44.8%; Score 139; DB 23; Length 321;  
Best Local Similarity 100.0%; Pred. No. 6.4e-128;  
Matches 139; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 ALRRPRLRLCARLPDFLLFRGCLIGAVNKKSNRTPVVOEFSEVLSCTITDSOTS 61  
DB 20 ALRRPRLRLCARLPDFLLFRGCLIGAVNKKSNRTPVVOEFSEVLSCTITDSOTS 79  
QY 62 DRIEMKKIODEQTYVFPDNKIQSDLAGRAELIGKTSLKIMWVTRDSALRCEVARN 121

```

DB      80 DPEIEKKIQDEQTTVFEDNKKIQGLAGRAEILGKTSIKIMVWTRDSALYRCEVAVRN 139
QY      122 DRKEIDEIVELTVQYKPV 140
DB      140 DRKEIDEIVELTVQYKPV 158

RESULT 38
AAB39254
ID      AAB39254 standard; Protein; 285 AA.
XX
AC      AAB39254;
XX
DT      02-FEB-2001 (first entry)
XX
DE      Human secreted protein sequence encoded by gene 15 SEQ ID NO:134.
XX
KW      Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
KW      antiproliferative; cyostatic; cardiant; vasotropic; cerebroprotective;
KW      neurotropic; neuroprotective; antibacterial; virucide; fungicide; neoplasm;
KW      ophthalmological; autoimmune disease; rheumatoid arthritis; angiogenesis;
KW      hyperproliferative disorder; cardiovascular disorder; infection;
KW      cerebrovascular disorder; nervous system disorder; ocular disorder;
KW      wound healing; chemotaxis.
XX
OS      Homo sapiens.
XX
MO      MO200056754-A1.
XX
PD      28-SEP-2000.
XX
PF      16-MAR-2000; 2000MO-US06792.
XX
PR      19-MAR-1999; 99US-0125362.
XX      10-DEC-1999; 99US-0169980.
XX
PA      (HUMA-) HUMAN GENOME SCI INC.
XX
PI      Rosen GA, Ruben SM, Komatsoulis G;
XX      WPI; 2000-579483/54.
XX      N-PSDB; AAC74237.
XX
PT      Isolated nucleic acid molecule encoding a human secreted protein is
XX      used in preventing, treating or ameliorating a medical condition -
XX
PS      Disclosure; Page 32; 434pp; English.
XX
CC      The polynucleotide sequences given in AAC74223-C74279 encode the human
CC      secreted proteins represented in AAB39179-B39226. Sequences
CC      AAB39227-B39308 are alternative proteins encoded by the genes, and also
CC      protein sequences with which they share homology. The proteins have
CC      activities based on the tissues and cells in which they are expressed.
CC      Examples of activities include: immunosuppressive; antiarthritic;
CC      antirheumatic; antiproliferative; cyostatic; cardiant; vasotropic;
CC      cerebroprotective; neurotropic; neuroprotective; antibacterial; virucide;
CC      fungicide; and ophthalmological. The human secreted proteins,
CC      polynucleotides, antagonists and agonists of the invention may be useful
CC      in the treatment, prevention, and/or diagnosis of various disease,
CC      disorders and conditions such as autoimmune diseases e.g. rheumatoid
CC      arthritis, hyperproliferative disorders e.g. neoplasms of the breast or
CC      liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular
CC      disorders e.g. cerebral ischemia, angiogenesis, nervous system disorders
CC      e.g. Alzheimer's disease, infections caused by bacteria, viruses and
CC      fungi and ocular disorders e.g. corneal infection. The polypeptides can
CC      also be used to aid wound healing and epithelial cell proliferation, to
CC      regenerate tissues, maintain organs before transplantation, in
CC      chemotaxis and as a food additive or preservative e.g. to increase
CC      storage capabilities. Sequences AAC74214-C74222 and AAB39178 are used
CC      during the isolation and characterisation of the genes of the invention.
XX
SQ      Sequence 285 AA;

```

```

Query Match      37.1%; Score 115; DB 21; Length 285;
Best Local Similarity 100.0%; Pred. No. 2,2e-104;
Matches 115; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      196 HUNSETGTVLPTFAVHKDSDGQYYCIASNDAGSARCEBDEMEYVDINIGIIGVLVLAV 255
DB      171 HUNSETGTVLPTFAVHKDSDGQYYCIASNDAGSARCEBDEMEYVDINIGIIGVLVLAV 230

QY      256 LALITLIGICAAVRCGYFINNKODGESYKNPKGPDGVNRYRTDEGDFRHKSSFVI 310
DB      231 LALITLIGICAAVRCGYFINNKODGESYKNPKGPDGVNRYRTDEGDFRHKSSFVI 285

RESULT 39
AA016453
ID      AA016453 standard; protein; 310 AA.
XX
AC      AA016453;
XX
DT      17-APR-2003 (first entry)
XX
DE      Human junctional adhesion molecule 3 (hujam3).
XX
KW      Human; gene therapy; extracellular region; junctional adhesion molecules;
KW      hujam; immune system disorder; immune deficiency; autoimmune disorder;
KW      inflammatory disorder; cancer; wound healing; cardiovascular disease;
KW      full-length membrane-bound hujam protein.
XX
OS      Homo sapiens.
XX
FH      Key Location/Qualifiers
FH      Peptide 1..30
FT      Misc-difference 15 /label= Signal_peptide
FT      Domain /note= "Encoded by ATG"
FT      Protein /note= "Extracellular domain; Specifically claimed region"
FT      Protein 31..310 /note= "Mature hujam3"
FT      Misc-difference 46 /note= "Encoded by TTT"
FT      Misc-difference 87 /note= "Encoded by AGC"
FT      Misc-difference 136 /note= "Encoded by CAA"
FT      Misc-difference 191 /note= "Encoded by GC"
FT      Misc-difference 195 /note= "Encoded by TCC"
XX
PN      MO2003008541-A2.
XX
PD      30-JAN-2003.
XX
PF      05-JUL-2002; 2002MO-US19800.
XX
PR      16-JUL-2001; 2001US-305752P.
XX      05-FEB-2002; 2002US-354345P.
XX
PA      (ELIL) LILLY & CO ELLI.
XX
PI      Heuer JG, Smith RC, Su EW;
XX      WPI; 2003-221848/21.
XX      N-PSDB; AAL51600.
XX
PT      New extracellular human junctional adhesion molecule (hujam)
PT      polypeptide, useful for treating an immune system disorder such as an
PT      immune deficiency or an inflammatory disorder, cancer, wound healing,
PT      or a cardiovascular disease
XX

```

PS Disclosure; Fig 1; 131pp; English.

XX The invention comprises the DNA and protein sequences of the

CC extracellular region of human junctional adhesion molecules (hJAM). The

CC extracellular hJAM DNA and protein sequences are useful in the treatment

CC of: immune system disorders (e.g. immune deficiency); autoimmune

CC disorders; inflammatory disorders; cancer; wound healing; or a

CC cardiovascular disease. The present amino acid sequence represents the

CC full-length membrane-bound hJAM3 protein.

XX

SEQ Sequence 310 AA;

Query Match 37.1%; Score 115; DB 24; Length 310;

Best Local Similarity 100.0%; Pred. No. 2.3e-104;

Matches 115; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 196 HLNSTGTLVFAVHKDSDGQYCIASNDAGSARCEDEMEYDINIGIIGVILVLAIV 255

DB 196 HLNSTGTLVFAVHKDSDGQYCIASNDAGSARCEDEMEYDINIGIIGVILVLAIV 255

OY 256 LALITLIGICCAVRGFFINNKODGESYKPKGPDGVNITRDEGDFPHKSFVI 310

DB 256 LALITLIGICCAVRGFFINNKODGESYKPKGPDGVNITRDEGDFPHKSFVI 310

RESULT 40

ABG04645

ID ABG04645 standard; Protein; 291 AA.

XX

AC ABG04645;

XX

DT 13-FEB-2002 (first entry)

XX

DB Novel human diagnostic protein #4636.

XX

DE Human; chromosome mapping; gene mapping; gene therapy; forensic;

XX

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;

XX

KW food supplement; medical imaging; diagnostic; genetic disorder.

XX

OS Homo sapiens.

XX

PN WO200175067-A2.

XX

PD 11-OCT-2001.

XX

PF 30-MAR-2001; 2001WO-US08631.

XX

PR 31-MAR-2000; 2000US-0540217.

XX

PR 23-AUG-2000; 2000US-0649167.

XX

PA (HYSE-) HYSEQ INC.

XX

PI Drmanac RT, Liu C, Tang YT;

XX

PI

XX

DR WPI: 2001-639362/73.

XX

DR N-PSDB; AAS68832.

XX

PT New isolated polynucleotide and encoded polypeptides, useful in

XX

PT diagnostics, forensics, gene mapping, identification of mutations

XX

PT responsible for genetic disorders or other traits and to assess

XX

PT biodiversity -

XX

PS Claim 20; SEQ ID No 35004; 103pp; English.

XX

XX The invention relates to isolated polynucleotide (I) and

XX

CC polypeptide (II) sequences. (I) is useful as hybridization probes,

XX

CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome

XX

CC and gene mapping, and in recombinant production of (II). The

XX

CC polynucleotides are also used in diagnostics as expressed sequence tags

XX

CC for identifying expressed genes. (I) is useful in gene therapy techniques

XX

CC to restore normal activity of (II) or to treat disease states involving

XX

CC (II). (II) is useful for generating antibodies against it, detecting or

XX

CC quantitating a polypeptide in tissue, as molecular weight markers and as

XX

CC a food supplement. (II) and its binding partners are useful in medical

CC imaging of sites expressing (II). (I) and (II) are useful for treating

CC disorders involving aberrant protein expression or biological activity.

CC The polypeptide and polynucleotide sequences have applications in

CC diagnostics, forensics, gene mapping, identification of mutations

CC and to produce other types of data and products dependent on DNA and

CC amino acid sequences. ABG00010-ABG30377 represent novel human

CC diagnostic amino acid sequences of the invention.

CC Note: The sequence data for this patent did not appear in the printed

CC specification, but was obtained in electronic format directly from WIPO

XX

CC at ftp.wipo.int/pub/published\_pct\_sequences.

XX

SEQ Sequence 291 AA;

Query Match 34.8%; Score 108; DB 22; Length 291;

Best Local Similarity 100.0%; Pred. No. 1.7e-97;

Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 87 DLAGRAEILGKTSIKINWTRRDSALYRCVAVANDRKEIDEIVIELTVQKPTVPCRV 146

DB 134 DLAGRAEILGKTSIKINWTRRDSALYRCVAVANDRKEIDEIVIELTVQKPTVPCRV 193

OY 147 PKAVPVGMATLHCQSEEGHPRPHYSWYRNDVPLPTDSRANPRFRNS 194

DB 194 PKAVPVGMATLHCQSEEGHPRPHYSWYRNDVPLPTDSRANPRFRNS 241

RESULT 41

ABG12109

ID ABG12109 standard; Protein; 404 AA.

XX

AC ABG12109;

XX

DT 18-FEB-2002 (first entry)

XX

DB Novel human diagnostic protein #12100.

XX

DE Human; chromosome mapping; gene mapping; gene therapy; forensic;

XX

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;

XX

KW food supplement; medical imaging; diagnostic; genetic disorder.

XX

OS Homo sapiens.

XX

PN WO200175067-A2.

XX

PD 11-OCT-2001.

XX

PF 30-MAR-2001; 2001WO-US08631.

XX

PR 31-MAR-2000; 2000US-0540217.

XX

PR 23-AUG-2000; 2000US-0649167.

XX

PA (HYSE-) HYSEQ INC.

XX

PI Drmanac RT, Liu C, Tang YT;

XX

PI

XX

DR WPI: 2001-639362/73.

XX

DR N-PSDB; AAS76296.

XX

PT New isolated polynucleotide and encoded polypeptides, useful in

XX

PT diagnostics, forensics, gene mapping, identification of mutations

XX

PT responsible for genetic disorders or other traits and to assess

XX

PT biodiversity -

XX

PS Claim 20; SEQ ID No 42468; 103pp; English.

XX

XX The invention relates to isolated polynucleotide (I) and

XX

CC polypeptide (II) sequences. (I) is useful as hybridization probes,

XX

CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome

XX

CC and gene mapping, and in recombinant production of (II). The

XX

CC polynucleotides are also used in diagnostics as expressed sequence tags

XX

CC for identifying expressed genes. (I) is useful in gene therapy techniques

XX

CC to restore normal activity of (II) or to treat disease states involving

XX

CC (II). (II) is useful for generating antibodies against it, detecting or

quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (ii) and its binding partners are useful in medical imaging of sites expressing (ii). (i) and (ii) are useful for treating disorders involving aberrant protein expression or biological activity. The polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG0010-ABG3037 represent novel human diagnostic amino acid sequences of the invention.

Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

CC Sequence 404 AA;

Query Match 34.8%; Score 108; DB 22; Length 404;  
Best Local Similarity 100.0%; Pred. No. 2.2e-97;  
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 87 DLGAEILGKTSIKIMVTRDSALYRCCEVVAANDRKEIDEIVIELTVQKPTVPCRY 146  
DB 134 DLGAEILGKTSIKIMVTRDSALYRCCEVVAANDRKEIDEIVIELTVQKPTVPCRY 193

QY 147 PKAVPVGKATLHCQSESEGHPRPHYSWYRNDVLPPTDSRANPRFRNSS 194  
DB 194 PKAVPVGKATLHCQSESEGHPRPHYSWYRNDVLPPTDSRANPRFRNSS 241

#### RESULT 42

ABG22401  
ID ABG22401 standard; Protein: 361 AA.

AC ABG22401;

DT 18-FEB-2002 (first entry)

DE Novel human diagnostic protein #22392.

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.

OS Homo sapiens.

PN MO200175067-A2.

XX 11-OCT-2001.

PF 30-MAR-2001; 2001MO-US08631.

PR 31-MAR-2000; 2000US-0540217.

XX 23-AUG-2000; 2000US-0649167.

PA (HYSE-) HYSEQ INC.

PI Drmanac RT, Liu C, Tang YT;

DR WPI; 2001-639362/73.

XX N-PSDB; AAS86388.

PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity -

XX Claim 20; SEQ ID No 52760; 103pp; English.

CC The invention relates to isolated polynucleotide (i) and  
CC polypeptide (ii) sequences. (i) is useful as hybridisation probes,  
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
CC and gene mapping, and in recombinant production of (ii). The  
CC polynucleotides are also used in diagnostics as expressed sequence tags  
CC for identifying expressed genes. (i) is useful in gene therapy techniques

to restore normal activity of (ii) or to treat disease states involving (ii). (ii) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (ii) and its binding partners are useful in medical imaging of sites expressing (ii). (i) and (ii) are useful for treating disorders involving aberrant protein expression or biological activity. The polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG0010-ABG3037 represent novel human diagnostic amino acid sequences of the invention.

Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

CC Sequence 361 AA;

Query Match 33.5%; Score 104; DB 22; Length 361;  
Best Local Similarity 100.0%; Pred. No. 1.7e-93;  
Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 26 GCLIGAVNKKSNRPVVOEFESVELSCITTSOTSDDPRIEMKTIODEQTIVFPDNKIQ 85  
DB 35 GCLIGAVNKKSNRPVVOEFESVELSCITTSOTSDDPRIEMKTIODEQTIVFPDNKIQ 94

QY 86 GDLGAEILGKTSIKIMVTRDSALYRCCEVVAANDRKEIDEI 129  
DB 95 GDLGAEILGKTSIKIMVTRDSALYRCCEVVAANDRKEIDEI 138

#### RESULT 43

AAV11472  
ID AAV11472 standard; Protein: 89 AA.

AC AAV11472;

DT 21-JUN-1999 (first entry)

DE Human 5' EST secreted protein SEQ ID No 294.

KW Human; secreted protein; EST; expressed sequence tag; diagnosis;

KW forensic; gene therapy; chromosome mapping; signal peptide;

KW upstream regulatory sequence; cytokine activity; cell proliferation;

KW differentiation; haematopoiesis regulation; tissue growth regulation;

KW reproductive hormone regulation; chemotactic; haemostatic;

KW thrombolytic; anti-inflammatory; tumour inhibition.

OS Homo sapiens.

PN MO9906551-A2.

XX 11-FEB-1999.

PF 31-JUL-1998; 98WO-1B01235.

PR 01-AUG-1997; 97US-0905133.

XX (GEST) GENSET.

PI Duclert A, Dumas Milne Edwards J, Lacroix B;

DR WPI; 1999-153781/13.

XX N-PSDB; AAX39538.

PT New nucleic acids encoding human secreted - proteins obtained from  
PT cDNA libraries prepared from substantia nigra, cerebellum, surreals  
PT and fetal brain tissue  
XX  
PS Claim 34; Page 394; 434pp; English.  
XX AAX39440 to AAX39597 represent 5' expressed sequence tags (ESTs) for  
CC human secreted proteins, and encode the proteins given in AAV11374 to

CC AAY151, respectively. The proteins given represent the signal peptide  
CC and an N-terminal fragment of a secreted protein. The nucleic acid  
CC sequences can be used for producing secreted human gene products. They  
CC can also be used to develop products for diagnosis and therapy. The  
CC proteins obtained may have cytokine activity, haematopoiesis regulating  
CC proliferation/differentiation activity, reproductive hormone  
CC activity, tissue growth regulating activity, reproductive hormone  
CC regulating activity, chemotactic/chemokinetic activity, haemostatic and  
CC thrombolytic activity, receptor/ligand activity, anti-inflammatory  
CC activity, tumour inhibition activity or other activities. The products  
CC can be used in forensic, gene therapy and chromosome mapping procedures.  
CC The sequences can also be used for obtaining corresponding promoter  
CC sequences. The nucleic acids encoding the signal peptide can be used for  
CC directing extracellular secretion of a polypeptide or the insertion of a  
CC polypeptide into a membrane, or importing a polypeptide into a cell.

XX Sequence 89 AA;

SO Query Match 28.7%; Score 89; DB 20; Length 89;

Best Local Similarity 100.0%; Pred. No. 2.8e-79;

Matches 89; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALRPPRLRCARLPDFLLLFRCGLIGAVNLKSNRTPVQEPSEYELSCITTSQT 60

DB 1 MALRPPRLRCARLPDFLLLFRCGLIGAVNLKSNRTPVQEPSEYELSCITTSQT 60

QY 61 SDPRIEMKKIODEQTYVPFDMKIQGDLA 89

DB 61 SDPRIEMKKIODEQTYVPFDMKIQGDLA 89

RESULT 44

ABG27038 standard; Protein: 267 AA.

XX AC ABG27038;

DT 18-FEB-2002 (first entry)

DE Novel human diagnostic protein #27029.

XX Human; chromosome mapping; gene mapping; gene therapy; forensic;

KW food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN WO200175067-A2.

XX PD 11-OCT-2001.

PF 30-MAR-2001; 2001WO-US08631.

PR 31-MAR-2000; 2000US-0540217.

PR 23-AUG-2000; 2000US-0649167.

PA (HYSE-) HYSEQ INC.

PI Drmanac RT, Liu C, Tang YT;

DR WPI: 2001-639362/73.

DR N-PSDB; AAS91225.

XX New isolated polynucleotide and encoded polypeptides, useful in

PT diagnostics, forensics, gene mapping, identification of mutations

PT responsible for genetic disorders or other traits and to assess

PT biodiversity -

PS Claim 20; SEQ ID No 57397; 103bp; English.

XX The invention relates to isolated polynucleotide (I) and

CC polypeptide (II) sequences. (I) is useful as hybridisation probes,

CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome

CC and gene mapping, and in recombinant production of (II). The

CC polynucleotides are also used in diagnostics as expressed sequence tags  
CC for identifying expressed genes. (I) is useful in gene therapy techniques  
CC to restore normal activity of (II) or to treat disease states involving  
CC (II). (II) is useful for generating antibodies against it, detecting or  
CC quantitating a polypeptide in tissue, as molecular weight markers and as  
CC a food supplement. (II) and its binding partners are useful in medical  
CC imaging of sites expressing (II). (I) and (II) are useful for treating  
CC disorders involving aberrant protein expression or biological activity.  
CC The polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human  
CC diagnostic amino acid sequences of the invention.  
CC Note: The sequence data for this patent did not appear in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_poc\_sequences.

XX Sequence 267 AA;

SO Query Match 20.3%; Score 63; DB 22; Length 267;

Best Local Similarity 100.0%; Pred. No. 2.5e-53;

Matches 63; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 239 DLNIGIIGVVLAVLALITLIGICAYRGRYPINNKODESYKNFGKPGGVYIRIDE 298

DB 130 DLNIGIIGVVLAVLALITLIGICAYRGRYPINNKODESYKNFGKPGGVYIRIDE 189

QY 299 EGD 301

DB 190 EGD 192

RESULT 45

ABG07157 standard; Protein: 264 AA.

XX AC ABG07157;

DT 13-FEB-2002 (first entry)

DE Novel human diagnostic protein #7148.

XX Human; chromosome mapping; gene mapping; gene therapy; forensic;

KW food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN WO200175067-A2.

XX PD 11-OCT-2001.

PF 30-MAR-2001; 2001WO-US08631.

PR 31-MAR-2000; 2000US-0540217.

PR 23-AUG-2000; 2000US-0649167.

PA (HYSE-) HYSEQ INC.

PI Drmanac RT, Liu C, Tang YT;

DR WPI: 2001-639362/73.

DR N-PSDB; AAS71344.

XX New isolated polynucleotide and encoded polypeptides, useful in

PT diagnostics, forensics, gene mapping, identification of mutations

PT responsible for genetic disorders or other traits and to assess

PT biodiversity -

PS Claim 20; SEQ ID No 37516; 103bp; English.

XX The invention relates to isolated polynucleotide (I) and

CC polypeptide (II) sequences. (I) is useful as hybridisation probes,

polymerase chain reaction (PCR) primers, oligomers, and for chromosome CC  
and gene mapping, and in recombinant production of (II). The CC  
CC polynucleotides are also used in diagnostics as expressed sequence tags CC  
CC for identifying expressed genes. (I) is useful in gene therapy techniques CC  
CC to restore normal activity of (II) or to treat disease states involving CC  
CC (II). (II) is useful for generating antibodies against it, detecting or CC  
CC quantitating a polypeptide in tissue, as molecular weight markers and as CC  
CC a food supplement. (II) and its binding partners are useful in medical CC  
CC imaging of sites expressing (II). (I) and (II) are useful for treating CC  
CC disorders involving aberrant protein expression or biological activity. CC  
CC The polypeptide and polynucleotide sequences have applications in CC  
CC diagnostics, forensics, gene mapping, identification of mutations CC  
CC responsible for genetic disorders or other traits to assess biodiversity CC  
CC and to produce other types of data and products dependent on DNA and CC  
CC amino acid sequences. ABG00010-ABG30377 represent novel human CC  
CC diagnostic amino acid sequences of the invention. CC  
CC Note: The sequence data for this patent did not appear in the printed CC  
CC specification, but was obtained in electronic format directly from WIPO CC  
CC at ftp.wipo.int/pub/published\_pct\_sequences. CC  
XX

XX SQ Sequence 264 AA;

Query Match 16.5%; Score 51; DB 22; Length 264;  
Best Local Similarity 100.0%; Pred. No. 1.5e-41;  
Matches 51; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 86 GDLGRAEILGKTSLKIMVTRDSALYRCEVAVANDRKEIDVIELTVQ 136  
214 GDLGRAEILGKTSLKIMVTRDSALYRCEVAVANDRKEIDVIELTVQ 264

Db

RESULT 46  
ABG22399  
ID ABG22399 standard; Protein; 301 AA.  
XX  
AC ABG22399;  
XX  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #22390.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US08631.  
XX  
PR 31-MAR-2000; 2000US-0540217.  
XX 23-AUG-2000; 2000US-0649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR MPI; 2001-639362/73.  
XX N-PSDB; AAS86586.  
XX  
XX New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity -  
XX  
XX Claim 20; SEQ ID No 52758; 103pp; English.

XX PS The invention relates to isolated polynucleotide (I) and  
XX polypeptide (II) sequences. (I) is useful as hybridisation probes,  
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
CC mapping, and in recombinant production of (II). The  
CC and gene mapping, and in recombinant production of (II). The

polynucleotides are also used in diagnostics as expressed sequence tags CC  
CC for identifying expressed genes. (I) is useful in gene therapy techniques CC  
CC to restore normal activity of (II) or to treat disease states involving CC  
CC (II). (II) is useful for generating antibodies against it, detecting or CC  
CC quantitating a polypeptide in tissue, as molecular weight markers and as CC  
CC a food supplement. (II) and its binding partners are useful in medical CC  
CC imaging of sites expressing (II). (I) and (II) are useful for treating CC  
CC disorders involving aberrant protein expression or biological activity. CC  
CC The polypeptide and polynucleotide sequences have applications in CC  
CC diagnostics, forensics, gene mapping, identification of mutations CC  
CC responsible for genetic disorders or other traits to assess biodiversity CC  
CC and to produce other types of data and products dependent on DNA and CC  
CC amino acid sequences. ABG00010-ABG30377 represent novel human CC  
CC diagnostic amino acid sequences of the invention. CC  
CC Note: The sequence data for this patent did not appear in the printed CC  
CC specification, but was obtained in electronic format directly from WIPO CC  
CC at ftp.wipo.int/pub/published\_pct\_sequences. CC  
XX

XX SQ Sequence 301 AA;

Query Match 16.5%; Score 51; DB 22; Length 301;  
Best Local Similarity 100.0%; Pred. No. 1.7e-41;  
Matches 51; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 86 GDLGRAEILGKTSLKIMVTRDSALYRCEVAVANDRKEIDVIELTVQ 136  
214 GDLGRAEILGKTSLKIMVTRDSALYRCEVAVANDRKEIDVIELTVQ 264

Db

RESULT 47  
ABG22398  
ID ABG22398 standard; Protein; 68 AA.  
XX  
AC ABG22398;  
XX  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #22389.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US08631.  
XX  
PR 31-MAR-2000; 2000US-0540217.  
XX 23-AUG-2000; 2000US-0649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR MPI; 2001-639362/73.  
XX N-PSDB; AAS86585.  
XX  
XX New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity -  
XX  
XX Claim 20; SEQ ID No 52757; 103pp; English.

XX PS The invention relates to isolated polynucleotide (I) and  
XX polypeptide (II) sequences. (I) is useful as hybridisation probes,  
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
CC mapping, and in recombinant production of (II). The  
CC polynucleotides are also used in diagnostics as expressed sequence tags  
CC for identifying expressed genes. (I) is useful in gene therapy techniques

CC to restore normal activity of (II) or to treat disease states involving  
CC (II). (II) is useful for generating antibodies against it, detecting or  
CC quantitating a polypeptide in tissue, as molecular weight markers and as  
CC a food supplement. (II) and its binding partners are useful in medical  
CC imaging of sites expressing (II). (I) and (II) are useful for treating  
CC disorders involving aberrant protein expression or biological activity.  
CC The polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human  
CC diagnostic amino acid sequences of the invention.  
CC Note: The sequence data for this patent did not appear in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences.

SQ Sequence 68 AA;

Query Match 12.3%; Score 38; DB 22; Length 68;  
Best Local Similarity 100.0%; Pred. No. 2.9e-29;  
Matches 38; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 49 VELSCITIDSDSPRIEKKIODEQTTVYFPDNKIQG 86  
DB 28 VELSCITIDSDSPRIEKKIODEQTTVYFPDNKIQG 65

RESULT 48

ID AAB27272 standard; Protein; 310 AA.

AC AAB27272;

DT 23-FEB-2001 (first entry)

DE Human confluency regulated adhesion molecule 1 #1.

KW Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;

KW inflammation; cancer; wound; angiogenesis; human;

OS Homo sapiens.

PN WO200053749-A2.

PD 14-SEP-2000.

PF 13-MAR-2000; 2000WO-EP02219.

PR 11-MAR-1999; 99EP-0200746.

PA (RMFD-) RMF DICTAGENE SA.

PI Imhof BA, Aurand-Lions M;

DR WPI; 2000-587436/55.

PT Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (GRAM-1 or  
PT CRAM-2) polypeptide, useful for treatment of tumors, inflammation  
PT reactions and modulating vascular permeability -

PS Claim 1; Fig 3; 59pp; English.

CC The present sequence is the human confluency regulated adhesion molecule  
CC 1 (GRAM-1, also known as JAM-2). GRAM-1 is one of the vascular adhesion  
CC proteins of the immunoglobulin superfamily (Ig Sf). The GRAM-1 protein  
CC and coding sequence can be used in the treatment of cancer,  
CC inflammation, to modulate cell-cell interactions and angiogenesis, and  
CC in the modulation of wound healing.

SQ Sequence 310 AA;

Query Match 7.7%; Score 24; DB 21; Length 310;

Best Local Similarity 100.0%; Pred. No. 5.9e-15;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 167 PRPHYSWYRNDVPLPTDSRANPRF 190  
DB 167 PRPHYSWYRNDVPLPTDSRANPRF 190

RESULT 49

ID AAB27278 standard; Protein; 310 AA.

AC AAB27278;

DT 23-FEB-2001 (first entry)

DE Murine confluency regulated adhesion molecule 1.

KW Immunoglobulin superfamily; Ig Sf; vascular adhesion molecule;

KW inflammation; cancer; wound; angiogenesis; mouse;

KW confluency regulated adhesion molecule 1; GRAM-1; JAM-2.

OS Mus sp.

PN WO200053749-A2.

PD 14-SEP-2000.

PF 13-MAR-2000; 2000WO-EP02219.

PR 11-MAR-1999; 99EP-0200746.

PA (RMFD-) RMF DICTAGENE SA.

PI Imhof BA, Aurand-Lions M;

DR WPI; 2000-587436/55.

PT Isolated human Confluency Regulated Adhesion Molecule 1 or 2 (GRAM-1 or  
PT CRAM-2) polypeptide, useful for treatment of tumors, inflammation  
PT reactions and modulating vascular permeability -

PS Example; Fig 8; 59pp; English.

CC The present sequence is the murine confluency regulated adhesion molecule  
CC 1 (GRAM-1, also known as JAM-2). GRAM-1 is one of the vascular adhesion  
CC proteins of the immunoglobulin superfamily (Ig Sf). The GRAM-1 protein  
CC and coding sequence can be used in the treatment of cancer, inflammation,  
CC to modulate cell-cell interactions and angiogenesis, and in the  
CC modulation of wound healing.

SQ Sequence 310 AA;

Query Match 7.7%; Score 24; DB 21; Length 310;  
Best Local Similarity 100.0%; Pred. No. 5.9e-15;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 167 PRPHYSWYRNDVPLPTDSRANPRF 190  
DB 167 PRPHYSWYRNDVPLPTDSRANPRF 190

RESULT 50

ID ABG49183 standard; Peptide; 31 AA.

AC ABG49183;

DT 25-FEB-2003 (first entry)

DE Human liver peptide, SEQ ID No 27831.

KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;  
 KW hypercholesterolaemia; coronary heart disease.

OS Homo sapiens.

PN WO200157273-A2.

PD 09-AUG-2001.

PF 30-JAN-2001; 2001WO-US00664.

XX 04-FEB-2000; 2000US-0180312.

PR 26-MAY-2000; 2000US-0207456.

PR 30-JUN-2000; 2000US-0608408.

PR 03-AUG-2000; 2000US-0632366.

PR 21-SEP-2000; 2000US-0234687.

PR 27-SEP-2000; 2000US-0236359.

PR 04-OCT-2000; 2000GB-0024263.

XX (MOLE-) MOLECULAR DYNAMICS INC.

PI Penn SG, Hanzel DK, Chen W, Rank DR;

DR WPI; 2001-488898/53.

XX Human genome-derived single exon nucleic acid probes useful for

PT analysing gene expression in human adult liver -

XX Claim 27; SEQ ID No 27831; 658bp; English.

XX The invention relates to a single exon nucleic acid probe (SENP) (1) for

CC measuring human gene expression in a sample derived from human adult

CC liver, comprising one of 13109 defined nucleotide sequences given in the

CC specification (or complements/ fragments). The probe hybridises at high

CC stringency to a nucleic acid molecule expressed in the human adult

CC liver. (1) may be used for predicting, measuring and displaying gene

CC expression in samples derived from human adult liver. The genes

CC identified may be involved in genetic liver diseases such as cirrhosis,

CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which

CC is associated with coronary heart disease. ABG47348-ABG59930 represent

CC human liver single exon encoded peptides of the invention.

CC Note: The sequence information for this patent does not appear in the

CC printed specification but was obtained in electronic format directly

CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences.

XX

SO Sequence 31 AA;

Query Match 2.6%; Score 8; DB 22; Length 31;

Best Local Similarity 100.0%; Pred. No. 4.4;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 249 VLVVLA VL 256

DB 10 VLVVLA VL 17

Search completed: December 15, 2003, 14:58:59  
 Job time : 44 secs